0001493152-22-013020.txt : 20220512 0001493152-22-013020.hdr.sgml : 20220512 20220512160549 ACCESSION NUMBER: 0001493152-22-013020 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 67 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220512 DATE AS OF CHANGE: 20220512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Co-Diagnostics, Inc. CENTRAL INDEX KEY: 0001692415 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 462609396 STATE OF INCORPORATION: UT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38148 FILM NUMBER: 22917735 BUSINESS ADDRESS: STREET 1: 4049 SOUTH HIGHLAND DRIVE CITY: SALT LAKE CITY STATE: UT ZIP: 84124 BUSINESS PHONE: 8012789769 MAIL ADDRESS: STREET 1: 4049 SOUTH HIGHLAND DRIVE CITY: SALT LAKE CITY STATE: UT ZIP: 84124 10-Q 1 form10-q.htm
0001692415 false Q1 --12-31 P3Y 0001692415 2022-01-01 2022-03-31 0001692415 2022-05-12 0001692415 2022-03-31 0001692415 2021-12-31 0001692415 2021-01-01 2021-03-31 0001692415 2020-12-31 0001692415 2021-03-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001692415 us-gaap:CommonStockMember 2021-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001692415 us-gaap:RetainedEarningsMember 2021-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001692415 us-gaap:CommonStockMember 2020-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001692415 us-gaap:RetainedEarningsMember 2020-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001692415 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001692415 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0001692415 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001692415 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0001692415 us-gaap:CommonStockMember 2022-03-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001692415 us-gaap:RetainedEarningsMember 2022-03-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-03-31 0001692415 us-gaap:CommonStockMember 2021-03-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001692415 us-gaap:RetainedEarningsMember 2021-03-31 0001692415 srt:MinimumMember 2022-01-01 2022-03-31 0001692415 srt:MaximumMember 2022-01-01 2022-03-31 0001692415 CODX:ThreeCustomersTogetherMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001692415 CODX:ThreeCustomersTogetherMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001692415 CODX:TwoCustomersTogetherMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001692415 CODX:TwoCustomersTogetherMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001692415 us-gaap:AccountingStandardsUpdate201602Member 2022-01-02 0001692415 CODX:AdvancedConceptionsIncAndIdahoMolecularIncMember 2021-12-30 2021-12-31 0001692415 CODX:AdvancedConceptionsIncAndIdahoMolecularIncMember 2021-12-31 0001692415 us-gaap:InProcessResearchAndDevelopmentMember 2022-01-01 2022-03-31 0001692415 us-gaap:InProcessResearchAndDevelopmentMember 2022-03-31 0001692415 us-gaap:NoncompeteAgreementsMember 2022-01-01 2022-03-31 0001692415 us-gaap:NoncompeteAgreementsMember 2022-03-31 0001692415 us-gaap:InProcessResearchAndDevelopmentMember 2021-01-01 2021-12-31 0001692415 us-gaap:InProcessResearchAndDevelopmentMember 2021-12-31 0001692415 us-gaap:NoncompeteAgreementsMember 2021-01-01 2021-12-31 0001692415 us-gaap:NoncompeteAgreementsMember 2021-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2022-03-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2022-03-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2022-03-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001692415 us-gaap:MeasurementInputSharePriceMember 2022-03-31 0001692415 us-gaap:MeasurementInputSharePriceMember 2021-12-31 0001692415 CODX:MeasurementInputStrikePriceMember 2022-03-31 0001692415 CODX:MeasurementInputStrikePriceMember 2021-12-31 0001692415 us-gaap:MeasurementInputPriceVolatilityMember 2022-03-31 0001692415 us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001692415 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-03-31 0001692415 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001692415 srt:AmericasMember 2022-01-01 2022-03-31 0001692415 srt:AmericasMember 2021-01-01 2021-03-31 0001692415 CODX:RestOfWorldMember 2022-01-01 2022-03-31 0001692415 CODX:RestOfWorldMember 2021-01-01 2021-03-31 0001692415 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-03-31 0001692415 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-03-31 0001692415 CODX:RestOfWorldMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-03-31 0001692415 CODX:RestOfWorldMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-03-31 0001692415 us-gaap:WarrantMember 2022-01-01 2022-03-31 0001692415 CODX:TwoThousandFifteenLongTermIncentivePlanMember 2022-03-31 0001692415 CODX:StockOptionsMember 2022-01-01 2022-03-31 0001692415 CODX:StockOptionsMember 2022-03-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2022-03-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0001692415 CODX:StockOptionsMember 2021-01-01 2021-03-31 0001692415 us-gaap:WarrantMember 2022-03-31 0001692415 CODX:ThirdPartiesMember us-gaap:RestrictedStockMember 2022-01-01 2022-03-31 0001692415 CODX:ThirdPartiesMember us-gaap:RestrictedStockMember 2021-01-01 2021-03-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001692415 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001692415 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001692415 us-gaap:StockCompensationPlanMember 2022-01-01 2022-03-31 0001692415 us-gaap:StockCompensationPlanMember 2021-01-01 2021-03-31 0001692415 CODX:ExclusiveLicenseAgreementMember CODX:DrBrentSatterfieldMember 2017-01-30 0001692415 CODX:ExclusiveLicenseAgreementMember CODX:DrBrentSatterfieldMember 2017-01-01 2017-01-30 0001692415 CODX:ExclusiveLicenseAgreementMember CODX:DrBrentSatterfieldMember 2022-03-31 0001692415 CODX:ExclusiveLicenseAgreementMember CODX:DrBrentSatterfieldMember 2021-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:acre

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2022

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to __________

 

Commission File No. 001-38148

 

CO-DIAGNOSTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Utah   46-2609396
(State or other jurisdiction of
incorporation or organization)		   (I.R.S. Employer
Identification Number)

 

2401 S. Foothill Drive, Suite D, Salt Lake City, Utah 84109

(Address of principal executive offices and zip code)

 

(801) 438-1036

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   CODX   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

  Large accelerated filer ☐ Accelerated filer ☐
  Non-accelerated filer ☐ Smaller reporting company ☒
      Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

 

As of May 12, 2022, there were 33,987,736 shares of common stock, par value $0.001 per share, outstanding.

 

 

 

 

 

 

CO-DIAGNOSTICS, INC. AND SUBSIDIARIES

 

TABLE OF CONTENTS

 

PART I FINANCIAL INFORMATION:  
     
Item 1. Financial Statements (unaudited): 3
     
  Consolidated Balance Sheets 3
     
  Consolidated Statements of Operations 4
     
  Consolidated Statements of Cash Flows 5
     
  Consolidated Statements of Stockholders’ Equity 6
     
  Notes to Consolidated Financial Statements 7
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 16
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 20
     
Item 4. Controls and Procedures 20
     
PART II OTHER INFORMATION:  
     
Item 1. Legal Proceedings 21
     
Item 1A. Risk Factors 21
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 21
     
Item 3. Defaults Upon Senior Securities 21
     
Item 4. Mine Safety Disclosures 21
     
Item 5. Other Information 21
     
Item 6. Exhibits 22
     
  Signatures 23

 

2

 

 

PART I. FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

CO – DIAGNOSTICS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(Unaudited)

 

 

   March 31, 2022   December 31, 2021 
Assets          
Current assets          
Cash and cash equivalents  $97,421,739   $88,607,234 
Marketable investment securities   -    1,255,266 
Accounts receivable, net   21,662,403    20,839,182 
Inventory   4,901,057    2,004,169 
Prepaid expenses and other current assets   1,278,598    2,338,444 
Note receivable   75,000    75,000 
Total current assets   125,338,797    115,119,295 
Property and equipment, net   2,252,853    1,933,216 
Operating lease right-of-use asset   604,837    - 
Goodwill   14,808,411    14,706,818 
Intangible assets, net   27,088,333    27,195,000 
Investment in joint venture   983,614    1,004,953 
Note receivable   75,000    75,000 
Total assets  $171,151,845   $160,034,282 
Liabilities and stockholders’ equity          
Current liabilities          
Accounts payable  $1,215,049   $607,506 
Accrued expenses, current   2,613,218    3,859,652 
Operating lease liability, current   283,299    - 
Contingent consideration liabilities, current   4,065,537    5,767,304 
Income taxes payable   4,843,592    2,213,088 
Deferred revenue   -    150,000 
Total current liabilities   13,020,695    12,597,550 
Long-term liabilities          
Income taxes payable   1,284,745    1,067,853 
Deferred tax liability   5,868,728    7,228,444 
Operating lease liability   275,672    - 
Contingent consideration liabilities   2,987,214    4,665,337 
Total long-term liabilities   10,416,359    12,961,634 
Total liabilities   23,437,054    25,559,184 
Commitments and contingencies (Note 12)   -    - 
Stockholders’ equity          
Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively   -    - 
Common stock, $0.001 par value; 100,000,000 shares authorized; 33,984,068 and 33,819,862 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively   33,984    33,820 
Additional paid-in capital   81,796,933    80,271,999 
Accumulated earnings   65,883,874    54,169,279 
Total stockholders’ equity   147,714,791    134,475,098 
Total liabilities and stockholders’ equity  $171,151,845   $160,034,282 

 

See accompanying notes to unaudited consolidated financial statements

 

3

 

 

CO – DIAGNOSTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

   2022   2021 
   Three Months Ended March 31, 
   2022   2021 
Revenue  $22,699,044   $20,024,769 
Cost of revenue   3,281,951    3,272,565 
Gross profit   19,417,093    16,752,204 
Operating expenses          
Sales and marketing   2,652,148    1,197,546 
General and administrative   2,922,195    2,935,689 
Research and development   3,771,327    2,217,063 
Depreciation and amortization   247,264    67,005 
Total operating expenses   9,592,934    6,417,303 
Income from operations   9,824,159    10,334,901 
Other income (expense)          
Interest income   11,393    14,657 
Loss on disposition of assets   (93,421)   - 
Gain on remeasurement of acquisition contingencies   3,379,890    - 
(Loss) on equity method investment in joint venture   (21,339)   (464,943)
Total other income (expense)   3,276,523    (450,286)
Income before income taxes   13,100,682    9,884,615 
Income tax provision   1,386,087    1,985,640 
Net income  $11,714,595   $7,898,975 
Earnings per common share:          
Basic  $0.35   $0.28 
Diluted  $0.34   $0.26 
Weighted average shares outstanding:          
Basic   33,935,570    28,662,885 
Diluted   34,711,476    30,002,729 

 

See accompanying notes to unaudited consolidated financial statements

 

4

 

 

CO – DIAGNOSTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

   2022   2021 
   Three Months Ended March 31, 
   2022   2021 
Cash flows from operating activities          
Net income  $11,714,595   $7,898,975 
Adjustments to reconcile net income to cash used in operating activities:          
Depreciation and amortization   247,264    67,005 
Stock-based compensation expense   1,375,097    1,513,012 
Change in fair value of acquisition contingencies   (3,379,890)   - 
Non-cash lease expense   8,762    - 
Loss from equity method investment   21,339    464,943 
Loss on disposition of assets   93,421    - 
Deferred income taxes   (1,359,716)   302,399 
Bad debt expense   47,862    79,700 
Changes in assets and liabilities:          
Accounts receivable   (871,083)   (59,994)
Prepaid expenses   1,042,932    (114,473)
Inventory   (3,088,944)   1,797,581 
Deferred revenue   (150,000)   (146,516)
Income taxes payable   2,745,803    1,128,438 
Accounts payable, accrued expenses and other liabilities   (641,604)   (661,115)
Net cash provided by operating activities   7,805,838    12,269,955 
Cash flows from investing activities          
Purchases of property and equipment   (396,600)   (139,558)
Proceeds from maturities of marketable investment securities   1,255,266    2,032,802 
Investment in joint venture   -    500,000 
Net cash provided by investing activities   858,666    2,393,244 
Cash flows from financing activities          
Proceeds from exercise of options and warrants   150,001    148,981 
Net cash provided by financing activities   150,001    148,981 
Net increase in cash and cash equivalents   8,814,505    14,812,180 
Cash and cash equivalents at beginning of period   88,607,234    42,976,713 
Cash and cash equivalents at end of period  $97,421,739   $57,788,893 
Supplemental disclosure of cash flow information          
Interest paid  $-   $- 
Income taxes paid  $-   $- 
Supplemental disclosure of non-cash investing and financing transactions          
Inventory moved to property, plant and equipment  $192,056   $- 
Right-of-use assets obtained in exchange for new operating lease liabilities  $681,327   $- 

 

See accompanying notes to unaudited consolidated financial statements

 

5

 

 

CO – DIAGNOSTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

 

   Shares   Amount   Shares   Amount   Capital   (Deficit)   Equity 
   Convertible Preferred Stock   Common Stock   Additional Paid-in   Accumulated Earnings   Total Stockholders’ 
   Shares   Amount   Shares   Amount   Capital   (Deficit)   Equity 
Balance as of December 31, 2021        -   $         -    33,819,862   $33,820   $80,271,999   $54,169,279   $134,475,098 
Common stock issued for option exercises   -    -    45,456    45    49,956    -    50,001 
Common stock issued for warrant exercises   -    -    50,000    50    99,950         100,000 
Stock-based compensation   -    -    68,750    69    1,375,028    -    1,375,097 
Net income   -    -    -    -    -    11,714,595    11,714,595 
Balance as of March 31, 2022   -   $-    33,984,068   $33,984   $81,796,933   $65,883,874   $147,714,791 

 

   Convertible Preferred Stock   Common Stock   Additional Paid-in   Accumulated Earnings   Total Stockholders’ 
   Shares   Amount   Shares   Amount   Capital   (Deficit)   Equity 
Balance as of December 31, 2020          -   $        -    28,558,033   $28,558   $49,157,236   $17,510,715   $66,696,509 
Common stock issued for option exercises   -    -    65,891    66    148,914    -    148,980 
Stock-based compensation   -    -    73,040    42    1,512,970    -    1,513,012 
Net income   -    -    -    -    -    7,898,975    7,898,975 
Balance as of March 31, 2021   -   $-    28,696,964   $28,666   $50,819,120   $25,409,690   $76,257,476 

 

See accompanying notes to unaudited consolidated financial statements

 

6

 

 

CO – DIAGNOSTICS, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

Note 1 – Overview and Basis of Presentation

 

Description of Business

 

Co-Diagnostics, Inc., a Utah corporation (the “Company”, “Co-Dx” or “CODX”), develops, manufactures and sells reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including robust and innovative molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. In connection with the sale of our tests we may sell diagnostic equipment from other manufacturers as self-contained lab systems (which we refer to as the “MDx Device”). We are also developing a unique, groundbreaking portable PCR testing platform (the “Co-Dx PCR home testing platform”) designed to bring affordable, reliable gold-standard polymerase chain reaction (“PCR”) to patients in point-of-care and even at-home settings.

 

Unaudited Consolidated Financial Statements

 

The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q as they are prescribed for smaller reporting companies and emerging growth companies. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to make the financial statements not misleading have been included. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. These statements should be read in conjunction with the Company’s audited financial statements and related notes for the year ended December 31, 2021, included in the Company’s Annual Report on Form 10-K filed on March 24, 2022.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Such estimates include receivables and other long-lived assets, legal and regulatory contingencies, income taxes, share based arrangements, and others. These estimates and assumptions are based on management’s best estimates and judgments. Actual amounts and results could differ from those estimates.

 

Note 2 – Summary of Significant Accounting Policies

 

Cash and Cash Equivalents

 

Cash and cash equivalents consist of cash on hand, money market funds and highly liquid investments with an original maturity date of 90 days or less from the date of purchase. The fair value of cash equivalents approximated their carrying value as of March 31, 2022 and December 31, 2021. The Company has its cash and cash equivalents with a large creditworthy financial institution and the balance exceeded federally insured limits. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on cash and cash equivalents.

 

Marketable Investment Securities

 

The Company’s marketable investment securities are comprised of investments in certificates of deposit. The Company determines the appropriate classification of its marketable investment securities at the time of purchase and reevaluates such designation at each balance sheet date. The Company has classified and accounted for its marketable investment securities as available-for-sale securities as the Company may sell these securities at any time for use in its current operations or for other purposes, even prior to maturity. As a result, the Company classifies its marketable investment securities, including securities with stated maturities beyond twelve months, within current assets in the consolidated balance sheets. Any unrealized gains or losses are immaterial.

 

7

 

 

Accounts Receivable

 

Trade accounts receivable are recorded at the invoiced amount (net of allowance) and do not bear interest. The Company maintains an allowance for doubtful accounts for amounts the Company does not expect to collect. In establishing the required allowance, management considers historical losses, current market condition, customers’ financial condition, the age of receivables, and current payment patterns. Account balances are written off against the allowance once the receivable is deemed uncollectible. Recoveries of trade receivables previously written off are recorded when collected. At March 31, 2022, total accounts receivable was $22,379,861 with an allowance for uncollectable accounts of $717,458 resulting in a net amount of $21,662,403. At December 31, 2021, total accounts receivable was $21,508,779 with an allowance for uncollectable accounts of $669,597 resulting in a net amount of $20,839,182.

 

Equity-Method Investments

 

Our equity method investments are initially recorded at cost and are included in other long-term assets in the accompanying consolidated balance sheet. We adjust the carrying value of our investment based on our share of the earnings or losses in the periods which they are reported by the investee until the carrying amount is zero. The earnings or losses are included in other income (expense) in the accompanying consolidated statements of operations.

 

Inventory

 

Inventory is stated at the lower of cost or net-realizable value. Inventory cost is determined on a first-in first-out basis that approximates average cost in accordance with ASC 330-10-30-12. At March 31, 2022, the Company had $4,901,057 in inventory, of which $4,119,549 was finished goods and $781,508 was raw materials. At December 31, 2021, the Company had $2,004,169 in inventory, of which $983,088 was finished goods and $1,021,081 was raw materials. The Company establishes reserves to reduce slow-moving, obsolete, or unusable inventories to their estimated useful or scrap values.

 

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the property, generally from three to five years. Repairs and maintenance costs are expensed as incurred except when such repairs significantly add to the useful life or productive capacity of the asset, in which case the repairs are capitalized.

 

The Company reviews its long-lived assets, including property and equipment, for impairment whenever an event or change in facts and circumstances indicates that their carrying amounts may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated. If the carrying amount exceeds the undiscounted cash flows, the assets are determined to be impaired and an impairment charge is recognized as the amount by which the carrying amount exceeds fair value.

 

Business Combinations

 

We estimate the fair value of assets acquired and liabilities assumed in a business combination. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable, and as a result, actual results may differ from estimates.

 

Leases

 

As described in “Recently Adopted Accounting Standards” below, the Company adopted ASC 842, Leases (“ASC 842”) effective January 1, 2022. Under ASC 842, the Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (ROU) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.

 

As the implicit rate in the Company’s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The Company considers its credit risk, term of the lease, total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. Lease costs for the Company’s operating leases are recognized on a straight-line basis within operating expenses and cost of revenue over the reasonably assured lease term.

 

The Company has elected to not separate lease and non-lease components for leases of office space and, as a result, accounts for any lease and non-lease components for office space as a single lease component, to the extent they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease payments. The Company’s office leases typically include non-lease components such as common-area maintenance costs. The Company has also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less.

 

Revenue Recognition

 

The Company generates revenue from product sales and license sales. The Company recognizes revenue when all of the following criteria are satisfied: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as the Company satisfies each performance obligation.

 

8

 

 

The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as deferred revenue.

 

Deferred Revenue

 

Deferred revenue primarily consists of payments received from customers prior to the Company fulfilling its performance obligation of providing the product. When this occurs, the Company records a contract liability as deferred revenue. Deferred revenue is recognized as revenue as the related performance obligations are satisfied.

 

Research and Development

 

Research and development costs are expensed when incurred. For the three months ended March 31, 2022, the Company expensed $3,771,327 of research and development costs, respectively. For the three months ended March 31, 2021, the Company expensed $2,217,063.

 

Stock-based Compensation

 

The Company has granted stock-based awards, including restricted stock, stock options, stock warrants and restricted stock units (“RSUs”), to its employees, certain consultants and members of its board of directors. The Company records stock-based compensation based on the grant date fair value of the awards and recognizes the fair value of those awards as expense using the straight-line method over the requisite service period of the award. The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model. When an award is forfeited prior to the vesting date, the Company recognizes an adjustment for the previously recognized expense in the period of the forfeiture.

 

Income Taxes

 

The Company accounts for income taxes in accordance with the liability method of accounting for income taxes. Under this method, deferred income tax assets and deferred income tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at enacted tax rates in effect for the year in which the differences are expected to reverse. The Company recognizes only the impact of tax positions that, based on their technical merits, are more likely than not to be sustained upon an audit by the taxing authority.

 

Valuation allowances are provided when it is more-likely-than-not that some or all of the deferred income tax assets may not be realized. In assessing the need for a valuation allowance, the Company has considered its historical levels of income, expectations of future taxable income and ongoing tax planning strategies.

 

Developing the provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred income tax assets and liabilities and any estimated valuation allowances deemed necessary to value deferred income tax assets. Judgments and tax strategies are subject to audit by various taxing authorities. While the Company believes it has no significant uncertain income tax positions in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial positions, result of operations, or cash flows.

 

Net Income per Share

 

Basic net income or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted average number of shares outstanding during each period.

 

Diluted net income or loss per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period increased by common shares that could be issued upon conversion or exercise of other outstanding securities to the extent those additional common shares would be dilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income or loss per share by application of the treasury stock method. During periods when the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the effects of potentially dilutive securities are anti-dilutive.

 

Concentrations Risk and Significant Customers

 

The Company had certain customers which are each responsible for generating 10% or more of the total revenue for the three months ended March 31, 2022. Three customers together accounted for approximately 54% and 57% of total revenue for the three months ended March 31, 2022 and March 31, 2021, respectively.

 

Two customers each accounted for more than 10% of accounts receivable at March 31, 2022 and December 31, 2021. These two customers together accounted for approximately 62% and 66% of accounts receivable at March 31, 2022 and December 31, 2021, respectively.

 

9

 

 

Recent Accounting Pronouncements

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.

 

Recently Adopted Accounting Standards

 

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) (“ASU 2016-13”), which requires the measurement and recognition of expected credit losses for certain financial instruments, which includes the Company’s accounts receivable. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. The Company adopted ASU 2016-13 on January 1, 2022. The adoption did not have an impact on the Company’s financial statements.

 

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which requires a lessee to recognize most leases on the balance sheet as lease liabilities with corresponding right-of-use assets. The objective of ASU 2016-02 is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The recognized lease liabilities and lease assets represent the obligation to make payments and the right to use or control the use of a specified asset for the lease term, respectively.

 

On January 1, 2022, the Company adopted Topic 842 using the modified retrospective approach with the effective date as the date of initial application. Consequently, results for the three months ended March 31, 2022 are presented under Topic 842. No prior period amounts were adjusted and continue to be reported in accordance with previous lease guidance, ASC Topic 840, Leases. The Company elected the practical expedients available under the provisions of the new standard, including not reassessing whether expired or existing contracts are or contain leases; not reassessing the classification of expired or existing leases; and not reassessing the initial direct cost for any existing leases. Upon adoption, the Company recognized an operating lease liability of $626,699 and a corresponding operating right-of-use asset of $681,327.

 

Note 3 – Business Combinations

 

On December 31, 2021, the Company completed its acquisition of Advanced Conceptions, Inc. (“ACI”) and Idaho Molecular Inc. (“IdMo”), which were related entities developing, with the Company, an at-home/point-of-care medical diagnostic device. Upon the completion of the acquisition, all outstanding ACI and Idaho Molecular common stock was exchanged for approximately 3.2 million shares of the Company’s common stock and contingent consideration that includes up to approximately 1.4 million shares and approximately 456,000 warrants to purchase shares of the Company’s common stock. The contingent consideration is based on the achievement of certain milestones, which include regulatory approval for identified products, as well as production and net revenue targets. Upon the completion of the acquisition, both ACI and IdMo became 100% wholly-owned subsidiaries of the Company.

 

Note 4 – Goodwill and Intangible Assets

 

Goodwill

 

Goodwill represents the excess of purchase price and related costs over the value assigned to net tangible and identifiable intangible assets acquired in business combinations. The following table presents the changes in the carrying amount of goodwill for the three months ended March 31, 2022:

 

Balance as of December 31, 2021  $14,706,818 
Measurement period adjustments   101,593 
Balance as of March 31, 2022  $14,808,411 

 

Intangible Assets, Net

 

The following table presents details of the Company’s intangible assets, excluding goodwill:

 

   Weighted-Average  Gross       Net 
   Useful Life (1)  Carrying   Accumulated   Carrying 
   (in Years)  Amount   Amortization   Amount 
In-process research and development  Indefinite  $26,101,000   $-   $26,101,000 
Non-competition agreements  2.7   1,094,000    (106,667)   987,333 
Total intangible assets     $27,195,000   $(106,667)  $27,088,333 

 

   Weighted-Average  Gross       Net 
   Useful Life (1)  Carrying   Accumulated   Carrying 
   (in Years)  Amount   Amortization   Amount 
In-process research and development  Indefinite  $26,101,000   $              -   $26,101,000 
Non-competition agreements  2.7   1,094,000    -    1,094,000 
Total intangible assets     $27,195,000   $-   $27,195,000 

 

(1)Based on weighted-average useful life established as of the acquisition date.

 

Note 5 – Fair Value Measurements

 

The Company measures and records certain financial assets at fair value on a recurring basis. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

 

The Company’s financial instruments that are measured at fair value on a recurring basis consist of money market funds. The following three levels of inputs are used to measure the fair value of financial instruments:

 

Level 1: Quoted market prices in active markets for identical assets or liabilities.

 

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

 

Level 3: Unobservable inputs that are not corroborated by market data.

 

10

 

 

The following table summarizes the assets measured at fair value on a recurring basis as of March 31, 2022, and December 31, 2021, by level within the fair value hierarchy:

 

   (Level 1)   (Level 2)   (Level 3)   Total 
   March 31, 2022 
   (Level 1)   (Level 2)   (Level 3)   Total 
Liabilities:                    
Contingent consideration - common stock  $      -   $     -   $6,013,939   $6,013,939 
Contingent consideration - warrants   -    -    1,038,812    1,038,812 
Total liabilities measured at fair value  $-   $-   $7,052,751   $7,052,751 

 

   (Level 1)   (Level 2)   (Level 3)   Total 
   December 31, 2021 
   (Level 1)   (Level 2)   (Level 3)   Total 
Assets:                    
Marketable securities (certificates of deposit)  $     -   $1,255,266   $-   $1,255,266 
Total assets measured at fair value  $-   $1,255,266   $-   $1,255,266 
Liabilities:                    
Contingent consideration - common stock  $-   $-   $8,684,669   $8,684,669 
Contingent consideration - warrants   -    -    1,747,972    1,747,972 
Total liabilities measured at fair value  $-   $-   $10,432,641   $10,432,641 

 

The Company’s financial instruments that are measured at fair value on a recurring basis consist of certificates of deposit.

 

The changes for Level 3 items measured at fair value on a recurring basis are as follows:

 

      
Fair value as of December 31, 2021  $10,432,641 
Change in fair value of contingent consideration issued for business acquisitions   (3,379,890)
Fair value as of March 31, 2022  $7,052,751 

 

The fair value of the contingent consideration is based on the fair value of the contingent consideration-common stock and contingent consideration-warrants. The fair value of the contingent consideration-common stock is equal to the probability-adjusted value of the Company’s common stock as of March 31, 2022. The fair value of the contingent consideration-warrants is equal to the probability adjusted value of a call option with terms consistent with the terms of the warrants as of March 31, 2022. Prior to the probability adjustments, the warrants were valued based on the following inputs:

 

  

March 31, 2022

   December 31, 2021 
Stock price  $6.18   $8.93 
Strike price  $9.13   $9.13 
Volatility   77.50%   80.00%
Risk-free rate   2.40%   1.30%
Expected term   4.8    5.0 

 

Note 6 – Revenue

 

The following table sets forth revenue by geographic area:

 

   Three Months Ended March 31, 
   2022   2021 
United States  $14,218,398   $12,493,950 
Rest of World   8,480,646    7,530,819 
Total  $22,699,044   $20,024,769 
Percentage of revenue by area:          
United States   63%   62%
Rest of World   37%   38%

 

Deferred Revenue

 

Changes in the Company’s deferred revenue balance for the three months ended March 31, 2022 were as follows:

 

Balance as of December 31, 2021  $150,000 
Revenue recognized included in deferred revenue balance at the beginning of the period   (150,000)
Balance as of March 31, 2022  $- 

 

11

 

 

Note 7 – Earnings Per Share

 

The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share for three months ended March 31, 2022:

 

   2022   2021 
   Three Months Ended March 31, 
   2022   2021 
Numerator          
Net income, as reported  $11,714,595   $7,898,975 
           
Denominator          
Weighted average shares, basic   33,935,570    28,662,885 
Dilutive effect of stock options, warrants and RSUs   775,906    1,339,844 
Shares used to compute diluted earnings per share   34,711,476    30,002,729 
           
Basic earnings per share  $0.35   $0.28 
Diluted earnings per share  $0.34   $0.26 

 

For the three months ended March 31, 2022, potentially dilutive securities of 1,271,304 were excluded from the calculation because their effect would have been anti-dilutive. For the three months ended March 31, 2021, potentially dilutive securities of 2,320,907 were excluded from the calculation because their effect would have been anti-dilutive. The computation of diluted earnings per share for the three months ended March 31, 2022 also excludes the approximately 1.4 million shares of common stock and approximately 456,000 warrants to purchase shares of common stock that are contingent upon the achievement of certain milestones.

 

Note 8 – Stock-Based Compensation

 

Stock Incentive Plans

 

The Co-Diagnostics, Inc. Amended and Restated 2015 Long Term Incentive Plan (the “Incentive Plan”) reserves an aggregate of 6,000,000 shares of common stock issuable upon the grant of awards under the Incentive Plan. The number of awards available for issuance under the Incentive Plan was 2,095,266 at March 31, 2022.

 

Stock Options

 

The following table summarizes option activity during the three months ended March 31, 2022:

 

   Number of Options   Weighted Average Exercise Price   Weighted Average Fair Value   Weighted Average Remaining Contractual Life (Years) 
Outstanding at December 31, 2021   1,111,363   $2.12   $1.31    6.62 
Granted   -    -    -      
Expired   -    -    -      
Forfeited/Cancelled   -    -    -      
Exercised   (45,456)   1.10    0.51      
Outstanding at March 31, 2022   1,065,907   $2.17   $1.35    6.65 
                     
Exercisable at March 31, 2022   1,049,241   $2.05   $1.21    6.63 

 

The total intrinsic value of options exercised during the three months ended March 31, 2022 was approximately $0.3 million. The aggregate intrinsic value of outstanding options at March 31, 2022 was approximately $4.5 million.

 

12

 

 

Stock-based compensation cost is measured at the grant date based on the fair value of the award granted and recognized as expense over the vesting period using the straight-line method. The Company uses the Black-Scholes model to value options granted.

 

As of March 31, 2022, there were 16,666 of unvested options and $37,241 of unrecognized stock-based compensation expense. The unrecognized stock-based compensation expense is expected to be recognized over 0.2 years.

 

Restricted Stock Units

 

The grant date fair value of RSUs granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the awards. The following table sets forth the outstanding RSUs and related activity for the three months ended March 31, 2022:

 

   Number of RSUs   Weighted Average Grant Date Fair Value 
Unvested at December 31, 2021   1,267,415   $9.94 
Granted   -    - 
Vested   (68,750)   10.23 
Forfeited/Cancelled   -    - 
Unvested at March 31, 2022   1,198,665   $9.92 

 

As of March 31, 2022, there was approximately $10.3 million of unrecognized stock-based compensation expense related to outstanding RSUs which is expected to be recognized over a weighted-average period of 2.1 years.

 

Warrants

 

The Company has issued warrants related to financings, acquisitions and as compensation to third parties for services provided. The Company estimates the fair value of issued warrants on the date of issuance as determined using a Black-Scholes pricing model. The Company amortizes the fair value of issued warrants using a vesting schedule based on the terms and conditions of each warrant if granted for services.

 

The following table summarizes warrant activity during the three months ended March 31, 2022:

 

   Number of Warrants   Weighted Average Exercise Price   Weighted Average Fair Value   Weighted Average Remaining Contractual Life (Years) 
Outstanding at December 31, 2021   526,281   $8.15   $4.01    4.7 
Granted   -    -    -      
Expired   -    -    -      
Forfeited/Cancelled   -    -    -      
Exercised   (50,000)   2.00    1.22      
Outstanding at March 31, 2022   476,281   $8.80   $2.82    4.8 

 

13

 

 

The intrinsic value of warrants exercised during the three months ended March 31, 2022 and 2021 was approximately $0.3 million and $0, respectively. The aggregate intrinsic value of outstanding warrants at March 31, 2022 was approximately $0.1 million.

 

The total number of warrants exercisable at March 31, 2022 are 20,000. The ability to exercise the approximately 456,000 warrants issued in connection with acquisitions in the prior year is contingent upon the achievement of certain development and revenue milestones on or before January 1, 2027. There was no unrecognized stock-based compensation expense related to warrants.

 

Stock Issued for Services

 

The Company has issued restricted stock to third parties for services provided. The grant date fair value of the restricted stock granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the stock awards. The Company issued 0 and 4,290 shares of restricted stock for services during the three months ended March 31, 2022 and 2021, respectively. There was no unrecognized stock-based compensation expense related to restricted stock issued.

 

Stock-Based Compensation Expense

 

The Company recognized stock-based compensation expense related to the types of awards discussed above as follows:

 

   2022   2021 
   Three Months Ended March 31, 
   2022   2021 
Options  $40,874   $76,672 
Restricted stock units   1,334,223    1,396,440 
Stock   -    39,900 
Total stock-based compensation expense  $1,375,097   $1,513,012 

 

Note 9 – Income Taxes

 

For the three months ended March 31, 2022, the Company recognized expense from income taxes of $1,386,087, representing an effective tax rate of 10.6%. The Company’s effective tax rate will generally differ from the U.S. Federal statutory rate of 21.0% due to state taxes, permanent items, and discrete items. For the three months ended March 31, 2021, the Company recognized expense from income taxes of $1,985,640.

 

Note 10 – Related Party Transactions

 

The Company acquired the exclusive rights to the CoPrimer technology pursuant to an exclusive license agreement, dated April 2014 (the “Exclusive License Agreement”), between the Company and DNA Logix, Inc., which was assigned to Dr. Brent Satterfield, a former executive officer, prior to the Company’s acquisition of DNA Logix, Inc. On March 1, 2017, the Company entered into an amendment to its Exclusive License Agreement for its Cooperative Primers (“License”) technology with Dr. Satterfield. The amendment provides in part that all accrued royalties under the License cease as of January 1, 2017, and the Company began in January 2017 to pay to Dr. Satterfield $700,000 of accrued royalties at the rate of $10,000 per month. At March 31, 2022 and 2021, the aggregate balance of this related party liability was $0 and $120,000, respectively.

 

14

 

 

Note 11 – Leases

 

The Company leases office space under a non-cancelable operating lease and leases cancellable with one month notice. The Company expenses the cancellable leases in the period incurred in accordance with the practical expedient elected. As such, one lease makes up the entirety of the right-of-use asset and lease liability disclosed.

 

For the three months ended March 31, 2022, components of lease expense are summarized as follows:

 

   Three Months Ended March 31, 2022 
Operating lease costs  $86,588 
Short-term lease costs   76,080 
Total lease costs  $162,668 

 

Short-term lease costs under month-to-month lease agreements are paid to related parties.

 

As of March 31, 2022, the maturities of the Company’s lease liabilities are as follows:

 

  

Year Ending

December 31,

 
2022 (remainder)  $221,350 
2023   303,059 
2024   50,774 
2025   - 
2026   - 
Thereafter   - 
Total lease payments   575,183 
Less: imputed interest   16,212 
Present value of operating lease liabilities   558,971 
Less: current portion   283,299 
Long-term portion  $275,672 

 

Other information related to operating leases was as follows:

 

   Three Months Ended March 31, 2022 
Cash paid for operating leases included in operating cash flows  $154,882 
Remaining lease term of operating leases   2 years 
Discount rate of operating leases   3.1%

 

As previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021, future lease payments under ASC 840 for operating leases were as follows:

 

Year Ending December 31,    
2022  $293,595 
2023   303,059 
2024   50,774 
Total lease payments  $647,428 

 

Note 12 – Commitments and Contingencies

 

Litigation

 

Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.

 

The Company is currently a defendant in five different securities class action complaints that were filed by certain stockholders of the Company claiming that the Company promulgated false and misleading press releases to increase the price of our stock to improperly benefit the officers and directors of the Company. The plaintiffs demand compensatory damages sustained as a result of the Company’s alleged wrongdoing in an amount to be proven at trial. The Company believes these lawsuits are without merit and intends to defend the cases vigorously. The Company is unable to estimate a range of loss, if any, that could result were there to be an adverse final decision in these cases. As of the date of this report, the Company does not believe it is probable that these cases will result in an unfavorable outcome; however, if an unfavorable outcome were to occur in these cases, it is possible that the impact could be material to the Company’s results of operations in the period(s) in which any such outcome becomes probable and estimable.

 

Note 13 – Share Repurchase Program

 

In March 2022, the Company’s Board of Directors authorized a share repurchase program that would allow the Company to repurchase up to $30.0 million of CODX common stock. The repurchase program does not obligate the Company to acquire any particular amount of common shares, and the repurchase program may be suspended or discontinued at any time at the Company’s discretion. The timing and amount of any share repurchases under the share repurchase program will be determined by Co-Diagnostics’ management at its discretion based on ongoing assessments of the capital needs of the business, the market price of the Company’s common stock, corporate and regulatory requirements, and general market conditions.

 

The Company has not made any repurchases under the share purchase program since its implementation.

 

Note 14 – Subsequent Events

 

The Company evaluated subsequent events pursuant to ASC Topic 855 and has determined that there are no events that need to be reported.

 

15

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Cautionary Note Regarding Forward-Looking Statements

 

This Quarterly Report on Form 10-Q contains “forward-looking statements” that involve risks and uncertainties. All statements other than statements of historical fact contained in this Quarterly Report and the documents incorporated by reference herein, including statements regarding future events, our future financial performance, business strategy, and plans and objectives of management for future operations, are forward-looking statements. We have attempted to identify forward-looking statements by terminology including “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “should,” or “will” or the negative of these terms or other comparable terminology. Although we do not make forward looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. These statements are only predictions and involve known and unknown risks, uncertainties and other factors and the documents incorporated by reference herein, which may affect our or our industry’s actual results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Moreover, we operate in a highly regulated, very competitive, and rapidly changing environment. New risks emerge from time to time, and it is not possible for us to predict all risk factors, nor can we address the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause our actual results to differ materially from those contained in any forward-looking statements.

 

We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short term and long-term business operations, and financial needs. These forward-looking statements are subject to certain risks and uncertainties that could cause our actual results to differ materially from those reflected in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this Quarterly Report, and in particular, the risks discussed below and under the heading “Risk Factors” in other documents we file with the SEC. The following discussion should be read in conjunction with the Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on March 24, 2022, and the audited financial statements and notes included therein.

 

You should not place undue reliance on any forward-looking statement, each of which applies only as of the date of this Quarterly Report. Except as required by law, we undertake no obligation to update or revise publicly any of the forward-looking statements after the date of this Quarterly Report to conform our statements to actual results or changed expectations.

 

You are advised, however, to consult any further disclosures we make on related subjects in our periodic and current reports filed with the SEC. You should understand that it is not possible to predict or identify all risk factors. Consequently, you should not consider this list to be a complete set of all potential risks or uncertainties.

 

Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation:

 

● the results of clinical trials and the regulatory approval process;
   
● market acceptance of any products that may be approved for commercialization;
   
● our ability to protect our intellectual property rights;
   
● the impact of any infringement actions or other litigation brought against us;
   
● competition from other providers and products;
   
● our ability to develop and commercialize new and improved products and services;
   
● changes in government regulation;
   
● and other factors (including the risks contained in the section entitled “Risk Factors” in other documents we file with the SEC) relating to our industry, our operations and results of operations.

 

Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

 

Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

 

As used in this Quarterly Report, the terms “we”, “us”, “our”, and “Co-Diagnostics” means Co-Diagnostics, Inc., a Utah corporation and its consolidated subsidiaries (the “Company”), unless otherwise indicated.

 

Executive Overview

 

The following management’s discussion and analysis of financial condition and results of operations describes the principal factors affecting the results of our operations, financial condition, and changes in financial condition. This discussion should be read in conjunction with the accompanying unaudited financial statements and notes thereto included elsewhere in this report. The information contained in this discussion is subject to a number of risks and uncertainties. We urge you to review carefully the section of this report entitled “Cautionary Note Regarding Forward-Looking Statements” for a summary of the risks and uncertainties associated with an investment in our securities.

 

16

 

 

Business Overview

 

Co-Diagnostics, Inc., a Utah corporation (the “Company”, “Co-Dx” or “CODX”), develops, manufactures and sells reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including robust and innovative molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. In connection with the sale of our tests we may sell diagnostic equipment from other manufacturers as self-contained lab systems (which we refer to as the “MDx Device”). We are also developing a unique, groundbreaking portable PCR testing platform (the “Co-Dx PCR home testing platform”) designed to bring affordable, reliable gold-standard polymerase chain reaction (“PCR”) to patients in point-of-care and even at-home settings.

 

Our diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. CODX’s technical advance involves a novel, patented approach to PCR test design of primer and probe structure (“CoPrimers™”) that eliminates one of the key vexing issues of PCR amplification, the exponential growth of primer-dimer pairs (false positives and false negatives) which adversely interferes with identification of the target DNA/RNA.

 

We believe our proprietary molecular diagnostics technology is paving the way for innovation in disease detection and life sciences research through our enhanced detection of genetic material. For various reasons, including owning our own platform, we believe we will be able to accomplish this faster and more economically, allowing for significant margins while still positioning the Company to be a low-cost provider of molecular diagnostics and screening services.

 

In addition, continued development has demonstrated the unique properties of our CoPrimers™ technology that we believe makes it ideally suited for a variety of applications where specificity is key to optimal results, including multiplexing several targets, enhanced Single Nucleotide Polymorphism (“SNP”) detection and enrichment for next generation sequencing.

 

Our scientists use the complex mathematics of DNA/RNA test design to engineer and optimize DNA/RNA tests and to automate algorithms that rapidly screen millions of possible options to pinpoint the optimum design. Dr. Brent Satterfield, our founder, developed the Company’s intellectual property consisting of the predictive mathematical algorithms and patented molecular structure used in the testing process, which together represent a major advance in PCR testing systems. CODX technologies are now protected by more than 20 granted or pending US and foreign patents, as well as certain trade secrets and copyrights. Ownership of our proprietary platform permits us the advantage of avoiding payment of patent royalties required by other PCR test systems, which may allow the sale of diagnostic PCR tests at a lower price than competitors, while enabling us to maintain profit margins.

 

We may either sell or lease the MDx Device to labs and diagnostic centers, through sale or lease agreements, and sell the reagents that comprise our proprietary tests to those laboratories and testing facilities.

 

Our proprietary test design process involves identifying the optimal locations on the target genes for amplification and pair the locations with the optimized primer and probe structure to achieve outputs that meet the design input requirements identified from market research. This is done by following planned and documented processes, procedures and testing. In other words, we use the data resulting from our tests to verify whether we succeeded in designing what we intended at the outset. Verification is a series of testing that concludes that the product is ready to proceed to validation in an evaluation either in our laboratory or in an independent laboratory setting using initial production tests to confirm that the product as designed meets the user needs.

 

Using our proprietary test design system and proprietary reagents, we have designed and obtained regulatory approval in the European Community and in India to sell PCR diagnostic tests for the detection of COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In the United States, CODX has obtained Emergency Use Authorization (“EUA”) for its Logix Smart™ COVID-19 detection test from the Food and Drug Administration, or FDA, and sells that test to qualified labs. In addition, our COVID-19 detection test and certain of our other suite of COVID-19 products have been approved for sale in countries such as the United Kingdom, Australia and Mexico by the regulatory bodies in those countries and have been registered for sale in many more countries.

 

In addition to testing for infectious disease, the technology lends itself to identifying any section of a DNA or RNA strand that describe any type of genetic trait, which creates a number of significant applications. We, in conjunction with our customers, are active in designing and licensing tests that identify genetic traits in plant and animal genomes. We also have three multiplexed tests developed to test mosquitos for the identification of diseases carried by the mosquitos to enable municipalities to concentrate their efforts in managing mosquito populations on the specific areas known to be breeding the mosquitos that carry deadly viruses.

 

Because we believe that testing for COVID-19 is going to be a consideration for public health worldwide even after the current pandemic has subsided, we have initiated the Co-Dx PCR home testing platform to facilitate frequent testing in homes, schools, businesses, and the hospitality industry. We believe this may be accomplished through the development of a low-cost testing device, easy to use by non-professionals, that can provide PCR test results in around 30 minutes. The initial project built on this platform, an at-home and point-of-care COVID-19 PCR test, was ultimately facilitated by our development of a saliva or nasal swab-based PCR test that does not require the RNA/DNA extraction. While the final result is believed to be approximately equivalent to those processed by a high-complexity clinical laboratory, it has the advantages of increased speed and ease of handling thanks to lyophilization (or freeze-drying) of our testing reagents to allow for stability at room temperatures.

 

On February 15, 2021, we engaged the services of a group of professionals at Idaho Molecular, Inc. (IdMo) and Advanced Conceptions, Inc (ACI) with the expertise to develop the hardware for such a device using our CoPrimers™ as the reagent chemistry. On December 22, 2021, we announced that we would be acquiring IdMo and ACI, and on December 31, 2021, we completed the acquisitions, along with all existing and future assets and intellectual property related to the platform and device. It is expected that the device and test will be available to homes, schools, offices, and the travel industry among other locations at a cost that will allow screening frequently to prevent spread of the COVID-19 virus in the future. The device would also be available to test for other pathogens detectable through saliva or other samples as we develop those tests and offer them to the marketplace. All such tests will be subject to regulatory approval.

 

17

 

 

RESULTS OF OPERATIONS

 

The Three Months Ended March 31, 2022 Compared to the Three Months ended March 31, 2021

 

Revenues

 

For the three months ended March 31, 2022, we generated revenues of $22,699,044, compared to revenues of $20,024,769 for the three months ended March 31, 2021. The increase in revenue of $2,674,275 was primarily due to sales of our Logix Smart™ COVID-19 test developed in response to the current COVID-19 pandemic. Of the total revenue in the three months ended March 31, 2022, $364,950 related to the sale of third party manufactured equipment and consumables, which we sourced and sold to customers to facilitate the sales of our COVID-19 test compared to $266,515 of revenue from the sales of such equipment for the three months ended March 31, 2021.

 

Cost of Revenues

 

We recorded cost of revenues of $3,281,951 for the three months ended March 31, 2022, compared to $3,272,565 for the three months ended March 31, 2021. The increase in revenues combined with a reduction of product production costs resulted in improved gross margin. Of the total cost of sales during the three months ended March 31, 2022, $374,683 was from equipment sold to our customers compared to $202,636 for equipment sold to customers for the three months ended March 31, 2021.

 

Expenses

 

We incurred total operating expenses of $9,592,934 for the three months ended March 31, 2022, compared to total operating expenses of $6,417,303 for the three months ended March 31, 2021. The increase in operating expenses was due to the increase in business activities experienced as a result of our increase in revenue, increased third party sales commissions reflected in sales and marketing, and increased investment in research and development.

 

Our sales and marketing expenses for the three months ended March 31, 2022 were $2,652,148, compared to $1,197,546 for the three months ended March 31, 2021. The increase was primarily a result of increased third-party sales commissions, advertising and promotional expenses, including tradeshows and related travel, and increased stock-based compensation due to the growth in revenue.

 

General and administrative expenses decreased from $2,935,689 for the three months ended March 31, 2021 to $2,922,195 for the three months ended March 31, 2022. The slight decrease in general and administrative expenses was primarily due to decreased stock-based compensation expense, partially offset by increased activity to support the growth of our business, including increased insurance expense and professional and advisory fees related to our recent acquisitions.

 

Our research and development expenses increased from $2,217,063 for the three months ended March 31, 2021 to $3,771,327 for the three months ended March 31, 2022. The primary increase in expenses was a result of increases in personnel expenses related to our acquisitions of IdMo and ACI on December 31, 2021.

 

18

 

 

Other Income (Expense)

 

For the three months ended March 31, 2022 we had total other income of $3,276,523, compared to total other expense of $450,286 for the three months ended March 31, 2021. The increase was due primarily to a change in the fair value of contingent consideration liabilities recorded in conjunction with the acquisitions of IdMo and ACI.

 

Net Income

 

We realized net income for the three months ended March 31, 2022 of $11,714,595, compared with net income for the three months ended March 31, 2021 of $7,898,975. The increase in net income was primarily the result of an increase in operating expenses, offset by an increase of product revenues and resulting margins from those sales, as well as changes in the fair value of acquisition contingencies. Additionally, we recorded income tax expense of $1,386,087 for the three months ended March 31, 2022, compared to $1,985,640 for the three months ended March 31, 2021.

 

Liquidity and Capital Resources

 

At March 31, 2022, we had cash and cash equivalents of $97,421,739 that could readily be converted into cash if needed. Additionally, our total current assets of March 31, 2022, were $125,338,797 compared to total current liabilities of $13,020,695.

 

Net cash provided by operating activities during the three months ended March 31, 2022 was $7,805,838, compared to $12,269,955 for the three months ended March 31, 2021. The decrease in cash from operating activities was primarily due to increased operating expenses, increases in inventory, and the effects of non-cash items.

 

We received $858,666 of cash from investing activities during the three months ended March 31, 2022, primarily from maturities of marketable investments offset by purchases of property and equipment, compared to cash from investing activities of $2,393,244 during the three months ended March 31, 2021.

 

Net cash provided by financing activities was $150,001 for the three months ended March 31, 2022 realized from the exercise of options and warrants, compared to $148,981 for the same period in the prior year.

 

Since commencing sales of our Logix Smart™ COVID-19 test in March 2020, we have used our cash generated from those sales to fund the increase in our inventories and receivables and pay our operating expenses. We have increased our work force primarily in the area of research and development to complete development of additional tests to enable us to use our distributor network to sell other products throughout the world and remain profitable in the future. In March 2022 our board of directors authorized repurchasing up to $30.0 million of the company’s outstanding common stock. We have no obligation to repurchase any shares under the repurchase program and may suspend or discontinue it at any time without prior notice. We have not repurchased any of our outstanding common shares under the repurchase program.

 

We believe that our existing capital resources and the cash generated from future sales will be sufficient to meet our projected operating requirements for the next 12 months. However, our available capital resources may be consumed more rapidly than currently expected and we may need or want to raise additional financing for strategic opportunities.

 

If needed, we expect additional investment capital to come from (i) additional issuances of our common stock with existing and new investors or (ii) the private placement of other securities with investors similar to those that have provided funding in the past. We may not be able to secure such financing in a timely manner or on favorable terms, if at all.

 

19

 

 

The foregoing estimates, expectations and forward-looking statements are subject to change as we make strategic operating decisions from time to time and as our revenue and expenses fluctuate from period to period.

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet arrangements.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

Not required under Regulation S-K for “smaller reporting companies.”

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

We maintain “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2022. Based on the evaluation of our disclosure controls and procedures as of March 31, 2022, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls were effective.

 

Changes in Internal Control over Financial Reporting

 

There have been no changes in our internal control over financial reporting during the three months ended March 31, 2022, that have materially affected or, are reasonably likely to materially affect, our internal control over financial reporting.

 

20

 

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings

 

There have been no material developments to the legal proceedings previously disclosed under Part I. Item 3 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.

 

From time to time, we may become involved in litigation relating to claims arising out of our operations in the normal course of business. Although we have received inquiries from FINRA, NASDAQ and the SEC, to which we have responded, to the best of our knowledge, no governmental authority is contemplating any proceeding to which we are a party or to which any of our properties or businesses are subject, which would reasonably be likely to have a material adverse effect on the Company.

 

Item 1A. Risk Factors.

 

Not required under Regulation S-K for “smaller reporting companies.”

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

Dividends

 

We have never declared or paid any cash dividends on our capital stock. The payment of dividends on our common stock in the future will depend on our earnings, capital requirements, operating and financial condition and such other factors as our Board of Directors may consider appropriate. We currently expect to use all available funds to finance the future development and expansion of our business and do not anticipate paying dividends on our common stock in the foreseeable future.

 

Pursuant to Section 16-10a-640 of the Utah Revised Business Corporation Act, no distribution may be made if, after giving it effect:

 

  (a) the corporation would not be able to pay its debts as they become due in the usual course of business; or
     
  (b) the corporation’s total assets would be less than the sum of its total liabilities plus, unless the articles of incorporation permit otherwise, the amount that would be needed, if the corporation were to be dissolved at the time of the distribution, to satisfy the preferential rights upon dissolution of shareholders whose preferential rights are superior to those receiving the distribution.

 

Share Repurchase Program

 

In March 2022 our board of directors authorized repurchasing up to $30.0 million of the company’s outstanding common stock. We did not repurchase any of our outstanding common shares under the repurchase program during the first quarter ending March 31, 2022.

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

None.

 

21

 

 

Item 6. Exhibits

 

Exhibit Index

 

(a) Exhibits

 

Exhibit   Number Description
     
3.1   Amended and Restated Bylaws of Co-Diagnostics, Inc. (Incorporated by reference herein from Form 8-K (Exhibit 3.1), filed 04/01/22, SEC File No. 001-38148.
31.1*   Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*   Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*   Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*   Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Taxonomy Extension Schema Document
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File

 

* Filed herewith.

 

22

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  CO-DIAGNOSTICS, INC.

 

Date: May 12, 2022 By: /s/ Dwight H. Egan
  Name: Dwight H. Egan
  Title: Chief Executive Officer, President and Principal Executive Officer
     
Date: May 12, 2022 By: /s/ Brian Brown
  Name: Brian Brown
  Title: Chief Financial Officer and Principal Financial and Accounting Officer

 

23

 

 EX-31.1 2 ex31-1.htm

 

EXHIBIT 31.1

 

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

AND RULE 13a-14 OF THE EXCHANGE ACT OF 1934

 

I, Dwight H. Egan, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Co-Diagnostics, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
   
  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepting accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.
     
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   
  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 12, 2022 By: /s/ Dwight H. Egan
    Dwight H. Egan
    Chief Executive Officer, President and Principal Executive Officer

 

 

 

 EX-31.2 3 ex31-2.htm

 

EXHIBIT 31.2

 

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

AND RULE 13a-14 OF THE EXCHANGE ACT OF 1934

 

I, Brian Brown, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Co-Diagnostics, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
   
  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepting accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.
     
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   
  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 12, 2022 By: /s/ Brian Brown
    Brian Brown
    Chief Financial Officer and Principal Financial and Accounting Officer

 

 

 

 EX-32.1 4 ex32-1.htm

 

EXHIBIT 32.1

 

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S. C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Co-Diagnostics, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2022, as filed with the Securities and Exchange Commission on the date hereof, I, Dwight H. Egan, Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

  (1) The Form 10-Q fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  (2) The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: May 12, 2022 By: /s/ Dwight H. Egan
    Dwight H. Egan
    Chief Executive Officer, President and Principal Executive Officer

 

 

 

 EX-32.2 5 ex32-2.htm

 

EXHIBIT 32.2

 

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S. C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Co-Diagnostics, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2022, as filed with the Securities and Exchange Commission on the date hereof, I, Brian Brown, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

  (1) The Form 10-Q fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  (2) The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: May 12, 2022 By: /s/ Brian Brown
    Brian Brown
    Chief Financial Officer and Principal Financial and Accounting Officer

 

 

 

 EX-101.SCH 6 codx-20220331.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Overview and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Business Combinations link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Share Repurchase Program link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Goodwill and Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Business Combinations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Schedule of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Schedule of Intangible Assets, Net (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Schedule of Fair Value Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Schedule of Changes in Fair Value Measurement (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Schedule of Contingent Consideration Common Stock and Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Summary of Revenue by Geographic Area (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Schedule of Deferred Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Schedule of Basic and Diluted Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Earnings Per Share (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Schedule of Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Schedule of Outstanding Restricted Stock Units and Related Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Schedule of Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Schedule of Recognized Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Stock-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Schedule of Lease Expense (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Schedule of Maturities on Company Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Schedule of Other Information Related to Operating Lease (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Schedule of Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Share Repurchase Program (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 codx-20220331_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 codx-20220331_def.xml XBRL DEFINITION FILE EX-101.LAB 9 codx-20220331_lab.xml XBRL LABEL FILE Class of Stock [Axis] Convertible Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Customer [Axis] Three Customers Together [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Two Customers Together [Member] Accounts Receivable [Member] Accounting Standards Update [Axis] Accounting Standards Update 2016-02 [Member] Business Acquisition [Axis] Advanced Conceptions, Inc. and Idaho Molecular, Inc. [Member] Finite-Lived Intangible Assets by Major Class [Axis] In Process Research and Development [Member] Noncompete Agreements [Member] Measurement Frequency [Axis] Fair Value, Recurring [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Measurement Input Type [Axis] Measurement Input, Share Price [Member] Measurement Input Strike Price [Member] Measurement Input, Price Volatility [Member] Measurement Input, Risk Free Interest Rate [Member] Geographical [Axis] Americas [Member] Rest of World [Member] Geographic Concentration Risk [Member] Warrant [Member] Plan Name [Axis] 2015 Long Term Incentive Plan [Member] Award Type [Axis] Stock Options [Member] Restricted Stock Units (RSUs) [Member] Title of Individual [Axis] Third Parties [Member] Restricted Stock [Member] Share-Based Payment Arrangement, Option [Member] Share-Based Payment Arrangement [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Exclusive License Agreement [Member] Dr. Brent Satterfield [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] Assets Current assets Cash and cash equivalents Marketable investment securities Accounts receivable, net Inventory Prepaid expenses and other current assets Note receivable Total current assets Property and equipment, net Operating lease right-of-use asset Goodwill Intangible assets, net Investment in joint venture Note receivable Total assets Liabilities and stockholders’ equity Current liabilities Accounts payable Accrued expenses, current Operating lease liability, current Contingent consideration liabilities, current Income taxes payable Deferred revenue Total current liabilities Long-term liabilities Income taxes payable Deferred tax liability Operating lease liability Contingent consideration liabilities Total long-term liabilities Total liabilities Commitments and contingencies (Note 12) Stockholders’ equity Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively Common stock, $0.001 par value; 100,000,000 shares authorized; 33,984,068 and 33,819,862 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively Additional paid-in capital Accumulated earnings Total stockholders’ equity Total liabilities and stockholders’ equity Convertible preferred stock, par value Convertible preferred stock , shares authorized Convertible preferred stock, shares issued Convertible preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue Cost of revenue Gross profit Operating expenses Sales and marketing General and administrative Research and development Depreciation and amortization Total operating expenses Income from operations Other income (expense) Interest income Loss on disposition of assets Gain on remeasurement of acquisition contingencies (Loss) on equity method investment in joint venture Total other income (expense) Income before income taxes Income tax provision Net income Earnings per common share: Basic Diluted Weighted average shares outstanding: Basic Diluted Statement of Cash Flows [Abstract] Cash flows from operating activities Net income Adjustments to reconcile net income to cash used in operating activities: Stock-based compensation expense Change in fair value of acquisition contingencies Non-cash lease expense Loss from equity method investment Loss on disposition of assets Deferred income taxes Bad debt expense Changes in assets and liabilities: Accounts receivable Prepaid expenses Inventory Deferred revenue Income taxes payable Accounts payable, accrued expenses and other liabilities Net cash provided by operating activities Cash flows from investing activities Purchases of property and equipment Proceeds from maturities of marketable investment securities Investment in joint venture Net cash provided by investing activities Cash flows from financing activities Proceeds from exercise of options and warrants Net cash provided by financing activities Net increase in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental disclosure of cash flow information Interest paid Income taxes paid Supplemental disclosure of non-cash investing and financing transactions Inventory moved to property, plant and equipment Right-of-use assets obtained in exchange for new operating lease liabilities Statement [Table] Statement [Line Items] Beginning balance, value Beginning balance, shares Common stock issued for option exercises Common stock issued for option exercises, shares Common stock issued for warrant exercises Common stock issued for warrant exercises, shares Stock-based compensation Stock-based compensation expense, shares Ending balance, value Ending balance, shares Accounting Policies [Abstract] Overview and Basis of Presentation Summary of Significant Accounting Policies Business Combination and Asset Acquisition [Abstract] Business Combinations Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Fair Value Disclosures [Abstract] Fair Value Measurements Revenue from Contract with Customer [Abstract] Revenue Earnings Per Share [Abstract] Earnings Per Share Share-Based Payment Arrangement [Abstract] Stock-Based Compensation Income Tax Disclosure [Abstract] Income Taxes Related Party Transactions [Abstract] Related Party Transactions Leases Leases Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Equity [Abstract] Share Repurchase Program Subsequent Events [Abstract] Subsequent Events Cash and Cash Equivalents Marketable Investment Securities Accounts Receivable Equity-Method Investments Inventory Property and Equipment Business Combinations Leases Revenue Recognition Deferred Revenue Research and Development Stock-based Compensation Income Taxes Net Income per Share Concentrations Risk and Significant Customers Recent Accounting Pronouncements Recently Adopted Accounting Standards Schedule of Goodwill Schedule of Intangible Assets, Net Schedule of Fair Value Assets and Liabilities Schedule of Changes in Fair Value Measurement Schedule of Contingent Consideration Common Stock and Warrants Summary of Revenue by Geographic Area Schedule of Deferred Revenue Schedule of Basic and Diluted Earnings Per Share Schedule of Option Activity Schedule of Outstanding Restricted Stock Units and Related Activity Schedule of Warrant Activity Schedule of Recognized Stock-based Compensation Expense Schedule of Lease Expense Schedule of Maturities on Company Lease Liabilities Schedule of Other Information Related to Operating Lease Schedule of Future Minimum Lease Payments Schedule of Product Information [Table] Product Information [Line Items] Accounts receivable Doubtful accounts Inventory finished goods Inventory raw materials Estimated useful life of property Concentration risk percentage Operating lease liability Operating right use of asset Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Line Items] Number of shares exchanged Number of shares on contingent consideration Warrants to purchase shares of common stock Equity method investment ownership percentage Goodwil - beginning Measurement period adjustments Goodwill - Ending Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Estimated useful lives in years, term Intangible assets, gross Less accumulated amortization Estimated useful lives in years Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Contingent consideration - common stock Contingent consideration - warrants Total liabilities measured at fair value Marketable securities (certificates of deposit) Total assets measured at fair value Fair value as of December 31, 2021 Change in fair value of contingent consideration issued for business acquisitions Fair value as of March 31, 2022 Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Warrants measurement input Expected term Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Revenue Percentage of revenue Deferred revenue, beginning balance Revenue recognized included in deferred revenue balance at the beginning of the period Deferred revenue, Ending balance Net income, as reported Weighted average shares, basic Dilutive effect of stock options, warrants and RSUs Shares used to compute diluted earnings per share Basic earnings per share Diluted earnings per share Securities excluded from computation of diluted earnings per share Number of Options Outstanding, Beginning Weighted Average Exercise Price Outstanding, Beginning Weighted Average Fair Value Outstanding, Beginning Weighted-average Remaining Contractual Life (years) Outstanding, Beginning Number of Options Outstanding, Granted Weighted Average Exercise Price Granted Weighted Average Fair Value Granted Number of Options Outstanding, Expired Weighted Average Exercise Price Expired Weighted Average Fair Value Expired Number of Options Outstanding, Forfeited/Cancelled Weighted Average Exercise Price Forfeited/Cancelled Weighted Average Fair Value Forfeited/Cancelled Number of Options Outstanding, Exercised Weighted Average Exercise Price Exercised Weighted Average Fair Value Exercised Number of Options Outstanding, Ending Weighted Average Exercise Price Outstanding, Ending Weighted Average Fair Value Outstanding, Ending Weighted-average Remaining Contractual Life (years) Outstanding, Ending Number of Options Exercisable Ending Weighted Average Exercise Price, Exercisable Ending Weighted Average Fair Value, Exercisable Ending Weighted-average Remaining Contractual Life (years), Exercisable Ending Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Number of Restricted Stock Units, Outstanding Beginning Weighted Average Grant Date Fair Value, Outstanding Beginning Number of Restricted Stock Units, Granted Weighted Average Grant Date Fair Value, Granted Number of Restricted Stock Units, Vested Weighted Average Grant Date Fair Value, Vested Number of Restricted Stock Units, Forfeited/Cancelled Weighted Average Grant Date Fair Value, Forfeited/Cancelled Number of Restricted Stock Units, Outstanding Ending Weighted Average Grant Date Fair Value, Outstanding Ending Number of Warrants Outstanding, Beginning Weighted Average Exercise Price, Beginning Weighted Average Fair Value, Beginning Weighted-average Remaining Contractual Life (Years) Outstanding, Beginning Number of Warrants Outstanding, Granted Weighted Average Exercise Price, Granted Weighted Average Fair Value, Granted Number of Warrants Outstanding, Expired Weighted Average Exercise Price, Expired Weighted Average Fair Value, Expired Number of Warrants Outstanding, Forfeited/Cancelled Weighted Average Exercise Price, Forfeited/Cancelled Weighted Average Fair Value, Forfeited/Cancelled Number of Warrants Outstanding, Exercised Weighted Average Exercise Price, Exercised Weighted Average Fair Value, Exercised Number of Warrants Outstanding, Ending Weighted Average Exercise Price, Ending Weighted Average Fair Value, Ending Weighted-average Remaining Contractual Life (Years) Outstanding, Ending Total stock-based compensation expense Aggregate number of common shares reserved Number of common shares availalble for issuance Intrinsic value of options value exercised Aggregate intrinsic value of options outstanding Unvested options Unrecognized stock-based compensation Unrecognized stock-based compensation recognition period Intrinsic value of warrants exercised Warrants exercisable Warrants to purchase a common stock Number of shares issued for services Income tax expense benefit Effective tax rate Effective federal statutory tax rate Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Accrued royalties Payment for royalties per month Due to related party Schedule Of Lease Expense Operating lease costs Short-term lease costs Total lease costs Schedule Of Maturities On Company Lease Liabilities 2022 (remainder) 2023 2024 2025 2026 Thereafter Total lease payments Less: imputed interest Present value of operating lease liabilities Less: current portion Long-term portion Cash paid for operating leases included in operating cash flows Remaining lease term of operating leases Discount rate of operating leases 2022 2023 2024 Total lease payments Stock repurchase program authorized amount Taxes payable non current. Payments to acquire interest in joint ventures Proceeds from exercise of options and warrants Noncash or part noncash inventory moved to property plant and equipment Noncash lease expense Loss on equity method investment in joint venture Two Customers Together [Member] Schedule of operating lease [Table Text Block] Schedule of maturities on company lease liabilities [Table Text Block] Advanced Conceptions, Inc. and Idaho Molecular, Inc. [Member] Stock issued during period shares contingent consideration. Indefinite lived intangible asset useful life. Fair value of contingent consideration to common stock. Fair value of contigent consideration to warrants. Contingent considered issued for business acquisitions. Measurement Input Strike Price [Member] Rest of World [Member] Weighted average number of basic shares outstanding. Earnings basic per share. 2015 Long Term Incentive Plan [Member] Number of share options (or share units) exercised during the current period. Share based compensation arrangement by share based payment award options non vested weighted average grant date fair value exercised. Share based compensation arrangement by share based payment award options non vested weighted average grant date fair value exercisable. Share based compensation arrangement by share based payment award options non vested weighted average term. Stock Options [Member] Weighted average price at which grantees can acquire the shares reserved for issuance under the non-option plan. Weighted average fair value, beginning. Weighted-average remaining contractual life (years) outstanding, ending. Weighted average exercise price, forfeited/cancelled. Weighted average fair value, exercised. Weighted average exercise price, forfeited/cancelled. Weighted average price at which grantees could have acquired the underlying shares with respect to non-options of the plan that expired. Weighted average exercise price, granted. Weighted average exercise price, beginning. Share-based compensation arrangement by share-based payment award, non-option, granted in period, weighted average exercise price. Share based compensation arrangement by share based payment award options non vested weighted average grant date fair value exercised. Weighted average fair value, forfeited/cancelled. Weighted-average remaining contractual life (years) outstanding, beginning. Intrinsic value of warrants exercised. Class of warrant exercisable. Third Parties [Member] Exclusive License Agreement [Member] Dr. Brent Satterfield [Member] Recently adopted accounting standards [Policy Text Block] Three Customers Together [Member] Stock issued during period shares exchanged. Lessee operating lease liability payments due after year four. Gain on remeasurement of acquisition contingencies. Assets, Current Accounts Receivable, after Allowance for Credit Loss, Noncurrent Assets [Default Label] Liabilities, Current TaxesPayableNoncurrent Liabilities, Noncurrent Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Weighted Average Number of Shares Outstanding, Basic Gain (Loss) on Sale of Investments Increase (Decrease) in Accounts Receivable Increase (Decrease) in Prepaid Expense Increase (Decrease) in Inventories Increase (Decrease) in Contract with Customer, Liability Increase (Decrease) in Income Taxes Payable Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment PaymentsToAcquireInterestInJointVentures Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Shares, Outstanding Revenue from Contract with Customer [Text Block] Lessee, Operating Leases [Text Block] Inventory, Policy [Policy Text Block] Business Combinations Policy [Policy Text Block] Lessee, Leases [Policy Text Block] Income Tax, Policy [Policy Text Block] Finite-Lived Intangible Assets, Accumulated Amortization Business Combination, Contingent Consideration, Liability, Noncurrent Revenue from Contract with Customer, Including Assessed Tax Contract with Customer, Liability Contract with Customer, Liability, Revenue Recognized Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price StockIssuedDuringPeriodSharesStockOptionsExercised1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOutstandingWeightedAverageExercisePrice Lease, Cost Lessee, Operating Lease, Liability, to be Paid Operating Leases, Future Minimum Payments Due, Next 12 Months Operating Leases, Future Minimum Payments, Due in Two Years Operating Leases, Future Minimum Payments Due EX-101.PRE 10 codx-20220331_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover - shares
 3 Months Ended
Mar. 31, 2022
May 12, 2022
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Mar. 31, 2022  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2022  
Current Fiscal Year End Date --12-31  
Entity File Number 001-38148  
Entity Registrant Name CO-DIAGNOSTICS, INC.  
Entity Central Index Key 0001692415  
Entity Tax Identification Number 46-2609396  
Entity Incorporation, State or Country Code UT  
Entity Address, Address Line One 2401 S. Foothill Drive  
Entity Address, Address Line Two Suite D  
Entity Address, City or Town Salt Lake City  
Entity Address, State or Province UT  
Entity Address, Postal Zip Code 84109  
City Area Code (801)  
Local Phone Number 438-1036  
Title of 12(b) Security Common Stock  
Trading Symbol CODX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Elected Not To Use the Extended Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   33,987,736
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Balance Sheets (Unaudited) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Current assets    
Cash and cash equivalents $ 97,421,739 $ 88,607,234
Marketable investment securities 1,255,266
Accounts receivable, net 21,662,403 20,839,182
Inventory 4,901,057 2,004,169
Prepaid expenses and other current assets 1,278,598 2,338,444
Note receivable 75,000 75,000
Total current assets 125,338,797 115,119,295
Property and equipment, net 2,252,853 1,933,216
Operating lease right-of-use asset 604,837
Goodwill 14,808,411 14,706,818
Intangible assets, net 27,088,333 27,195,000
Investment in joint venture 983,614 1,004,953
Note receivable 75,000 75,000
Total assets 171,151,845 160,034,282
Current liabilities    
Accounts payable 1,215,049 607,506
Accrued expenses, current 2,613,218 3,859,652
Operating lease liability, current 283,299
Contingent consideration liabilities, current 4,065,537 5,767,304
Income taxes payable 4,843,592 2,213,088
Deferred revenue 150,000
Total current liabilities 13,020,695 12,597,550
Long-term liabilities    
Income taxes payable 1,284,745 1,067,853
Deferred tax liability 5,868,728 7,228,444
Operating lease liability 275,672
Contingent consideration liabilities 2,987,214 4,665,337
Total long-term liabilities 10,416,359 12,961,634
Total liabilities 23,437,054 25,559,184
Commitments and contingencies (Note 12)
Stockholders’ equity    
Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively
Common stock, $0.001 par value; 100,000,000 shares authorized; 33,984,068 and 33,819,862 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively 33,984 33,820
Additional paid-in capital 81,796,933 80,271,999
Accumulated earnings 65,883,874 54,169,279
Total stockholders’ equity 147,714,791 134,475,098
Total liabilities and stockholders’ equity $ 171,151,845 $ 160,034,282
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Mar. 31, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Convertible preferred stock, par value $ 0.001 $ 0.001
Convertible preferred stock , shares authorized 5,000,000 5,000,000
Convertible preferred stock, shares issued 0 0
Convertible preferred stock, shares outstanding 0 0
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 33,984,068 33,819,862
Common stock, shares outstanding 33,984,068 33,819,862
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Income Statement [Abstract]    
Revenue $ 22,699,044 $ 20,024,769
Cost of revenue 3,281,951 3,272,565
Gross profit 19,417,093 16,752,204
Operating expenses    
Sales and marketing 2,652,148 1,197,546
General and administrative 2,922,195 2,935,689
Research and development 3,771,327 2,217,063
Depreciation and amortization 247,264 67,005
Total operating expenses 9,592,934 6,417,303
Income from operations 9,824,159 10,334,901
Other income (expense)    
Interest income 11,393 14,657
Loss on disposition of assets (93,421)
Gain on remeasurement of acquisition contingencies 3,379,890
(Loss) on equity method investment in joint venture (21,339) (464,943)
Total other income (expense) 3,276,523 (450,286)
Income before income taxes 13,100,682 9,884,615
Income tax provision 1,386,087 1,985,640
Net income $ 11,714,595 $ 7,898,975
Earnings per common share:    
Basic $ 0.35 $ 0.28
Diluted $ 0.34 $ 0.26
Weighted average shares outstanding:    
Basic 33,935,570 28,662,885
Diluted 34,711,476 30,002,729
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Cash flows from operating activities    
Net income $ 11,714,595 $ 7,898,975
Adjustments to reconcile net income to cash used in operating activities:    
Depreciation and amortization 247,264 67,005
Stock-based compensation expense 1,375,097 1,513,012
Change in fair value of acquisition contingencies (3,379,890)
Non-cash lease expense 8,762
Loss from equity method investment 21,339 464,943
Loss on disposition of assets 93,421
Deferred income taxes (1,359,716) 302,399
Bad debt expense 47,862 79,700
Changes in assets and liabilities:    
Accounts receivable (871,083) (59,994)
Prepaid expenses 1,042,932 (114,473)
Inventory (3,088,944) 1,797,581
Deferred revenue (150,000) (146,516)
Income taxes payable 2,745,803 1,128,438
Accounts payable, accrued expenses and other liabilities (641,604) (661,115)
Net cash provided by operating activities 7,805,838 12,269,955
Cash flows from investing activities    
Purchases of property and equipment (396,600) (139,558)
Proceeds from maturities of marketable investment securities 1,255,266 2,032,802
Investment in joint venture 500,000
Net cash provided by investing activities 858,666 2,393,244
Cash flows from financing activities    
Proceeds from exercise of options and warrants 150,001 148,981
Net cash provided by financing activities 150,001 148,981
Net increase in cash and cash equivalents 8,814,505 14,812,180
Cash and cash equivalents at beginning of period 88,607,234 42,976,713
Cash and cash equivalents at end of period 97,421,739 57,788,893
Supplemental disclosure of cash flow information    
Interest paid
Income taxes paid
Supplemental disclosure of non-cash investing and financing transactions    
Inventory moved to property, plant and equipment 192,056
Right-of-use assets obtained in exchange for new operating lease liabilities $ 681,327
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
Convertible Preferred Stock [Member]
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2020 $ 28,558 $ 49,157,236 $ 17,510,715 $ 66,696,509
Beginning balance, shares at Dec. 31, 2020   28,558,033      
Common stock issued for option exercises $ 66 148,914 148,980
Common stock issued for option exercises, shares   65,891      
Stock-based compensation $ 42 1,512,970 1,513,012
Stock-based compensation expense, shares   73,040      
Net income 7,898,975 7,898,975
Ending balance, value at Mar. 31, 2021 $ 28,666 50,819,120 25,409,690 76,257,476
Ending balance, shares at Mar. 31, 2021   28,696,964      
Beginning balance, value at Dec. 31, 2021 $ 33,820 80,271,999 54,169,279 134,475,098
Beginning balance, shares at Dec. 31, 2021   33,819,862      
Common stock issued for option exercises $ 45 49,956 50,001
Common stock issued for option exercises, shares   45,456      
Common stock issued for warrant exercises $ 50 99,950   100,000
Common stock issued for warrant exercises, shares   50,000      
Stock-based compensation $ 69 1,375,028 1,375,097
Stock-based compensation expense, shares   68,750      
Net income 11,714,595 11,714,595
Ending balance, value at Mar. 31, 2022 $ 33,984 $ 81,796,933 $ 65,883,874 $ 147,714,791
Ending balance, shares at Mar. 31, 2022   33,984,068      
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Overview and Basis of Presentation
 3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Overview and Basis of Presentation

Note 1 – Overview and Basis of Presentation

 

Description of Business

 

Co-Diagnostics, Inc., a Utah corporation (the “Company”, “Co-Dx” or “CODX”), develops, manufactures and sells reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including robust and innovative molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. In connection with the sale of our tests we may sell diagnostic equipment from other manufacturers as self-contained lab systems (which we refer to as the “MDx Device”). We are also developing a unique, groundbreaking portable PCR testing platform (the “Co-Dx PCR home testing platform”) designed to bring affordable, reliable gold-standard polymerase chain reaction (“PCR”) to patients in point-of-care and even at-home settings.

 

Unaudited Consolidated Financial Statements

 

The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q as they are prescribed for smaller reporting companies and emerging growth companies. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to make the financial statements not misleading have been included. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. These statements should be read in conjunction with the Company’s audited financial statements and related notes for the year ended December 31, 2021, included in the Company’s Annual Report on Form 10-K filed on March 24, 2022.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Such estimates include receivables and other long-lived assets, legal and regulatory contingencies, income taxes, share based arrangements, and others. These estimates and assumptions are based on management’s best estimates and judgments. Actual amounts and results could differ from those estimates.

 
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies
 3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 2 – Summary of Significant Accounting Policies

 

Cash and Cash Equivalents

 

Cash and cash equivalents consist of cash on hand, money market funds and highly liquid investments with an original maturity date of 90 days or less from the date of purchase. The fair value of cash equivalents approximated their carrying value as of March 31, 2022 and December 31, 2021. The Company has its cash and cash equivalents with a large creditworthy financial institution and the balance exceeded federally insured limits. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on cash and cash equivalents.

 

Marketable Investment Securities

 

The Company’s marketable investment securities are comprised of investments in certificates of deposit. The Company determines the appropriate classification of its marketable investment securities at the time of purchase and reevaluates such designation at each balance sheet date. The Company has classified and accounted for its marketable investment securities as available-for-sale securities as the Company may sell these securities at any time for use in its current operations or for other purposes, even prior to maturity. As a result, the Company classifies its marketable investment securities, including securities with stated maturities beyond twelve months, within current assets in the consolidated balance sheets. Any unrealized gains or losses are immaterial.

 

 

Accounts Receivable

 

Trade accounts receivable are recorded at the invoiced amount (net of allowance) and do not bear interest. The Company maintains an allowance for doubtful accounts for amounts the Company does not expect to collect. In establishing the required allowance, management considers historical losses, current market condition, customers’ financial condition, the age of receivables, and current payment patterns. Account balances are written off against the allowance once the receivable is deemed uncollectible. Recoveries of trade receivables previously written off are recorded when collected. At March 31, 2022, total accounts receivable was $22,379,861 with an allowance for uncollectable accounts of $717,458 resulting in a net amount of $21,662,403. At December 31, 2021, total accounts receivable was $21,508,779 with an allowance for uncollectable accounts of $669,597 resulting in a net amount of $20,839,182.

 

Equity-Method Investments

 

Our equity method investments are initially recorded at cost and are included in other long-term assets in the accompanying consolidated balance sheet. We adjust the carrying value of our investment based on our share of the earnings or losses in the periods which they are reported by the investee until the carrying amount is zero. The earnings or losses are included in other income (expense) in the accompanying consolidated statements of operations.

 

Inventory

 

Inventory is stated at the lower of cost or net-realizable value. Inventory cost is determined on a first-in first-out basis that approximates average cost in accordance with ASC 330-10-30-12. At March 31, 2022, the Company had $4,901,057 in inventory, of which $4,119,549 was finished goods and $781,508 was raw materials. At December 31, 2021, the Company had $2,004,169 in inventory, of which $983,088 was finished goods and $1,021,081 was raw materials. The Company establishes reserves to reduce slow-moving, obsolete, or unusable inventories to their estimated useful or scrap values.

 

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the property, generally from three to five years. Repairs and maintenance costs are expensed as incurred except when such repairs significantly add to the useful life or productive capacity of the asset, in which case the repairs are capitalized.

 

The Company reviews its long-lived assets, including property and equipment, for impairment whenever an event or change in facts and circumstances indicates that their carrying amounts may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated. If the carrying amount exceeds the undiscounted cash flows, the assets are determined to be impaired and an impairment charge is recognized as the amount by which the carrying amount exceeds fair value.

 

Business Combinations

 

We estimate the fair value of assets acquired and liabilities assumed in a business combination. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable, and as a result, actual results may differ from estimates.

 

Leases

 

As described in “Recently Adopted Accounting Standards” below, the Company adopted ASC 842, Leases (“ASC 842”) effective January 1, 2022. Under ASC 842, the Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (ROU) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.

 

As the implicit rate in the Company’s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The Company considers its credit risk, term of the lease, total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. Lease costs for the Company’s operating leases are recognized on a straight-line basis within operating expenses and cost of revenue over the reasonably assured lease term.

 

The Company has elected to not separate lease and non-lease components for leases of office space and, as a result, accounts for any lease and non-lease components for office space as a single lease component, to the extent they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease payments. The Company’s office leases typically include non-lease components such as common-area maintenance costs. The Company has also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less.

 

Revenue Recognition

 

The Company generates revenue from product sales and license sales. The Company recognizes revenue when all of the following criteria are satisfied: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as the Company satisfies each performance obligation.

 

 

The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as deferred revenue.

 

Deferred Revenue

 

Deferred revenue primarily consists of payments received from customers prior to the Company fulfilling its performance obligation of providing the product. When this occurs, the Company records a contract liability as deferred revenue. Deferred revenue is recognized as revenue as the related performance obligations are satisfied.

 

Research and Development

 

Research and development costs are expensed when incurred. For the three months ended March 31, 2022, the Company expensed $3,771,327 of research and development costs, respectively. For the three months ended March 31, 2021, the Company expensed $2,217,063.

 

Stock-based Compensation

 

The Company has granted stock-based awards, including restricted stock, stock options, stock warrants and restricted stock units (“RSUs”), to its employees, certain consultants and members of its board of directors. The Company records stock-based compensation based on the grant date fair value of the awards and recognizes the fair value of those awards as expense using the straight-line method over the requisite service period of the award. The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model. When an award is forfeited prior to the vesting date, the Company recognizes an adjustment for the previously recognized expense in the period of the forfeiture.

 

Income Taxes

 

The Company accounts for income taxes in accordance with the liability method of accounting for income taxes. Under this method, deferred income tax assets and deferred income tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at enacted tax rates in effect for the year in which the differences are expected to reverse. The Company recognizes only the impact of tax positions that, based on their technical merits, are more likely than not to be sustained upon an audit by the taxing authority.

 

Valuation allowances are provided when it is more-likely-than-not that some or all of the deferred income tax assets may not be realized. In assessing the need for a valuation allowance, the Company has considered its historical levels of income, expectations of future taxable income and ongoing tax planning strategies.

 

Developing the provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred income tax assets and liabilities and any estimated valuation allowances deemed necessary to value deferred income tax assets. Judgments and tax strategies are subject to audit by various taxing authorities. While the Company believes it has no significant uncertain income tax positions in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial positions, result of operations, or cash flows.

 

Net Income per Share

 

Basic net income or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted average number of shares outstanding during each period.

 

Diluted net income or loss per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period increased by common shares that could be issued upon conversion or exercise of other outstanding securities to the extent those additional common shares would be dilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income or loss per share by application of the treasury stock method. During periods when the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the effects of potentially dilutive securities are anti-dilutive.

 

Concentrations Risk and Significant Customers

 

The Company had certain customers which are each responsible for generating 10% or more of the total revenue for the three months ended March 31, 2022. Three customers together accounted for approximately 54% and 57% of total revenue for the three months ended March 31, 2022 and March 31, 2021, respectively.

 

Two customers each accounted for more than 10% of accounts receivable at March 31, 2022 and December 31, 2021. These two customers together accounted for approximately 62% and 66% of accounts receivable at March 31, 2022 and December 31, 2021, respectively.

 

 

Recent Accounting Pronouncements

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.

 

Recently Adopted Accounting Standards

 

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) (“ASU 2016-13”), which requires the measurement and recognition of expected credit losses for certain financial instruments, which includes the Company’s accounts receivable. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. The Company adopted ASU 2016-13 on January 1, 2022. The adoption did not have an impact on the Company’s financial statements.

 

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which requires a lessee to recognize most leases on the balance sheet as lease liabilities with corresponding right-of-use assets. The objective of ASU 2016-02 is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The recognized lease liabilities and lease assets represent the obligation to make payments and the right to use or control the use of a specified asset for the lease term, respectively.

 

On January 1, 2022, the Company adopted Topic 842 using the modified retrospective approach with the effective date as the date of initial application. Consequently, results for the three months ended March 31, 2022 are presented under Topic 842. No prior period amounts were adjusted and continue to be reported in accordance with previous lease guidance, ASC Topic 840, Leases. The Company elected the practical expedients available under the provisions of the new standard, including not reassessing whether expired or existing contracts are or contain leases; not reassessing the classification of expired or existing leases; and not reassessing the initial direct cost for any existing leases. Upon adoption, the Company recognized an operating lease liability of $626,699 and a corresponding operating right-of-use asset of $681,327.

 
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.1
Business Combinations
 3 Months Ended
Mar. 31, 2022
Business Combination and Asset Acquisition [Abstract]  
Business Combinations

Note 3 – Business Combinations

 

On December 31, 2021, the Company completed its acquisition of Advanced Conceptions, Inc. (“ACI”) and Idaho Molecular Inc. (“IdMo”), which were related entities developing, with the Company, an at-home/point-of-care medical diagnostic device. Upon the completion of the acquisition, all outstanding ACI and Idaho Molecular common stock was exchanged for approximately 3.2 million shares of the Company’s common stock and contingent consideration that includes up to approximately 1.4 million shares and approximately 456,000 warrants to purchase shares of the Company’s common stock. The contingent consideration is based on the achievement of certain milestones, which include regulatory approval for identified products, as well as production and net revenue targets. Upon the completion of the acquisition, both ACI and IdMo became 100% wholly-owned subsidiaries of the Company.

 
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Goodwill and Intangible Assets
 3 Months Ended
Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets

Note 4 – Goodwill and Intangible Assets

 

Goodwill

 

Goodwill represents the excess of purchase price and related costs over the value assigned to net tangible and identifiable intangible assets acquired in business combinations. The following table presents the changes in the carrying amount of goodwill for the three months ended March 31, 2022:

 

Balance as of December 31, 2021  $14,706,818 
Measurement period adjustments   101,593 
Balance as of March 31, 2022  $14,808,411 

 

Intangible Assets, Net

 

The following table presents details of the Company’s intangible assets, excluding goodwill:

 

   Weighted-Average  Gross       Net 
   Useful Life (1)  Carrying   Accumulated   Carrying 
   (in Years)  Amount   Amortization   Amount 
In-process research and development  Indefinite  $26,101,000   $-   $26,101,000 
Non-competition agreements  2.7   1,094,000    (106,667)   987,333 
Total intangible assets     $27,195,000   $(106,667)  $27,088,333 

 

   Weighted-Average  Gross       Net 
   Useful Life (1)  Carrying   Accumulated   Carrying 
   (in Years)  Amount   Amortization   Amount 
In-process research and development  Indefinite  $26,101,000   $              -   $26,101,000 
Non-competition agreements  2.7   1,094,000    -    1,094,000 
Total intangible assets     $27,195,000   $-   $27,195,000 

 

(1)Based on weighted-average useful life established as of the acquisition date.

 
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value Measurements
 3 Months Ended
Mar. 31, 2022
Fair Value Disclosures [Abstract]  
Fair Value Measurements

Note 5 – Fair Value Measurements

 

The Company measures and records certain financial assets at fair value on a recurring basis. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

 

The Company’s financial instruments that are measured at fair value on a recurring basis consist of money market funds. The following three levels of inputs are used to measure the fair value of financial instruments:

 

Level 1: Quoted market prices in active markets for identical assets or liabilities.

 

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

 

Level 3: Unobservable inputs that are not corroborated by market data.

 

 

The following table summarizes the assets measured at fair value on a recurring basis as of March 31, 2022, and December 31, 2021, by level within the fair value hierarchy:

 

   (Level 1)   (Level 2)   (Level 3)   Total 
   March 31, 2022 
   (Level 1)   (Level 2)   (Level 3)   Total 
Liabilities:                    
Contingent consideration - common stock  $      -   $     -   $6,013,939   $6,013,939 
Contingent consideration - warrants   -    -    1,038,812    1,038,812 
Total liabilities measured at fair value  $-   $-   $7,052,751   $7,052,751 

 

   (Level 1)   (Level 2)   (Level 3)   Total 
   December 31, 2021 
   (Level 1)   (Level 2)   (Level 3)   Total 
Assets:                    
Marketable securities (certificates of deposit)  $     -   $1,255,266   $-   $1,255,266 
Total assets measured at fair value  $-   $1,255,266   $-   $1,255,266 
Liabilities:                    
Contingent consideration - common stock  $-   $-   $8,684,669   $8,684,669 
Contingent consideration - warrants   -    -    1,747,972    1,747,972 
Total liabilities measured at fair value  $-   $-   $10,432,641   $10,432,641 

 

The Company’s financial instruments that are measured at fair value on a recurring basis consist of certificates of deposit.

 

The changes for Level 3 items measured at fair value on a recurring basis are as follows:

 

      
Fair value as of December 31, 2021  $10,432,641 
Change in fair value of contingent consideration issued for business acquisitions   (3,379,890)
Fair value as of March 31, 2022  $7,052,751 

 

The fair value of the contingent consideration is based on the fair value of the contingent consideration-common stock and contingent consideration-warrants. The fair value of the contingent consideration-common stock is equal to the probability-adjusted value of the Company’s common stock as of March 31, 2022. The fair value of the contingent consideration-warrants is equal to the probability adjusted value of a call option with terms consistent with the terms of the warrants as of March 31, 2022. Prior to the probability adjustments, the warrants were valued based on the following inputs:

 

  

March 31, 2022

   December 31, 2021 
Stock price  $6.18   $8.93 
Strike price  $9.13   $9.13 
Volatility   77.50%   80.00%
Risk-free rate   2.40%   1.30%
Expected term   4.8    5.0 

 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue
 3 Months Ended
Mar. 31, 2022
Revenue from Contract with Customer [Abstract]  
Revenue

Note 6 – Revenue

 

The following table sets forth revenue by geographic area:

 

   Three Months Ended March 31, 
   2022   2021 
United States  $14,218,398   $12,493,950 
Rest of World   8,480,646    7,530,819 
Total  $22,699,044   $20,024,769 
Percentage of revenue by area:          
United States   63%   62%
Rest of World   37%   38%

 

Deferred Revenue

 

Changes in the Company’s deferred revenue balance for the three months ended March 31, 2022 were as follows:

 

Balance as of December 31, 2021  $150,000 
Revenue recognized included in deferred revenue balance at the beginning of the period   (150,000)
Balance as of March 31, 2022  $- 

 

 
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.1
Earnings Per Share
 3 Months Ended
Mar. 31, 2022
Earnings Per Share [Abstract]  
Earnings Per Share

Note 7 – Earnings Per Share

 

The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share for three months ended March 31, 2022:

 

   2022   2021 
   Three Months Ended March 31, 
   2022   2021 
Numerator          
Net income, as reported  $11,714,595   $7,898,975 
           
Denominator          
Weighted average shares, basic   33,935,570    28,662,885 
Dilutive effect of stock options, warrants and RSUs   775,906    1,339,844 
Shares used to compute diluted earnings per share   34,711,476    30,002,729 
           
Basic earnings per share  $0.35   $0.28 
Diluted earnings per share  $0.34   $0.26 

 

For the three months ended March 31, 2022, potentially dilutive securities of 1,271,304 were excluded from the calculation because their effect would have been anti-dilutive. For the three months ended March 31, 2021, potentially dilutive securities of 2,320,907 were excluded from the calculation because their effect would have been anti-dilutive. The computation of diluted earnings per share for the three months ended March 31, 2022 also excludes the approximately 1.4 million shares of common stock and approximately 456,000 warrants to purchase shares of common stock that are contingent upon the achievement of certain milestones.

 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation
 3 Months Ended
Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation

Note 8 – Stock-Based Compensation

 

Stock Incentive Plans

 

The Co-Diagnostics, Inc. Amended and Restated 2015 Long Term Incentive Plan (the “Incentive Plan”) reserves an aggregate of 6,000,000 shares of common stock issuable upon the grant of awards under the Incentive Plan. The number of awards available for issuance under the Incentive Plan was 2,095,266 at March 31, 2022.

 

Stock Options

 

The following table summarizes option activity during the three months ended March 31, 2022:

 

   Number of Options   Weighted Average Exercise Price   Weighted Average Fair Value   Weighted Average Remaining Contractual Life (Years) 
Outstanding at December 31, 2021   1,111,363   $2.12   $1.31    6.62 
Granted   -    -    -      
Expired   -    -    -      
Forfeited/Cancelled   -    -    -      
Exercised   (45,456)   1.10    0.51      
Outstanding at March 31, 2022   1,065,907   $2.17   $1.35    6.65 
                     
Exercisable at March 31, 2022   1,049,241   $2.05   $1.21    6.63 

 

The total intrinsic value of options exercised during the three months ended March 31, 2022 was approximately $0.3 million. The aggregate intrinsic value of outstanding options at March 31, 2022 was approximately $4.5 million.

 

 

Stock-based compensation cost is measured at the grant date based on the fair value of the award granted and recognized as expense over the vesting period using the straight-line method. The Company uses the Black-Scholes model to value options granted.

 

As of March 31, 2022, there were 16,666 of unvested options and $37,241 of unrecognized stock-based compensation expense. The unrecognized stock-based compensation expense is expected to be recognized over 0.2 years.

 

Restricted Stock Units

 

The grant date fair value of RSUs granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the awards. The following table sets forth the outstanding RSUs and related activity for the three months ended March 31, 2022:

 

   Number of RSUs   Weighted Average Grant Date Fair Value 
Unvested at December 31, 2021   1,267,415   $9.94 
Granted   -    - 
Vested   (68,750)   10.23 
Forfeited/Cancelled   -    - 
Unvested at March 31, 2022   1,198,665   $9.92 

 

As of March 31, 2022, there was approximately $10.3 million of unrecognized stock-based compensation expense related to outstanding RSUs which is expected to be recognized over a weighted-average period of 2.1 years.

 

Warrants

 

The Company has issued warrants related to financings, acquisitions and as compensation to third parties for services provided. The Company estimates the fair value of issued warrants on the date of issuance as determined using a Black-Scholes pricing model. The Company amortizes the fair value of issued warrants using a vesting schedule based on the terms and conditions of each warrant if granted for services.

 

The following table summarizes warrant activity during the three months ended March 31, 2022:

 

   Number of Warrants   Weighted Average Exercise Price   Weighted Average Fair Value   Weighted Average Remaining Contractual Life (Years) 
Outstanding at December 31, 2021   526,281   $8.15   $4.01    4.7 
Granted   -    -    -      
Expired   -    -    -      
Forfeited/Cancelled   -    -    -      
Exercised   (50,000)   2.00    1.22      
Outstanding at March 31, 2022   476,281   $8.80   $2.82    4.8 

 

 

The intrinsic value of warrants exercised during the three months ended March 31, 2022 and 2021 was approximately $0.3 million and $0, respectively. The aggregate intrinsic value of outstanding warrants at March 31, 2022 was approximately $0.1 million.

 

The total number of warrants exercisable at March 31, 2022 are 20,000. The ability to exercise the approximately 456,000 warrants issued in connection with acquisitions in the prior year is contingent upon the achievement of certain development and revenue milestones on or before January 1, 2027. There was no unrecognized stock-based compensation expense related to warrants.

 

Stock Issued for Services

 

The Company has issued restricted stock to third parties for services provided. The grant date fair value of the restricted stock granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the stock awards. The Company issued 0 and 4,290 shares of restricted stock for services during the three months ended March 31, 2022 and 2021, respectively. There was no unrecognized stock-based compensation expense related to restricted stock issued.

 

Stock-Based Compensation Expense

 

The Company recognized stock-based compensation expense related to the types of awards discussed above as follows:

 

   2022   2021 
   Three Months Ended March 31, 
   2022   2021 
Options  $40,874   $76,672 
Restricted stock units   1,334,223    1,396,440 
Stock   -    39,900 
Total stock-based compensation expense  $1,375,097   $1,513,012 

 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes
 3 Months Ended
Mar. 31, 2022
Income Tax Disclosure [Abstract]  
Income Taxes

Note 9 – Income Taxes

 

For the three months ended March 31, 2022, the Company recognized expense from income taxes of $1,386,087, representing an effective tax rate of 10.6%. The Company’s effective tax rate will generally differ from the U.S. Federal statutory rate of 21.0% due to state taxes, permanent items, and discrete items. For the three months ended March 31, 2021, the Company recognized expense from income taxes of $1,985,640.

 
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Related Party Transactions
 3 Months Ended
Mar. 31, 2022
Related Party Transactions [Abstract]  
Related Party Transactions

Note 10 – Related Party Transactions

 

The Company acquired the exclusive rights to the CoPrimer technology pursuant to an exclusive license agreement, dated April 2014 (the “Exclusive License Agreement”), between the Company and DNA Logix, Inc., which was assigned to Dr. Brent Satterfield, a former executive officer, prior to the Company’s acquisition of DNA Logix, Inc. On March 1, 2017, the Company entered into an amendment to its Exclusive License Agreement for its Cooperative Primers (“License”) technology with Dr. Satterfield. The amendment provides in part that all accrued royalties under the License cease as of January 1, 2017, and the Company began in January 2017 to pay to Dr. Satterfield $700,000 of accrued royalties at the rate of $10,000 per month. At March 31, 2022 and 2021, the aggregate balance of this related party liability was $0 and $120,000, respectively.

 

 
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.1
Leases
 3 Months Ended
Mar. 31, 2022
Leases  
Leases

Note 11 – Leases

 

The Company leases office space under a non-cancelable operating lease and leases cancellable with one month notice. The Company expenses the cancellable leases in the period incurred in accordance with the practical expedient elected. As such, one lease makes up the entirety of the right-of-use asset and lease liability disclosed.

 

For the three months ended March 31, 2022, components of lease expense are summarized as follows:

 

   Three Months Ended March 31, 2022 
Operating lease costs  $86,588 
Short-term lease costs   76,080 
Total lease costs  $162,668 

 

Short-term lease costs under month-to-month lease agreements are paid to related parties.

 

As of March 31, 2022, the maturities of the Company’s lease liabilities are as follows:

 

  

Year Ending

December 31,

 
2022 (remainder)  $221,350 
2023   303,059 
2024   50,774 
2025   - 
2026   - 
Thereafter   - 
Total lease payments   575,183 
Less: imputed interest   16,212 
Present value of operating lease liabilities   558,971 
Less: current portion   283,299 
Long-term portion  $275,672 

 

Other information related to operating leases was as follows:

 

   Three Months Ended March 31, 2022 
Cash paid for operating leases included in operating cash flows  $154,882 
Remaining lease term of operating leases   2 years 
Discount rate of operating leases   3.1%

 

As previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021, future lease payments under ASC 840 for operating leases were as follows:

 

Year Ending December 31,    
2022  $293,595 
2023   303,059 
2024   50,774 
Total lease payments  $647,428 

 
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies
 3 Months Ended
Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 12 – Commitments and Contingencies

 

Litigation

 

Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.

 

The Company is currently a defendant in five different securities class action complaints that were filed by certain stockholders of the Company claiming that the Company promulgated false and misleading press releases to increase the price of our stock to improperly benefit the officers and directors of the Company. The plaintiffs demand compensatory damages sustained as a result of the Company’s alleged wrongdoing in an amount to be proven at trial. The Company believes these lawsuits are without merit and intends to defend the cases vigorously. The Company is unable to estimate a range of loss, if any, that could result were there to be an adverse final decision in these cases. As of the date of this report, the Company does not believe it is probable that these cases will result in an unfavorable outcome; however, if an unfavorable outcome were to occur in these cases, it is possible that the impact could be material to the Company’s results of operations in the period(s) in which any such outcome becomes probable and estimable.

 
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Share Repurchase Program
 3 Months Ended
Mar. 31, 2022
Equity [Abstract]  
Share Repurchase Program

Note 13 – Share Repurchase Program

 

In March 2022, the Company’s Board of Directors authorized a share repurchase program that would allow the Company to repurchase up to $30.0 million of CODX common stock. The repurchase program does not obligate the Company to acquire any particular amount of common shares, and the repurchase program may be suspended or discontinued at any time at the Company’s discretion. The timing and amount of any share repurchases under the share repurchase program will be determined by Co-Diagnostics’ management at its discretion based on ongoing assessments of the capital needs of the business, the market price of the Company’s common stock, corporate and regulatory requirements, and general market conditions.

 

The Company has not made any repurchases under the share purchase program since its implementation.

 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Subsequent Events
 3 Months Ended
Mar. 31, 2022
Subsequent Events [Abstract]  
Subsequent Events

Note 14 – Subsequent Events

 

The Company evaluated subsequent events pursuant to ASC Topic 855 and has determined that there are no events that need to be reported.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Cash and Cash Equivalents

Cash and Cash Equivalents

 

Cash and cash equivalents consist of cash on hand, money market funds and highly liquid investments with an original maturity date of 90 days or less from the date of purchase. The fair value of cash equivalents approximated their carrying value as of March 31, 2022 and December 31, 2021. The Company has its cash and cash equivalents with a large creditworthy financial institution and the balance exceeded federally insured limits. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on cash and cash equivalents.

 
Marketable Investment Securities

Marketable Investment Securities

 

The Company’s marketable investment securities are comprised of investments in certificates of deposit. The Company determines the appropriate classification of its marketable investment securities at the time of purchase and reevaluates such designation at each balance sheet date. The Company has classified and accounted for its marketable investment securities as available-for-sale securities as the Company may sell these securities at any time for use in its current operations or for other purposes, even prior to maturity. As a result, the Company classifies its marketable investment securities, including securities with stated maturities beyond twelve months, within current assets in the consolidated balance sheets. Any unrealized gains or losses are immaterial.

 

 
Accounts Receivable

Accounts Receivable

 

Trade accounts receivable are recorded at the invoiced amount (net of allowance) and do not bear interest. The Company maintains an allowance for doubtful accounts for amounts the Company does not expect to collect. In establishing the required allowance, management considers historical losses, current market condition, customers’ financial condition, the age of receivables, and current payment patterns. Account balances are written off against the allowance once the receivable is deemed uncollectible. Recoveries of trade receivables previously written off are recorded when collected. At March 31, 2022, total accounts receivable was $22,379,861 with an allowance for uncollectable accounts of $717,458 resulting in a net amount of $21,662,403. At December 31, 2021, total accounts receivable was $21,508,779 with an allowance for uncollectable accounts of $669,597 resulting in a net amount of $20,839,182.

 
Equity-Method Investments

Equity-Method Investments

 

Our equity method investments are initially recorded at cost and are included in other long-term assets in the accompanying consolidated balance sheet. We adjust the carrying value of our investment based on our share of the earnings or losses in the periods which they are reported by the investee until the carrying amount is zero. The earnings or losses are included in other income (expense) in the accompanying consolidated statements of operations.

 
Inventory

Inventory

 

Inventory is stated at the lower of cost or net-realizable value. Inventory cost is determined on a first-in first-out basis that approximates average cost in accordance with ASC 330-10-30-12. At March 31, 2022, the Company had $4,901,057 in inventory, of which $4,119,549 was finished goods and $781,508 was raw materials. At December 31, 2021, the Company had $2,004,169 in inventory, of which $983,088 was finished goods and $1,021,081 was raw materials. The Company establishes reserves to reduce slow-moving, obsolete, or unusable inventories to their estimated useful or scrap values.

 
Property and Equipment

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the property, generally from three to five years. Repairs and maintenance costs are expensed as incurred except when such repairs significantly add to the useful life or productive capacity of the asset, in which case the repairs are capitalized.

 

The Company reviews its long-lived assets, including property and equipment, for impairment whenever an event or change in facts and circumstances indicates that their carrying amounts may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated. If the carrying amount exceeds the undiscounted cash flows, the assets are determined to be impaired and an impairment charge is recognized as the amount by which the carrying amount exceeds fair value.

 
Business Combinations

Business Combinations

 

We estimate the fair value of assets acquired and liabilities assumed in a business combination. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable, and as a result, actual results may differ from estimates.

 
Leases

Leases

 

As described in “Recently Adopted Accounting Standards” below, the Company adopted ASC 842, Leases (“ASC 842”) effective January 1, 2022. Under ASC 842, the Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (ROU) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.

 

As the implicit rate in the Company’s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The Company considers its credit risk, term of the lease, total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. Lease costs for the Company’s operating leases are recognized on a straight-line basis within operating expenses and cost of revenue over the reasonably assured lease term.

 

The Company has elected to not separate lease and non-lease components for leases of office space and, as a result, accounts for any lease and non-lease components for office space as a single lease component, to the extent they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease payments. The Company’s office leases typically include non-lease components such as common-area maintenance costs. The Company has also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less.

 
Revenue Recognition

Revenue Recognition

 

The Company generates revenue from product sales and license sales. The Company recognizes revenue when all of the following criteria are satisfied: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as the Company satisfies each performance obligation.

 

 

The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as deferred revenue.

 
Deferred Revenue

Deferred Revenue

 

Deferred revenue primarily consists of payments received from customers prior to the Company fulfilling its performance obligation of providing the product. When this occurs, the Company records a contract liability as deferred revenue. Deferred revenue is recognized as revenue as the related performance obligations are satisfied.

 
Research and Development

Research and Development

 

Research and development costs are expensed when incurred. For the three months ended March 31, 2022, the Company expensed $3,771,327 of research and development costs, respectively. For the three months ended March 31, 2021, the Company expensed $2,217,063.

 
Stock-based Compensation

Stock-based Compensation

 

The Company has granted stock-based awards, including restricted stock, stock options, stock warrants and restricted stock units (“RSUs”), to its employees, certain consultants and members of its board of directors. The Company records stock-based compensation based on the grant date fair value of the awards and recognizes the fair value of those awards as expense using the straight-line method over the requisite service period of the award. The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model. When an award is forfeited prior to the vesting date, the Company recognizes an adjustment for the previously recognized expense in the period of the forfeiture.

 
Income Taxes

Income Taxes

 

The Company accounts for income taxes in accordance with the liability method of accounting for income taxes. Under this method, deferred income tax assets and deferred income tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at enacted tax rates in effect for the year in which the differences are expected to reverse. The Company recognizes only the impact of tax positions that, based on their technical merits, are more likely than not to be sustained upon an audit by the taxing authority.

 

Valuation allowances are provided when it is more-likely-than-not that some or all of the deferred income tax assets may not be realized. In assessing the need for a valuation allowance, the Company has considered its historical levels of income, expectations of future taxable income and ongoing tax planning strategies.

 

Developing the provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred income tax assets and liabilities and any estimated valuation allowances deemed necessary to value deferred income tax assets. Judgments and tax strategies are subject to audit by various taxing authorities. While the Company believes it has no significant uncertain income tax positions in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial positions, result of operations, or cash flows.

 
Net Income per Share

Net Income per Share

 

Basic net income or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted average number of shares outstanding during each period.

 

Diluted net income or loss per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period increased by common shares that could be issued upon conversion or exercise of other outstanding securities to the extent those additional common shares would be dilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income or loss per share by application of the treasury stock method. During periods when the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the effects of potentially dilutive securities are anti-dilutive.

 
Concentrations Risk and Significant Customers

Concentrations Risk and Significant Customers

 

The Company had certain customers which are each responsible for generating 10% or more of the total revenue for the three months ended March 31, 2022. Three customers together accounted for approximately 54% and 57% of total revenue for the three months ended March 31, 2022 and March 31, 2021, respectively.

 

Two customers each accounted for more than 10% of accounts receivable at March 31, 2022 and December 31, 2021. These two customers together accounted for approximately 62% and 66% of accounts receivable at March 31, 2022 and December 31, 2021, respectively.

 

 
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.

 
Recently Adopted Accounting Standards

Recently Adopted Accounting Standards

 

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) (“ASU 2016-13”), which requires the measurement and recognition of expected credit losses for certain financial instruments, which includes the Company’s accounts receivable. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. The Company adopted ASU 2016-13 on January 1, 2022. The adoption did not have an impact on the Company’s financial statements.

 

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which requires a lessee to recognize most leases on the balance sheet as lease liabilities with corresponding right-of-use assets. The objective of ASU 2016-02 is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The recognized lease liabilities and lease assets represent the obligation to make payments and the right to use or control the use of a specified asset for the lease term, respectively.

 

On January 1, 2022, the Company adopted Topic 842 using the modified retrospective approach with the effective date as the date of initial application. Consequently, results for the three months ended March 31, 2022 are presented under Topic 842. No prior period amounts were adjusted and continue to be reported in accordance with previous lease guidance, ASC Topic 840, Leases. The Company elected the practical expedients available under the provisions of the new standard, including not reassessing whether expired or existing contracts are or contain leases; not reassessing the classification of expired or existing leases; and not reassessing the initial direct cost for any existing leases. Upon adoption, the Company recognized an operating lease liability of $626,699 and a corresponding operating right-of-use asset of $681,327.
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.1
Goodwill and Intangible Assets (Tables)
 3 Months Ended
Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill

Balance as of December 31, 2021  $14,706,818 
Measurement period adjustments   101,593 
Balance as of March 31, 2022  $14,808,411 
Schedule of Intangible Assets, Net

The following table presents details of the Company’s intangible assets, excluding goodwill:

 

   Weighted-Average  Gross       Net 
   Useful Life (1)  Carrying   Accumulated   Carrying 
   (in Years)  Amount   Amortization   Amount 
In-process research and development  Indefinite  $26,101,000   $-   $26,101,000 
Non-competition agreements  2.7   1,094,000    (106,667)   987,333 
Total intangible assets     $27,195,000   $(106,667)  $27,088,333 

 

   Weighted-Average  Gross       Net 
   Useful Life (1)  Carrying   Accumulated   Carrying 
   (in Years)  Amount   Amortization   Amount 
In-process research and development  Indefinite  $26,101,000   $              -   $26,101,000 
Non-competition agreements  2.7   1,094,000    -    1,094,000 
Total intangible assets     $27,195,000   $-   $27,195,000 

 

(1)Based on weighted-average useful life established as of the acquisition date.

XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value Measurements (Tables)
 3 Months Ended
Mar. 31, 2022
Fair Value Disclosures [Abstract]  
Schedule of Fair Value Assets and Liabilities

The following table summarizes the assets measured at fair value on a recurring basis as of March 31, 2022, and December 31, 2021, by level within the fair value hierarchy:

 

   (Level 1)   (Level 2)   (Level 3)   Total 
   March 31, 2022 
   (Level 1)   (Level 2)   (Level 3)   Total 
Liabilities:                    
Contingent consideration - common stock  $      -   $     -   $6,013,939   $6,013,939 
Contingent consideration - warrants   -    -    1,038,812    1,038,812 
Total liabilities measured at fair value  $-   $-   $7,052,751   $7,052,751 

 

   (Level 1)   (Level 2)   (Level 3)   Total 
   December 31, 2021 
   (Level 1)   (Level 2)   (Level 3)   Total 
Assets:                    
Marketable securities (certificates of deposit)  $     -   $1,255,266   $-   $1,255,266 
Total assets measured at fair value  $-   $1,255,266   $-   $1,255,266 
Liabilities:                    
Contingent consideration - common stock  $-   $-   $8,684,669   $8,684,669 
Contingent consideration - warrants   -    -    1,747,972    1,747,972 
Total liabilities measured at fair value  $-   $-   $10,432,641   $10,432,641 
Schedule of Changes in Fair Value Measurement

The changes for Level 3 items measured at fair value on a recurring basis are as follows:

 

      
Fair value as of December 31, 2021  $10,432,641 
Change in fair value of contingent consideration issued for business acquisitions   (3,379,890)
Fair value as of March 31, 2022  $7,052,751 
Schedule of Contingent Consideration Common Stock and Warrants

The fair value of the contingent consideration is based on the fair value of the contingent consideration-common stock and contingent consideration-warrants. The fair value of the contingent consideration-common stock is equal to the probability-adjusted value of the Company’s common stock as of March 31, 2022. The fair value of the contingent consideration-warrants is equal to the probability adjusted value of a call option with terms consistent with the terms of the warrants as of March 31, 2022. Prior to the probability adjustments, the warrants were valued based on the following inputs:

 

  

March 31, 2022

   December 31, 2021 
Stock price  $6.18   $8.93 
Strike price  $9.13   $9.13 
Volatility   77.50%   80.00%
Risk-free rate   2.40%   1.30%
Expected term   4.8    5.0 
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue (Tables)
 3 Months Ended
Mar. 31, 2022
Revenue from Contract with Customer [Abstract]  
Summary of Revenue by Geographic Area

The following table sets forth revenue by geographic area:

 

   Three Months Ended March 31, 
   2022   2021 
United States  $14,218,398   $12,493,950 
Rest of World   8,480,646    7,530,819 
Total  $22,699,044   $20,024,769 
Percentage of revenue by area:          
United States   63%   62%
Rest of World   37%   38%
Schedule of Deferred Revenue

Changes in the Company’s deferred revenue balance for the three months ended March 31, 2022 were as follows:

 

Balance as of December 31, 2021  $150,000 
Revenue recognized included in deferred revenue balance at the beginning of the period   (150,000)
Balance as of March 31, 2022  $- 
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.1
Earnings Per Share (Tables)
 3 Months Ended
Mar. 31, 2022
Earnings Per Share [Abstract]  
Schedule of Basic and Diluted Earnings Per Share

The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share for three months ended March 31, 2022:

 

   2022   2021 
   Three Months Ended March 31, 
   2022   2021 
Numerator          
Net income, as reported  $11,714,595   $7,898,975 
           
Denominator          
Weighted average shares, basic   33,935,570    28,662,885 
Dilutive effect of stock options, warrants and RSUs   775,906    1,339,844 
Shares used to compute diluted earnings per share   34,711,476    30,002,729 
           
Basic earnings per share  $0.35   $0.28 
Diluted earnings per share  $0.34   $0.26 
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation (Tables)
 3 Months Ended
Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Option Activity

The following table summarizes option activity during the three months ended March 31, 2022:

 

   Number of Options   Weighted Average Exercise Price   Weighted Average Fair Value   Weighted Average Remaining Contractual Life (Years) 
Outstanding at December 31, 2021   1,111,363   $2.12   $1.31    6.62 
Granted   -    -    -      
Expired   -    -    -      
Forfeited/Cancelled   -    -    -      
Exercised   (45,456)   1.10    0.51      
Outstanding at March 31, 2022   1,065,907   $2.17   $1.35    6.65 
                     
Exercisable at March 31, 2022   1,049,241   $2.05   $1.21    6.63 
Schedule of Outstanding Restricted Stock Units and Related Activity

The grant date fair value of RSUs granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the awards. The following table sets forth the outstanding RSUs and related activity for the three months ended March 31, 2022:

 

   Number of RSUs   Weighted Average Grant Date Fair Value 
Unvested at December 31, 2021   1,267,415   $9.94 
Granted   -    - 
Vested   (68,750)   10.23 
Forfeited/Cancelled   -    - 
Unvested at March 31, 2022   1,198,665   $9.92 
Schedule of Warrant Activity

The following table summarizes warrant activity during the three months ended March 31, 2022:

 

   Number of Warrants   Weighted Average Exercise Price   Weighted Average Fair Value   Weighted Average Remaining Contractual Life (Years) 
Outstanding at December 31, 2021   526,281   $8.15   $4.01    4.7 
Granted   -    -    -      
Expired   -    -    -      
Forfeited/Cancelled   -    -    -      
Exercised   (50,000)   2.00    1.22      
Outstanding at March 31, 2022   476,281   $8.80   $2.82    4.8 
Schedule of Recognized Stock-based Compensation Expense

The Company recognized stock-based compensation expense related to the types of awards discussed above as follows:

 

   2022   2021 
   Three Months Ended March 31, 
   2022   2021 
Options  $40,874   $76,672 
Restricted stock units   1,334,223    1,396,440 
Stock   -    39,900 
Total stock-based compensation expense  $1,375,097   $1,513,012 
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.1
Leases (Tables)
 3 Months Ended
Mar. 31, 2022
Leases  
Schedule of Lease Expense

For the three months ended March 31, 2022, components of lease expense are summarized as follows:

 

   Three Months Ended March 31, 2022 
Operating lease costs  $86,588 
Short-term lease costs   76,080 
Total lease costs  $162,668 
Schedule of Maturities on Company Lease Liabilities

As of March 31, 2022, the maturities of the Company’s lease liabilities are as follows:

 

  

Year Ending

December 31,

 
2022 (remainder)  $221,350 
2023   303,059 
2024   50,774 
2025   - 
2026   - 
Thereafter   - 
Total lease payments   575,183 
Less: imputed interest   16,212 
Present value of operating lease liabilities   558,971 
Less: current portion   283,299 
Long-term portion  $275,672 
Schedule of Other Information Related to Operating Lease

Other information related to operating leases was as follows:

 

   Three Months Ended March 31, 2022 
Cash paid for operating leases included in operating cash flows  $154,882 
Remaining lease term of operating leases   2 years 
Discount rate of operating leases   3.1%
Schedule of Future Minimum Lease Payments

As previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021, future lease payments under ASC 840 for operating leases were as follows:

 

Year Ending December 31,    
2022  $293,595 
2023   303,059 
2024   50,774 
Total lease payments  $647,428 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Jan. 02, 2022
Product Information [Line Items]        
Accounts receivable $ 22,379,861   $ 21,508,779  
Doubtful accounts 717,458   669,597  
Accounts receivable, net 21,662,403   20,839,182  
Inventory 4,901,057   2,004,169  
Inventory finished goods 4,119,549   983,088  
Inventory raw materials 781,508   1,021,081  
Research and development 3,771,327 $ 2,217,063    
Operating lease liability 558,971      
Operating right use of asset $ 604,837    
Accounting Standards Update 2016-02 [Member]        
Product Information [Line Items]        
Operating lease liability       $ 626,699
Operating right use of asset       $ 681,327
Three Customers Together [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]        
Product Information [Line Items]        
Concentration risk percentage 54.00% 57.00%    
Two Customers Together [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]        
Product Information [Line Items]        
Concentration risk percentage 62.00%   66.00%  
Minimum [Member]        
Product Information [Line Items]        
Estimated useful life of property 3 years      
Maximum [Member]        
Product Information [Line Items]        
Estimated useful life of property 5 years      
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.1
Business Combinations (Details Narrative) - shares
Dec. 31, 2021
Mar. 31, 2022
Business Acquisition [Line Items]    
Warrants to purchase shares of common stock   456,000
Advanced Conceptions, Inc. and Idaho Molecular, Inc. [Member]    
Business Acquisition [Line Items]    
Number of shares exchanged 3,200,000  
Number of shares on contingent consideration 1,400,000  
Warrants to purchase shares of common stock 456,000  
Equity method investment ownership percentage 100.00%  
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Goodwill (Details)
 3 Months Ended
Mar. 31, 2022
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwil - beginning $ 14,706,818
Measurement period adjustments 101,593
Goodwill - Ending $ 14,808,411
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Intangible Assets, Net (Details) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, gross $ 27,195,000 $ 27,195,000
Less accumulated amortization (106,667)
Intangible assets, net $ 27,088,333 $ 27,195,000
In Process Research and Development [Member]    
Finite-Lived Intangible Assets [Line Items]    
Estimated useful lives in years, term [1] Indefinite Indefinite
Intangible assets, gross $ 26,101,000 $ 26,101,000
Less accumulated amortization
Intangible assets, net 26,101,000 26,101,000
Noncompete Agreements [Member]    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, gross 1,094,000 1,094,000
Less accumulated amortization (106,667)
Intangible assets, net $ 987,333 $ 1,094,000
Estimated useful lives in years [1] 2 years 8 months 12 days 2 years 8 months 12 days
[1] Based on weighted-average useful life established as of the acquisition date.
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Fair Value Assets and Liabilities (Details) - Fair Value, Recurring [Member] - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration - common stock $ 6,013,939 $ 8,684,669
Contingent consideration - warrants 1,038,812 1,747,972
Total liabilities measured at fair value 7,052,751 10,432,641
Marketable securities (certificates of deposit)   1,255,266
Total assets measured at fair value   1,255,266
Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration - common stock
Contingent consideration - warrants
Total liabilities measured at fair value
Marketable securities (certificates of deposit)  
Total assets measured at fair value  
Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration - common stock
Contingent consideration - warrants
Total liabilities measured at fair value
Marketable securities (certificates of deposit)   1,255,266
Total assets measured at fair value   1,255,266
Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration - common stock 6,013,939 8,684,669
Contingent consideration - warrants 1,038,812 1,747,972
Total liabilities measured at fair value $ 7,052,751 10,432,641
Marketable securities (certificates of deposit)  
Total assets measured at fair value  
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Changes in Fair Value Measurement (Details)
 3 Months Ended
Mar. 31, 2022
USD ($)
Fair Value Disclosures [Abstract]  
Fair value as of December 31, 2021 $ 10,432,641
Change in fair value of contingent consideration issued for business acquisitions (3,379,890)
Fair value as of March 31, 2022 $ 7,052,751
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Contingent Consideration Common Stock and Warrants (Details)
Mar. 31, 2022
Dec. 31, 2021
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Expected term 4 years 9 months 18 days 5 years
Measurement Input, Share Price [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants measurement input 6.18 8.93
Measurement Input Strike Price [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants measurement input 9.13 9.13
Measurement Input, Price Volatility [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants measurement input 77.50 80.00
Measurement Input, Risk Free Interest Rate [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants measurement input 2.40 1.30
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Revenue by Geographic Area (Details) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Disaggregation of Revenue [Line Items]    
Revenue $ 22,699,044 $ 20,024,769
Americas [Member]    
Disaggregation of Revenue [Line Items]    
Revenue $ 14,218,398 $ 12,493,950
Americas [Member] | Revenue Benchmark [Member] | Geographic Concentration Risk [Member]    
Disaggregation of Revenue [Line Items]    
Percentage of revenue 63.00% 62.00%
Rest of World [Member]    
Disaggregation of Revenue [Line Items]    
Revenue $ 8,480,646 $ 7,530,819
Rest of World [Member] | Revenue Benchmark [Member] | Geographic Concentration Risk [Member]    
Disaggregation of Revenue [Line Items]    
Percentage of revenue 37.00% 38.00%
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Deferred Revenue (Details)
 3 Months Ended
Mar. 31, 2022
USD ($)
Revenue from Contract with Customer [Abstract]  
Deferred revenue, beginning balance $ 150,000
Revenue recognized included in deferred revenue balance at the beginning of the period (150,000)
Deferred revenue, Ending balance
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Basic and Diluted Earnings Per Share (Details) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Earnings Per Share [Abstract]    
Net income, as reported $ 11,714,595 $ 7,898,975
Weighted average shares, basic 33,935,570 28,662,885
Dilutive effect of stock options, warrants and RSUs 775,906 1,339,844
Shares used to compute diluted earnings per share 34,711,476 30,002,729
Basic earnings per share $ 0.35 $ 0.28
Diluted earnings per share $ 0.34 $ 0.26
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.1
Earnings Per Share (Details Narrative) - shares
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Securities excluded from computation of diluted earnings per share 1,271,304 2,320,907
Common Stock [Member]    
Securities excluded from computation of diluted earnings per share 1,400,000  
Warrant [Member]    
Securities excluded from computation of diluted earnings per share 456,000  
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Option Activity (Details)
 3 Months Ended
Mar. 31, 2022
$ / shares
shares
Share-Based Payment Arrangement [Abstract]  
Number of Options Outstanding, Beginning | shares 1,111,363
Weighted Average Exercise Price Outstanding, Beginning $ 2.12
Weighted Average Fair Value Outstanding, Beginning $ 1.31
Weighted-average Remaining Contractual Life (years) Outstanding, Beginning 6 years 7 months 13 days
Number of Options Outstanding, Granted | shares
Weighted Average Exercise Price Granted
Weighted Average Fair Value Granted
Number of Options Outstanding, Expired | shares
Weighted Average Exercise Price Expired
Weighted Average Fair Value Expired
Number of Options Outstanding, Forfeited/Cancelled | shares
Weighted Average Exercise Price Forfeited/Cancelled
Weighted Average Fair Value Forfeited/Cancelled
Number of Options Outstanding, Exercised | shares (45,456)
Weighted Average Exercise Price Exercised $ 1.10
Weighted Average Fair Value Exercised $ 0.51
Number of Options Outstanding, Ending | shares 1,065,907
Weighted Average Exercise Price Outstanding, Ending $ 2.17
Weighted Average Fair Value Outstanding, Ending $ 1.35
Weighted-average Remaining Contractual Life (years) Outstanding, Ending 6 years 7 months 24 days
Number of Options Exercisable Ending | shares 1,049,241
Weighted Average Exercise Price, Exercisable Ending $ 2.05
Weighted Average Fair Value, Exercisable Ending $ 1.21
Weighted-average Remaining Contractual Life (years), Exercisable Ending 6 years 7 months 17 days
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Outstanding Restricted Stock Units and Related Activity (Details) - Restricted Stock Units (RSUs) [Member]
 3 Months Ended
Mar. 31, 2022
$ / shares
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Number of Restricted Stock Units, Outstanding Beginning | shares 1,267,415
Weighted Average Grant Date Fair Value, Outstanding Beginning | $ / shares $ 9.94
Number of Restricted Stock Units, Granted | shares
Weighted Average Grant Date Fair Value, Granted | $ / shares
Number of Restricted Stock Units, Vested | shares (68,750)
Weighted Average Grant Date Fair Value, Vested | $ / shares $ 10.23
Number of Restricted Stock Units, Forfeited/Cancelled | shares
Weighted Average Grant Date Fair Value, Forfeited/Cancelled | $ / shares
Number of Restricted Stock Units, Outstanding Ending | shares 1,198,665
Weighted Average Grant Date Fair Value, Outstanding Ending | $ / shares $ 9.92
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Warrant Activity (Details)
 3 Months Ended
Mar. 31, 2022
$ / shares
shares
Share-Based Payment Arrangement [Abstract]  
Number of Warrants Outstanding, Beginning | shares 526,281
Weighted Average Exercise Price, Beginning $ 8.15
Weighted Average Fair Value, Beginning $ 4.01
Weighted-average Remaining Contractual Life (Years) Outstanding, Beginning 4 years 8 months 12 days
Number of Warrants Outstanding, Granted | shares
Weighted Average Exercise Price, Granted
Weighted Average Fair Value, Granted
Number of Warrants Outstanding, Expired | shares
Weighted Average Exercise Price, Expired
Weighted Average Fair Value, Expired
Number of Warrants Outstanding, Forfeited/Cancelled | shares
Weighted Average Exercise Price, Forfeited/Cancelled
Weighted Average Fair Value, Forfeited/Cancelled
Number of Warrants Outstanding, Exercised | shares (50,000)
Weighted Average Exercise Price, Exercised $ 2.00
Weighted Average Fair Value, Exercised $ 1.22
Number of Warrants Outstanding, Ending | shares 476,281
Weighted Average Exercise Price, Ending $ 8.80
Weighted Average Fair Value, Ending $ 2.82
Weighted-average Remaining Contractual Life (Years) Outstanding, Ending 4 years 9 months 18 days
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Recognized Stock-based Compensation Expense (Details) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Total stock-based compensation expense $ 1,375,097 $ 1,513,012
Share-Based Payment Arrangement, Option [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Total stock-based compensation expense 40,874 76,672
Restricted Stock Units (RSUs) [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Total stock-based compensation expense 1,334,223 1,396,440
Share-Based Payment Arrangement [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Total stock-based compensation expense $ 39,900
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation (Details Narrative) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Warrants exercisable 20,000  
Warrants to purchase a common stock 456,000  
Warrant [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Aggregate intrinsic value of options outstanding $ 100,000  
Stock Options [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Intrinsic value of options value exercised 300,000  
Aggregate intrinsic value of options outstanding $ 4,500,000  
Unvested options 16,666  
Unrecognized stock-based compensation $ 37,241  
Unrecognized stock-based compensation recognition period 2 months 12 days  
Intrinsic value of warrants exercised $ 300,000 $ 0
Restricted Stock Units (RSUs) [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Unrecognized stock-based compensation $ 10,300,000  
Unrecognized stock-based compensation recognition period 2 years 1 month 6 days  
Restricted Stock [Member] | Third Parties [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Number of shares issued for services 0 4,290
2015 Long Term Incentive Plan [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Aggregate number of common shares reserved 6,000,000  
Number of common shares availalble for issuance 2,095,266  
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes (Details Narrative) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Income Tax Disclosure [Abstract]    
Income tax expense benefit $ 1,386,087 $ 1,985,640
Effective tax rate 10.60%  
Effective federal statutory tax rate 21.00%  
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.22.1
Related Party Transactions (Details Narrative) - Exclusive License Agreement [Member] - Dr. Brent Satterfield [Member] - USD ($)
 1 Months Ended
Jan. 30, 2017
Mar. 31, 2022
Mar. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Accrued royalties $ 700,000    
Payment for royalties per month $ 10,000    
Due to related party   $ 0 $ 120,000
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Lease Expense (Details)
 3 Months Ended
Mar. 31, 2022
USD ($)
Leases  
Operating lease costs $ 86,588
Short-term lease costs 76,080
Total lease costs $ 162,668
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Maturities on Company Lease Liabilities (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Leases    
2022 (remainder) $ 221,350  
2023 303,059  
2024 50,774  
2025  
2026  
Thereafter  
Total lease payments 575,183  
Less: imputed interest 16,212  
Present value of operating lease liabilities 558,971  
Less: current portion 283,299
Long-term portion $ 275,672
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Other Information Related to Operating Lease (Details)
 3 Months Ended
Mar. 31, 2022
USD ($)
Leases  
Cash paid for operating leases included in operating cash flows $ 154,882
Remaining lease term of operating leases 2 years
Discount rate of operating leases 3.10%
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Future Minimum Lease Payments (Details)
Mar. 31, 2022
USD ($)
Leases  
2022 $ 293,595
2023 303,059
2024 50,774
Total lease payments $ 647,428
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.22.1
Share Repurchase Program (Details Narrative)
$ in Millions
Mar. 31, 2022
USD ($)
Equity [Abstract]  
Stock repurchase program authorized amount $ 30.0
XML 61 form10-q_htm.xml IDEA: XBRL DOCUMENT 0001692415 2022-01-01 2022-03-31 0001692415 2022-05-12 0001692415 2022-03-31 0001692415 2021-12-31 0001692415 2021-01-01 2021-03-31 0001692415 2020-12-31 0001692415 2021-03-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001692415 us-gaap:CommonStockMember 2021-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001692415 us-gaap:RetainedEarningsMember 2021-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001692415 us-gaap:CommonStockMember 2020-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001692415 us-gaap:RetainedEarningsMember 2020-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001692415 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001692415 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0001692415 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001692415 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0001692415 us-gaap:CommonStockMember 2022-03-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001692415 us-gaap:RetainedEarningsMember 2022-03-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-03-31 0001692415 us-gaap:CommonStockMember 2021-03-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001692415 us-gaap:RetainedEarningsMember 2021-03-31 0001692415 srt:MinimumMember 2022-01-01 2022-03-31 0001692415 srt:MaximumMember 2022-01-01 2022-03-31 0001692415 CODX:ThreeCustomersTogetherMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001692415 CODX:ThreeCustomersTogetherMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001692415 CODX:TwoCustomersTogetherMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001692415 CODX:TwoCustomersTogetherMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001692415 us-gaap:AccountingStandardsUpdate201602Member 2022-01-02 0001692415 CODX:AdvancedConceptionsIncAndIdahoMolecularIncMember 2021-12-30 2021-12-31 0001692415 CODX:AdvancedConceptionsIncAndIdahoMolecularIncMember 2021-12-31 0001692415 us-gaap:InProcessResearchAndDevelopmentMember 2022-01-01 2022-03-31 0001692415 us-gaap:InProcessResearchAndDevelopmentMember 2022-03-31 0001692415 us-gaap:NoncompeteAgreementsMember 2022-01-01 2022-03-31 0001692415 us-gaap:NoncompeteAgreementsMember 2022-03-31 0001692415 us-gaap:InProcessResearchAndDevelopmentMember 2021-01-01 2021-12-31 0001692415 us-gaap:InProcessResearchAndDevelopmentMember 2021-12-31 0001692415 us-gaap:NoncompeteAgreementsMember 2021-01-01 2021-12-31 0001692415 us-gaap:NoncompeteAgreementsMember 2021-12-31 0001692415 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001692415 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001692415 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001692415 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001692415 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001692415 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001692415 us-gaap:MeasurementInputSharePriceMember 2022-03-31 0001692415 us-gaap:MeasurementInputSharePriceMember 2021-12-31 0001692415 CODX:MeasurementInputStrikePriceMember 2022-03-31 0001692415 CODX:MeasurementInputStrikePriceMember 2021-12-31 0001692415 us-gaap:MeasurementInputPriceVolatilityMember 2022-03-31 0001692415 us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001692415 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-03-31 0001692415 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001692415 srt:AmericasMember 2022-01-01 2022-03-31 0001692415 srt:AmericasMember 2021-01-01 2021-03-31 0001692415 CODX:RestOfWorldMember 2022-01-01 2022-03-31 0001692415 CODX:RestOfWorldMember 2021-01-01 2021-03-31 0001692415 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-03-31 0001692415 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-03-31 0001692415 CODX:RestOfWorldMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-03-31 0001692415 CODX:RestOfWorldMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-03-31 0001692415 us-gaap:WarrantMember 2022-01-01 2022-03-31 0001692415 CODX:TwoThousandFifteenLongTermIncentivePlanMember 2022-03-31 0001692415 CODX:StockOptionsMember 2022-01-01 2022-03-31 0001692415 CODX:StockOptionsMember 2022-03-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2022-03-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0001692415 CODX:StockOptionsMember 2021-01-01 2021-03-31 0001692415 us-gaap:WarrantMember 2022-03-31 0001692415 CODX:ThirdPartiesMember us-gaap:RestrictedStockMember 2022-01-01 2022-03-31 0001692415 CODX:ThirdPartiesMember us-gaap:RestrictedStockMember 2021-01-01 2021-03-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001692415 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001692415 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001692415 us-gaap:StockCompensationPlanMember 2022-01-01 2022-03-31 0001692415 us-gaap:StockCompensationPlanMember 2021-01-01 2021-03-31 0001692415 CODX:DrBrentSatterfieldMember CODX:ExclusiveLicenseAgreementMember 2017-01-30 0001692415 CODX:DrBrentSatterfieldMember CODX:ExclusiveLicenseAgreementMember 2017-01-01 2017-01-30 0001692415 CODX:DrBrentSatterfieldMember CODX:ExclusiveLicenseAgreementMember 2022-03-31 0001692415 CODX:DrBrentSatterfieldMember CODX:ExclusiveLicenseAgreementMember 2021-03-31 iso4217:USD shares iso4217:USD shares pure utr:acre 0001692415 false Q1 --12-31 P3Y 10-Q true 2022-03-31 2022 false 001-38148 CO-DIAGNOSTICS, INC. UT 46-2609396 2401 S. Foothill Drive Suite D Salt Lake City UT 84109 (801) 438-1036 Common Stock CODX NASDAQ Yes Yes Non-accelerated Filer true true false false 33987736 97421739 88607234 1255266 21662403 20839182 4901057 2004169 1278598 2338444 75000 75000 125338797 115119295 2252853 1933216 604837 14808411 14706818 27088333 27195000 983614 1004953 75000 75000 171151845 160034282 1215049 607506 2613218 3859652 283299 4065537 5767304 4843592 2213088 150000 13020695 12597550 1284745 1067853 5868728 7228444 275672 2987214 4665337 10416359 12961634 23437054 25559184 0.001 0.001 5000000 5000000 0 0 0 0 0.001 0.001 100000000 100000000 33984068 33984068 33819862 33819862 33984 33820 81796933 80271999 65883874 54169279 147714791 134475098 171151845 160034282 22699044 20024769 3281951 3272565 19417093 16752204 2652148 1197546 2922195 2935689 3771327 2217063 247264 67005 9592934 6417303 9824159 10334901 11393 14657 -93421 3379890 -21339 -464943 3276523 -450286 13100682 9884615 1386087 1985640 11714595 7898975 0.35 0.28 0.34 0.26 33935570 28662885 34711476 30002729 11714595 7898975 247264 67005 1375097 1513012 3379890 8762 -21339 -464943 -93421 -1359716 302399 47862 79700 871083 59994 -1042932 114473 3088944 -1797581 -150000 -146516 2745803 1128438 -641604 -661115 7805838 12269955 396600 139558 1255266 2032802 -500000 858666 2393244 150001 148981 150001 148981 8814505 14812180 88607234 42976713 97421739 57788893 192056 681327 33819862 33820 80271999 54169279 134475098 45456 45 49956 50001 50000 50 99950 100000 68750 69 1375028 1375097 11714595 11714595 33984068 33984 81796933 65883874 147714791 28558033 28558 49157236 17510715 66696509 65891 66 148914 148980 73040 42 1512970 1513012 7898975 7898975 28696964 28666 50819120 25409690 76257476 <p id="xdx_80F_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zz9XBp7tea75" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 – <span id="xdx_822_zaRgwhQKhTU6">Overview and Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description of Business</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 27.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Co-Diagnostics, Inc., a Utah corporation (the “Company”, “Co-Dx” or “CODX”), develops, manufactures and sells reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including robust and innovative molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. In connection with the sale of our tests we may sell diagnostic equipment from other manufacturers as self-contained lab systems (which we refer to as the “MDx Device”). We are also developing a unique, groundbreaking portable PCR testing platform (the “Co-Dx PCR home testing platform”) designed to bring affordable, reliable gold-standard polymerase chain reaction (“PCR”) to patients in point-of-care and even at-home settings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unaudited Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q as they are prescribed for smaller reporting companies and emerging growth companies. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to make the financial statements not misleading have been included. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. These statements should be read in conjunction with the Company’s audited financial statements and related notes for the year ended December 31, 2021, included in the Company’s Annual Report on Form 10-K filed on March 24, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Such estimates include receivables and other long-lived assets, legal and regulatory contingencies, income taxes, share based arrangements, and others. These estimates and assumptions are based on management’s best estimates and judgments. Actual amounts and results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_80F_eus-gaap--SignificantAccountingPoliciesTextBlock_zB6FigEwh2B4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 – <span id="xdx_82A_zJfeACbnJRze">Summary of Significant Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zgP1fzlAOOTe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash and Cash Equivalents</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents consist of cash on hand, money market funds and highly liquid investments with an original maturity date of 90 days or less from the date of purchase. The fair value of cash equivalents approximated their carrying value as of March 31, 2022 and December 31, 2021. The Company has its cash and cash equivalents with a large creditworthy financial institution and the balance exceeded federally insured limits. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on cash and cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--MarketableSecuritiesPolicy_zB1GZqFRT1wb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Marketable Investment Securities</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s marketable investment securities are comprised of investments in certificates of deposit. The Company determines the appropriate classification of its marketable investment securities at the time of purchase and reevaluates such designation at each balance sheet date. The Company has classified and accounted for its marketable investment securities as available-for-sale securities as the Company may sell these securities at any time for use in its current operations or for other purposes, even prior to maturity. As a result, the Company classifies its marketable investment securities, including securities with stated maturities beyond twelve months, within current assets in the consolidated balance sheets. Any unrealized gains or losses are immaterial.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_849_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zyTPsu5XMaJ8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounts Receivable</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade accounts receivable are recorded at the invoiced amount (net of allowance) and do not bear interest. The Company maintains an allowance for doubtful accounts for amounts the Company does not expect to collect. In establishing the required allowance, management considers historical losses, current market condition, customers’ financial condition, the age of receivables, and current payment patterns. Account balances are written off against the allowance once the receivable is deemed uncollectible. Recoveries of trade receivables previously written off are recorded when collected. At March 31, 2022, total accounts receivable was $<span id="xdx_905_eus-gaap--AccountsReceivableGrossCurrent_iI_c20220331_zxP07cEI8Oki" title="Accounts receivable">22,379,861</span> with an allowance for uncollectable accounts of $<span id="xdx_908_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20220331_zC5TNQyfd03a" title="Doubtful accounts">717,458</span> resulting in a net amount of $<span id="xdx_902_eus-gaap--AccountsReceivableNetCurrent_iI_c20220331_zPrkPnLS3Pv5" title="Accounts receivable, net">21,662,403</span>. At December 31, 2021, total accounts receivable was $<span id="xdx_909_eus-gaap--AccountsReceivableGrossCurrent_iI_c20211231_zaPHySI4oaB1">21,508,779</span> with an allowance for uncollectable accounts of $<span id="xdx_908_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20211231_zxShRG1Rqs5e">669,597</span> resulting in a net amount of $<span id="xdx_906_eus-gaap--AccountsReceivableNetCurrent_iI_c20211231_zHw3ELPKGTrc">20,839,182</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--EquityMethodInvestmentsPolicy_z5B1vrwVJLQ1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity-Method Investments</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our equity method investments are initially recorded at cost and are included in other long-term assets in the accompanying consolidated balance sheet. We adjust the carrying value of our investment based on our share of the earnings or losses in the periods which they are reported by the investee until the carrying amount is zero. The earnings or losses are included in other income (expense) in the accompanying consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--InventoryPolicyTextBlock_zIoOuJSf0Oxb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inventory</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory is stated at the lower of cost or net-realizable value. Inventory cost is determined on a first-in first-out basis that approximates average cost in accordance with ASC 330-10-30-12. At March 31, 2022, the Company had $<span id="xdx_904_eus-gaap--InventoryNet_iI_c20220331_zWeIZTfEDPwc" title="Inventory">4,901,057</span> in inventory, of which $<span id="xdx_904_eus-gaap--InventoryFinishedGoods_iI_c20220331_zrIBb3uaUXMb" title="Inventory finished goods">4,119,549</span> was finished goods and $<span id="xdx_909_eus-gaap--InventoryRawMaterials_iI_c20220331_zQYNiHkaRDw6" title="Inventory raw materials">781,508</span> was raw materials. At December 31, 2021, the Company had $<span id="xdx_900_eus-gaap--InventoryNet_iI_c20211231_z55GydraidKi">2,004,169</span> in inventory, of which $<span id="xdx_90A_eus-gaap--InventoryFinishedGoods_iI_c20211231_z3p9z2hYbej">983,088</span> was finished goods and $<span id="xdx_903_eus-gaap--InventoryRawMaterials_iI_c20211231_zwVFypuKCfp4">1,021,081</span> was raw materials. The Company establishes reserves to reduce slow-moving, obsolete, or unusable inventories to their estimated useful or scrap values.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zfvh6Drr6V6g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Property and Equipment</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the property, generally from <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20220101__20220331__srt--RangeAxis__srt--MinimumMember_z9D5FsdDpQ15" title="::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0496">three</span></span> to <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dc_c20220101__20220331__srt--RangeAxis__srt--MaximumMember_zK8pvEATGOl7" title="Estimated useful life of property">five years</span>. Repairs and maintenance costs are expensed as incurred except when such repairs significantly add to the useful life or productive capacity of the asset, in which case the repairs are capitalized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reviews its long-lived assets, including property and equipment, for impairment whenever an event or change in facts and circumstances indicates that their carrying amounts may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated. If the carrying amount exceeds the undiscounted cash flows, the assets are determined to be impaired and an impairment charge is recognized as the amount by which the carrying amount exceeds fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--BusinessCombinationsPolicy_z7LzhubAB0Sf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business Combinations</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We estimate the fair value of assets acquired and liabilities assumed in a business combination. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable, and as a result, actual results may differ from estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_845_eus-gaap--LesseeLeasesPolicyTextBlock_zC983qpkCyib" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leases</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As described in “Recently Adopted Accounting Standards” below, the Company adopted ASC 842, Leases (“ASC 842”) effective January 1, 2022. Under ASC 842, the Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (ROU) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As the implicit rate in the Company’s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The Company considers its credit risk, term of the lease, total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. Lease costs for the Company’s operating leases are recognized on a straight-line basis within operating expenses and cost of revenue over the reasonably assured lease term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has elected to not separate lease and non-lease components for leases of office space and, as a result, accounts for any lease and non-lease components for office space as a single lease component, to the extent they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease payments. The Company’s office leases typically include non-lease components such as common-area maintenance costs. The Company has also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_849_eus-gaap--RevenueRecognitionPolicyTextBlock_zAtkVYfTVgP3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue Recognition</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company generates revenue from product sales and license sales. The Company recognizes revenue when all of the following criteria are satisfied: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as the Company satisfies each performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as deferred revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zcppXrJSBXXd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Deferred Revenue</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred revenue primarily consists of payments received from customers prior to the Company fulfilling its performance obligation of providing the product. When this occurs, the Company records a contract liability as deferred revenue. Deferred revenue is recognized as revenue as the related performance obligations are satisfied.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zzsm7sYzTWsa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research and Development</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development costs are expensed when incurred. For the three months ended March 31, 2022, the Company expensed $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220331_zoT4Gpan3zig" title="Research and development">3,771,327</span> of research and development costs, respectively. For the three months ended March 31, 2021, the Company expensed $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20210331_zxyNCpkq2ayl">2,217,063</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zLD9KSnNIb4d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-based Compensation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has granted stock-based awards, including restricted stock, stock options, stock warrants and restricted stock units (“RSUs”), to its employees, certain consultants and members of its board of directors. The Company records stock-based compensation based on the grant date fair value of the awards and recognizes the fair value of those awards as expense using the straight-line method over the requisite service period of the award. The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model. When an award is forfeited prior to the vesting date, the Company recognizes an adjustment for the previously recognized expense in the period of the forfeiture.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zEKwmtpEkMmk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income Taxes</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes in accordance with the liability method of accounting for income taxes. Under this method, deferred income tax assets and deferred income tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at enacted tax rates in effect for the year in which the differences are expected to reverse. The Company recognizes only the impact of tax positions that, based on their technical merits, are more likely than not to be sustained upon an audit by the taxing authority.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowances are provided when it is more-likely-than-not that some or all of the deferred income tax assets may not be realized. In assessing the need for a valuation allowance, the Company has considered its historical levels of income, expectations of future taxable income and ongoing tax planning strategies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing the provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred income tax assets and liabilities and any estimated valuation allowances deemed necessary to value deferred income tax assets. Judgments and tax strategies are subject to audit by various taxing authorities. While the Company believes it has no significant uncertain income tax positions in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial positions, result of operations, or cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_ziD63g3a2Ksk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net Income per Share</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net income or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted average number of shares outstanding during each period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted net income or loss per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period increased by common shares that could be issued upon conversion or exercise of other outstanding securities to the extent those additional common shares would be dilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income or loss per share by application of the treasury stock method. During periods when the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the effects of potentially dilutive securities are anti-dilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zWYCWNbSntV8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentrations Risk and Significant Customers</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had certain customers which are each responsible for generating 10% or more of the total revenue for the three months ended March 31, 2022. Three customers together accounted for approximately <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--ThreeCustomersTogetherMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGhPwyoulaY5" title="Concentration risk percentage">54</span>% and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210331__srt--MajorCustomersAxis__custom--ThreeCustomersTogetherMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zaj1LJyqynBe" title="Concentration risk percentage">57</span>% of total revenue for the three months ended March 31, 2022 and March 31, 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two customers each accounted for more than 10% of accounts receivable at March 31, 2022 and December 31, 2021. These two customers together accounted for approximately <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--TwoCustomersTogetherMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z71rrH0xurDh" title="Concentration risk percentage">62</span>% and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--TwoCustomersTogetherMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ziYiggZXUXhi" title="Concentration risk percentage">66</span>% of accounts receivable at March 31, 2022 and December 31, 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zyT1QLCRuJac" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recent Accounting Pronouncements</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_ecustom--RecentlyAdoptedAccountingStandardsPolicyTextBlock_zE3ij2MeBTIj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently Adopted Accounting Standards</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) (“ASU 2016-13”), which requires the measurement and recognition of expected credit losses for certain financial instruments, which includes the Company’s accounts receivable. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. The Company adopted ASU 2016-13 on January 1, 2022. The adoption did not have an impact on the Company’s financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which requires a lessee to recognize most leases on the balance sheet as lease liabilities with corresponding right-of-use assets. The objective of ASU 2016-02 is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The recognized lease liabilities and lease assets represent the obligation to make payments and the right to use or control the use of a specified asset for the lease term, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 1, 2022, the Company adopted Topic 842 using the modified retrospective approach with the effective date as the date of initial application. Consequently, results for the three months ended March 31, 2022 are presented under Topic 842. No prior period amounts were adjusted and continue to be reported in accordance with previous lease guidance, ASC Topic 840, Leases. The Company elected the practical expedients available under the provisions of the new standard, including not reassessing whether expired or existing contracts are or contain leases; not reassessing the classification of expired or existing leases; and not reassessing the initial direct cost for any existing leases. Upon adoption, the Company recognized an operating lease liability of $<span id="xdx_90B_eus-gaap--OperatingLeaseLiability_iI_c20220102__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_zrmqbtYG3kd5" title="Operating lease liability">626,699</span> and a corresponding operating right-of-use asset of $<span id="xdx_90F_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20220102__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_zmvU4EdFzMed" title="Operating right use of asset">681,327</span>.</span></p> <p id="xdx_85F_zxmbHXaOSlH7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zgP1fzlAOOTe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash and Cash Equivalents</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents consist of cash on hand, money market funds and highly liquid investments with an original maturity date of 90 days or less from the date of purchase. The fair value of cash equivalents approximated their carrying value as of March 31, 2022 and December 31, 2021. The Company has its cash and cash equivalents with a large creditworthy financial institution and the balance exceeded federally insured limits. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on cash and cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--MarketableSecuritiesPolicy_zB1GZqFRT1wb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Marketable Investment Securities</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s marketable investment securities are comprised of investments in certificates of deposit. The Company determines the appropriate classification of its marketable investment securities at the time of purchase and reevaluates such designation at each balance sheet date. The Company has classified and accounted for its marketable investment securities as available-for-sale securities as the Company may sell these securities at any time for use in its current operations or for other purposes, even prior to maturity. As a result, the Company classifies its marketable investment securities, including securities with stated maturities beyond twelve months, within current assets in the consolidated balance sheets. Any unrealized gains or losses are immaterial.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_849_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zyTPsu5XMaJ8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounts Receivable</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade accounts receivable are recorded at the invoiced amount (net of allowance) and do not bear interest. The Company maintains an allowance for doubtful accounts for amounts the Company does not expect to collect. In establishing the required allowance, management considers historical losses, current market condition, customers’ financial condition, the age of receivables, and current payment patterns. Account balances are written off against the allowance once the receivable is deemed uncollectible. Recoveries of trade receivables previously written off are recorded when collected. At March 31, 2022, total accounts receivable was $<span id="xdx_905_eus-gaap--AccountsReceivableGrossCurrent_iI_c20220331_zxP07cEI8Oki" title="Accounts receivable">22,379,861</span> with an allowance for uncollectable accounts of $<span id="xdx_908_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20220331_zC5TNQyfd03a" title="Doubtful accounts">717,458</span> resulting in a net amount of $<span id="xdx_902_eus-gaap--AccountsReceivableNetCurrent_iI_c20220331_zPrkPnLS3Pv5" title="Accounts receivable, net">21,662,403</span>. At December 31, 2021, total accounts receivable was $<span id="xdx_909_eus-gaap--AccountsReceivableGrossCurrent_iI_c20211231_zaPHySI4oaB1">21,508,779</span> with an allowance for uncollectable accounts of $<span id="xdx_908_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20211231_zxShRG1Rqs5e">669,597</span> resulting in a net amount of $<span id="xdx_906_eus-gaap--AccountsReceivableNetCurrent_iI_c20211231_zHw3ELPKGTrc">20,839,182</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 22379861 717458 21662403 21508779 669597 20839182 <p id="xdx_844_eus-gaap--EquityMethodInvestmentsPolicy_z5B1vrwVJLQ1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity-Method Investments</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our equity method investments are initially recorded at cost and are included in other long-term assets in the accompanying consolidated balance sheet. We adjust the carrying value of our investment based on our share of the earnings or losses in the periods which they are reported by the investee until the carrying amount is zero. The earnings or losses are included in other income (expense) in the accompanying consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--InventoryPolicyTextBlock_zIoOuJSf0Oxb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inventory</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory is stated at the lower of cost or net-realizable value. Inventory cost is determined on a first-in first-out basis that approximates average cost in accordance with ASC 330-10-30-12. At March 31, 2022, the Company had $<span id="xdx_904_eus-gaap--InventoryNet_iI_c20220331_zWeIZTfEDPwc" title="Inventory">4,901,057</span> in inventory, of which $<span id="xdx_904_eus-gaap--InventoryFinishedGoods_iI_c20220331_zrIBb3uaUXMb" title="Inventory finished goods">4,119,549</span> was finished goods and $<span id="xdx_909_eus-gaap--InventoryRawMaterials_iI_c20220331_zQYNiHkaRDw6" title="Inventory raw materials">781,508</span> was raw materials. At December 31, 2021, the Company had $<span id="xdx_900_eus-gaap--InventoryNet_iI_c20211231_z55GydraidKi">2,004,169</span> in inventory, of which $<span id="xdx_90A_eus-gaap--InventoryFinishedGoods_iI_c20211231_z3p9z2hYbej">983,088</span> was finished goods and $<span id="xdx_903_eus-gaap--InventoryRawMaterials_iI_c20211231_zwVFypuKCfp4">1,021,081</span> was raw materials. The Company establishes reserves to reduce slow-moving, obsolete, or unusable inventories to their estimated useful or scrap values.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 4901057 4119549 781508 2004169 983088 1021081 <p id="xdx_845_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zfvh6Drr6V6g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Property and Equipment</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the property, generally from <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20220101__20220331__srt--RangeAxis__srt--MinimumMember_z9D5FsdDpQ15" title="::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0496">three</span></span> to <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dc_c20220101__20220331__srt--RangeAxis__srt--MaximumMember_zK8pvEATGOl7" title="Estimated useful life of property">five years</span>. Repairs and maintenance costs are expensed as incurred except when such repairs significantly add to the useful life or productive capacity of the asset, in which case the repairs are capitalized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reviews its long-lived assets, including property and equipment, for impairment whenever an event or change in facts and circumstances indicates that their carrying amounts may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated. If the carrying amount exceeds the undiscounted cash flows, the assets are determined to be impaired and an impairment charge is recognized as the amount by which the carrying amount exceeds fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P5Y <p id="xdx_840_eus-gaap--BusinessCombinationsPolicy_z7LzhubAB0Sf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business Combinations</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We estimate the fair value of assets acquired and liabilities assumed in a business combination. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable, and as a result, actual results may differ from estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_845_eus-gaap--LesseeLeasesPolicyTextBlock_zC983qpkCyib" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leases</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As described in “Recently Adopted Accounting Standards” below, the Company adopted ASC 842, Leases (“ASC 842”) effective January 1, 2022. Under ASC 842, the Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (ROU) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As the implicit rate in the Company’s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The Company considers its credit risk, term of the lease, total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. Lease costs for the Company’s operating leases are recognized on a straight-line basis within operating expenses and cost of revenue over the reasonably assured lease term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has elected to not separate lease and non-lease components for leases of office space and, as a result, accounts for any lease and non-lease components for office space as a single lease component, to the extent they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease payments. The Company’s office leases typically include non-lease components such as common-area maintenance costs. The Company has also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_849_eus-gaap--RevenueRecognitionPolicyTextBlock_zAtkVYfTVgP3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue Recognition</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company generates revenue from product sales and license sales. The Company recognizes revenue when all of the following criteria are satisfied: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as the Company satisfies each performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as deferred revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zcppXrJSBXXd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Deferred Revenue</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred revenue primarily consists of payments received from customers prior to the Company fulfilling its performance obligation of providing the product. When this occurs, the Company records a contract liability as deferred revenue. Deferred revenue is recognized as revenue as the related performance obligations are satisfied.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zzsm7sYzTWsa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research and Development</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development costs are expensed when incurred. For the three months ended March 31, 2022, the Company expensed $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220331_zoT4Gpan3zig" title="Research and development">3,771,327</span> of research and development costs, respectively. For the three months ended March 31, 2021, the Company expensed $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20210331_zxyNCpkq2ayl">2,217,063</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 3771327 2217063 <p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zLD9KSnNIb4d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-based Compensation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has granted stock-based awards, including restricted stock, stock options, stock warrants and restricted stock units (“RSUs”), to its employees, certain consultants and members of its board of directors. The Company records stock-based compensation based on the grant date fair value of the awards and recognizes the fair value of those awards as expense using the straight-line method over the requisite service period of the award. The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model. When an award is forfeited prior to the vesting date, the Company recognizes an adjustment for the previously recognized expense in the period of the forfeiture.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zEKwmtpEkMmk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income Taxes</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes in accordance with the liability method of accounting for income taxes. Under this method, deferred income tax assets and deferred income tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at enacted tax rates in effect for the year in which the differences are expected to reverse. The Company recognizes only the impact of tax positions that, based on their technical merits, are more likely than not to be sustained upon an audit by the taxing authority.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowances are provided when it is more-likely-than-not that some or all of the deferred income tax assets may not be realized. In assessing the need for a valuation allowance, the Company has considered its historical levels of income, expectations of future taxable income and ongoing tax planning strategies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing the provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred income tax assets and liabilities and any estimated valuation allowances deemed necessary to value deferred income tax assets. Judgments and tax strategies are subject to audit by various taxing authorities. While the Company believes it has no significant uncertain income tax positions in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial positions, result of operations, or cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_ziD63g3a2Ksk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net Income per Share</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net income or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted average number of shares outstanding during each period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted net income or loss per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period increased by common shares that could be issued upon conversion or exercise of other outstanding securities to the extent those additional common shares would be dilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income or loss per share by application of the treasury stock method. During periods when the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the effects of potentially dilutive securities are anti-dilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zWYCWNbSntV8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentrations Risk and Significant Customers</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had certain customers which are each responsible for generating 10% or more of the total revenue for the three months ended March 31, 2022. Three customers together accounted for approximately <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--ThreeCustomersTogetherMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGhPwyoulaY5" title="Concentration risk percentage">54</span>% and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210331__srt--MajorCustomersAxis__custom--ThreeCustomersTogetherMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zaj1LJyqynBe" title="Concentration risk percentage">57</span>% of total revenue for the three months ended March 31, 2022 and March 31, 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two customers each accounted for more than 10% of accounts receivable at March 31, 2022 and December 31, 2021. These two customers together accounted for approximately <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--TwoCustomersTogetherMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z71rrH0xurDh" title="Concentration risk percentage">62</span>% and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--TwoCustomersTogetherMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ziYiggZXUXhi" title="Concentration risk percentage">66</span>% of accounts receivable at March 31, 2022 and December 31, 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.54 0.57 0.62 0.66 <p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zyT1QLCRuJac" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recent Accounting Pronouncements</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_ecustom--RecentlyAdoptedAccountingStandardsPolicyTextBlock_zE3ij2MeBTIj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently Adopted Accounting Standards</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) (“ASU 2016-13”), which requires the measurement and recognition of expected credit losses for certain financial instruments, which includes the Company’s accounts receivable. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. The Company adopted ASU 2016-13 on January 1, 2022. The adoption did not have an impact on the Company’s financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which requires a lessee to recognize most leases on the balance sheet as lease liabilities with corresponding right-of-use assets. The objective of ASU 2016-02 is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The recognized lease liabilities and lease assets represent the obligation to make payments and the right to use or control the use of a specified asset for the lease term, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 1, 2022, the Company adopted Topic 842 using the modified retrospective approach with the effective date as the date of initial application. Consequently, results for the three months ended March 31, 2022 are presented under Topic 842. No prior period amounts were adjusted and continue to be reported in accordance with previous lease guidance, ASC Topic 840, Leases. The Company elected the practical expedients available under the provisions of the new standard, including not reassessing whether expired or existing contracts are or contain leases; not reassessing the classification of expired or existing leases; and not reassessing the initial direct cost for any existing leases. Upon adoption, the Company recognized an operating lease liability of $<span id="xdx_90B_eus-gaap--OperatingLeaseLiability_iI_c20220102__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_zrmqbtYG3kd5" title="Operating lease liability">626,699</span> and a corresponding operating right-of-use asset of $<span id="xdx_90F_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20220102__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_zmvU4EdFzMed" title="Operating right use of asset">681,327</span>.</span></p> 626699 681327 <p id="xdx_802_eus-gaap--BusinessCombinationDisclosureTextBlock_zezkZV4G19X7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 3 – <span id="xdx_82A_znBmDVcai0xk">Business Combinations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 31, 2021, the Company completed its acquisition of Advanced Conceptions, Inc. (“ACI”) and Idaho Molecular Inc. (“IdMo”), which were related entities developing, with the Company, an at-home/point-of-care medical diagnostic device. Upon the completion of the acquisition, all outstanding ACI and Idaho Molecular common stock was exchanged for approximately <span id="xdx_90C_ecustom--StockIssuedDuringPeriodSharesExchanged_pn5n6_c20211230__20211231__us-gaap--BusinessAcquisitionAxis__custom--AdvancedConceptionsIncAndIdahoMolecularIncMember_zah1btN5jz1j" title="Number of shares exchanged">3.2</span> million shares of the Company’s common stock and contingent consideration that includes up to approximately <span id="xdx_904_ecustom--StockIssuedDuringPeriodSharesContingentConsideration_pn5n6_c20211230__20211231__us-gaap--BusinessAcquisitionAxis__custom--AdvancedConceptionsIncAndIdahoMolecularIncMember_z2wzDq5nLask" title="Number of shares on contingent consideration">1.4</span> million shares and approximately <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211231__us-gaap--BusinessAcquisitionAxis__custom--AdvancedConceptionsIncAndIdahoMolecularIncMember_zXgz8Km99jFd" title="Warrants to purchase shares of common stock">456,000</span> warrants to purchase shares of the Company’s common stock. The contingent consideration is based on the achievement of certain milestones, which include regulatory approval for identified products, as well as production and net revenue targets. Upon the completion of the acquisition, both ACI and IdMo became <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20211231__us-gaap--BusinessAcquisitionAxis__custom--AdvancedConceptionsIncAndIdahoMolecularIncMember_zvJ2mq5EbCUl" title="Equity method investment ownership percentage">100</span>% wholly-owned subsidiaries of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 3200000 1400000 456000 1 <p id="xdx_808_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zh0gcNIU0vek" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4 – <span id="xdx_827_zt0ipSyKNAE">Goodwill and Intangible Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Goodwill</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill represents the excess of purchase price and related costs over the value assigned to net tangible and identifiable intangible assets acquired in business combinations. The following table presents the changes in the carrying amount of goodwill for the three months ended March 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfGoodwillTextBlock_zNKvrRjW2GS9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B1_zChWuxf0sQvi" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of Goodwill</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Balance as of December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><span id="xdx_906_eus-gaap--Goodwill_iS_c20220101__20220331_zoVCUAo7egf3" title="Goodwil - beginning">14,706,818</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Measurement period adjustments</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--GoodwillTranslationAndPurchaseAccountingAdjustments_c20220101__20220331_zHygSGmTLytk" title="Measurement period adjustments">101,593</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of March 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--Goodwill_iE_c20220101__20220331_zRLiEXrabRhe" title="Goodwill - Ending">14,808,411</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zIF5JEsi2yfj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intangible Assets, Net</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zJa2P4Y8T406" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents details of the Company’s intangible assets, excluding goodwill:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zgE3NboDLkA8" style="display: none">Schedule of Intangible Assets, Net</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td id="xdx_F57_zBFu4bsO6F3f" style="text-align: center; font-weight: bold">Weighted-Average</td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Gross</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Net</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="text-align: center; font-weight: bold">Useful Life (1)</td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Carrying</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Accumulated</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Carrying</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(in Years)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Amount</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Amortization</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Amount</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 38%; text-align: left">In-process research and development</td><td style="width: 2%"> </td> <td style="text-align: center; width: 12%"><span id="xdx_90C_ecustom--IndefiniteLivedIntangibleAssetUsefulLife_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_fKDEp_zDKmPNrA2Mje" title="Estimated useful lives in years, term">Indefinite</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zkmfhabgZoP3" style="width: 12%; text-align: right" title="Intangible assets, gross">26,101,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_z6Z76aPq5Hpj" style="width: 12%; text-align: right" title="Less accumulated amortization"><span style="-sec-ix-hidden: xdx2ixbrl0563">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zvokvOusumng" style="width: 12%; text-align: right" title="Intangible assets, net">26,101,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">Non-competition agreements</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: center"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_fKDEp_zzdfILwGsPYc" title="Estimated useful lives in years">2.7</span></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zohu0FcEjMYf" style="border-bottom: Black 1pt solid; text-align: right" title="Intangible assets, gross">1,094,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_z4Ei9KS0LzZ8" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated amortization">(106,667</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_z53hK2brfdw2" style="border-bottom: Black 1pt solid; text-align: right" title="Intangible assets, net">987,333</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt; text-align: left">Total intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20220331_zkagNvevVauj" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, gross">27,195,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_c20220331_zXLIfDm0qjnj" style="border-bottom: Black 2.5pt double; text-align: right" title="Less accumulated amortization">(106,667</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20220331_zNQux8I6Hn0e" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">27,088,333</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="text-align: center; font-weight: bold">Weighted-Average</td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Gross</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Net</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td id="xdx_F5F_zELYSdNrVfW1" style="text-align: center; font-weight: bold">Useful Life (1)</td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Carrying</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Accumulated</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Carrying</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(in Years)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Amount</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Amortization</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Amount</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 38%; text-align: left">In-process research and development</td><td style="width: 2%"> </td> <td style="text-align: center; width: 12%"><span id="xdx_903_ecustom--IndefiniteLivedIntangibleAssetUsefulLife_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_fKDEp_zJx29r9pxK9g" title="Estimated useful lives in years, term">Indefinite</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_pp0p0" style="width: 12%; text-align: right" title="Intangible assets, gross">26,101,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zPXKJERjBEXd" style="width: 12%; text-align: right" title="Less accumulated amortization">             <span style="-sec-ix-hidden: xdx2ixbrl0585"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_pp0p0" style="width: 12%; text-align: right" title="Intangible assets, net">26,101,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">Non-competition agreements</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: center"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_fKDEp_zpya74ClTkIe" title="Estimated useful lives in years">2.7</span></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Intangible assets, gross">1,094,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_z74rMJDRk40h" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated amortization"><span style="-sec-ix-hidden: xdx2ixbrl0593">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Intangible assets, net">1,094,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt; text-align: left">Total intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20211231_zCJzpe3CXbJa" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, gross">27,195,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_c20211231_zsnEOWSQhXQb" style="border-bottom: Black 2.5pt double; text-align: right" title="Less accumulated amortization"><span style="-sec-ix-hidden: xdx2ixbrl0599">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20211231_zHPEkGXDPGm8" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">27,195,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td id="xdx_F04_zWP69sqgYFp1" style="width: 15pt; text-align: right">(1)</td><td style="width: 5pt"/><td id="xdx_F1D_zBPHoGCJYju4" style="text-align: justify">Based on weighted-average useful life established as of the acquisition date.</td> </tr></table> <p id="xdx_8A1_zUOYHPzJgJ2e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfGoodwillTextBlock_zNKvrRjW2GS9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B1_zChWuxf0sQvi" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of Goodwill</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Balance as of December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><span id="xdx_906_eus-gaap--Goodwill_iS_c20220101__20220331_zoVCUAo7egf3" title="Goodwil - beginning">14,706,818</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Measurement period adjustments</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--GoodwillTranslationAndPurchaseAccountingAdjustments_c20220101__20220331_zHygSGmTLytk" title="Measurement period adjustments">101,593</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of March 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--Goodwill_iE_c20220101__20220331_zRLiEXrabRhe" title="Goodwill - Ending">14,808,411</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 14706818 101593 14808411 <p id="xdx_89F_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zJa2P4Y8T406" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents details of the Company’s intangible assets, excluding goodwill:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zgE3NboDLkA8" style="display: none">Schedule of Intangible Assets, Net</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td id="xdx_F57_zBFu4bsO6F3f" style="text-align: center; font-weight: bold">Weighted-Average</td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Gross</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Net</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="text-align: center; font-weight: bold">Useful Life (1)</td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Carrying</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Accumulated</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Carrying</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(in Years)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Amount</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Amortization</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Amount</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 38%; text-align: left">In-process research and development</td><td style="width: 2%"> </td> <td style="text-align: center; width: 12%"><span id="xdx_90C_ecustom--IndefiniteLivedIntangibleAssetUsefulLife_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_fKDEp_zDKmPNrA2Mje" title="Estimated useful lives in years, term">Indefinite</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zkmfhabgZoP3" style="width: 12%; text-align: right" title="Intangible assets, gross">26,101,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_z6Z76aPq5Hpj" style="width: 12%; text-align: right" title="Less accumulated amortization"><span style="-sec-ix-hidden: xdx2ixbrl0563">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zvokvOusumng" style="width: 12%; text-align: right" title="Intangible assets, net">26,101,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">Non-competition agreements</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: center"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_fKDEp_zzdfILwGsPYc" title="Estimated useful lives in years">2.7</span></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zohu0FcEjMYf" style="border-bottom: Black 1pt solid; text-align: right" title="Intangible assets, gross">1,094,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_z4Ei9KS0LzZ8" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated amortization">(106,667</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_z53hK2brfdw2" style="border-bottom: Black 1pt solid; text-align: right" title="Intangible assets, net">987,333</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt; text-align: left">Total intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20220331_zkagNvevVauj" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, gross">27,195,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_c20220331_zXLIfDm0qjnj" style="border-bottom: Black 2.5pt double; text-align: right" title="Less accumulated amortization">(106,667</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20220331_zNQux8I6Hn0e" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">27,088,333</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="text-align: center; font-weight: bold">Weighted-Average</td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Gross</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Net</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td id="xdx_F5F_zELYSdNrVfW1" style="text-align: center; font-weight: bold">Useful Life (1)</td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Carrying</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Accumulated</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Carrying</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(in Years)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Amount</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Amortization</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Amount</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 38%; text-align: left">In-process research and development</td><td style="width: 2%"> </td> <td style="text-align: center; width: 12%"><span id="xdx_903_ecustom--IndefiniteLivedIntangibleAssetUsefulLife_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_fKDEp_zJx29r9pxK9g" title="Estimated useful lives in years, term">Indefinite</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_pp0p0" style="width: 12%; text-align: right" title="Intangible assets, gross">26,101,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zPXKJERjBEXd" style="width: 12%; text-align: right" title="Less accumulated amortization">             <span style="-sec-ix-hidden: xdx2ixbrl0585"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_pp0p0" style="width: 12%; text-align: right" title="Intangible assets, net">26,101,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">Non-competition agreements</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: center"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_fKDEp_zpya74ClTkIe" title="Estimated useful lives in years">2.7</span></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Intangible assets, gross">1,094,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_z74rMJDRk40h" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated amortization"><span style="-sec-ix-hidden: xdx2ixbrl0593">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Intangible assets, net">1,094,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt; text-align: left">Total intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20211231_zCJzpe3CXbJa" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, gross">27,195,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_c20211231_zsnEOWSQhXQb" style="border-bottom: Black 2.5pt double; text-align: right" title="Less accumulated amortization"><span style="-sec-ix-hidden: xdx2ixbrl0599">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20211231_zHPEkGXDPGm8" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">27,195,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td id="xdx_F04_zWP69sqgYFp1" style="width: 15pt; text-align: right">(1)</td><td style="width: 5pt"/><td id="xdx_F1D_zBPHoGCJYju4" style="text-align: justify">Based on weighted-average useful life established as of the acquisition date.</td> </tr></table> Indefinite 26101000 26101000 P2Y8M12D 1094000 106667 987333 27195000 106667 27088333 Indefinite 26101000 26101000 P2Y8M12D 1094000 1094000 27195000 27195000 <p id="xdx_80E_eus-gaap--FairValueDisclosuresTextBlock_ziMe1JWkYAM1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 5 – <span id="xdx_821_zWcDPj3icLLa">Fair Value Measurements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures and records certain financial assets at fair value on a recurring basis. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s financial instruments that are measured at fair value on a recurring basis consist of money market funds. The following three levels of inputs are used to measure the fair value of financial instruments:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1: Quoted market prices in active markets for identical assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3: Unobservable inputs that are not corroborated by market data.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_z1TUnPHxPCpf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the assets measured at fair value on a recurring basis as of March 31, 2022, and December 31, 2021, by level within the fair value hierarchy:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zn0KXPJ85aM5" style="display: none">Schedule of Fair Value Assets and Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_492_20220331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zGoKCJzpIDg1" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(Level 1)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20220331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zzmeErf3pD07" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(Level 2)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_490_20220331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zO0RfpKIVpef" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(Level 3)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_494_20220331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zKMZBJbGrbO4" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Total</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">March 31, 2022</td><td style="padding-bottom: 1pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(Level 1)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(Level 2)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(Level 3)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Total</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--FairValueOfContingentConsiderationToCommonStock_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 36%; text-align: left">Contingent consideration - common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">     <span style="-sec-ix-hidden: xdx2ixbrl0608"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">    <span style="-sec-ix-hidden: xdx2ixbrl0609"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">6,013,939</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">6,013,939</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--FairValueOfContingentConsiderationToWarrants_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Contingent consideration - warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0613"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0614"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,038,812</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,038,812</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left">Total liabilities measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0618">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0619">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,052,751</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,052,751</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zAmUwVrBVhw" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(Level 1)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_497_20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zYpB9BBZWTFb" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(Level 2)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4YHECf1mR8a" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(Level 3)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_496_20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zPwwxwJxes51" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Total</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December 31, 2021</td><td style="padding-bottom: 1pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(Level 1)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(Level 2)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(Level 3)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Total</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--MarketableSecurities_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt; width: 36%; text-align: left">Marketable securities (certificates of deposit)</td><td style="padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">    <span style="-sec-ix-hidden: xdx2ixbrl0623"> </span>-</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">1,255,266</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0625">-</span></td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">1,255,266</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_zgIfNXbnLOh2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Total assets measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0628">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,255,266</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0630">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,255,266</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--FairValueOfContingentConsiderationToCommonStock_iI_pp0p0_zgr84fZvOWrl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Contingent consideration - common stock</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0633">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0634">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,684,669</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,684,669</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--FairValueOfContingentConsiderationToWarrants_iI_pp0p0_z0x9aLWcjeha" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Contingent consideration - warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0638"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0639"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,747,972</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,747,972</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_zO5KsAJZbvZd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Total liabilities measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0643">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0644">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,432,641</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,432,641</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zdVDT85boOPb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s financial instruments that are measured at fair value on a recurring basis consist of certificates of deposit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zmbwcccQ4PC3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The changes for Level 3 items measured at fair value on a recurring basis are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 60pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zyJTykKEdo26" style="display: none">Schedule of Changes in Fair Value Measurement</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20220101__20220331_zg7E92CjoGm9" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--BusinessCombinationContingentConsiderationLiabilityNoncurrent_iS_pp0p0_zvJD5kRCGtD1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Fair value as of December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">10,432,641</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--ContingentConsideredIssuedForBusinessAcquisitions_i_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Change in fair value of contingent consideration issued for business acquisitions</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,379,890</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--BusinessCombinationContingentConsiderationLiabilityNoncurrent_iE_zrChinXAcgF1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Fair value as of March 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,052,751</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_z5p9XuLxjwv4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_890_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zwZSxdEWWSng" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the contingent consideration is based on the fair value of the contingent consideration-common stock and contingent consideration-warrants. The fair value of the contingent consideration-common stock is equal to the probability-adjusted value of the Company’s common stock as of March 31, 2022. The fair value of the contingent consideration-warrants is equal to the probability adjusted value of a call option with terms consistent with the terms of the warrants as of March 31, 2022. Prior to the probability adjustments, the warrants were valued based on the following inputs:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_zPgps9VUSTF9" style="display: none">Schedule of Contingent Consideration Common Stock and Warrants</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0"><b>March 31, 2022</b></p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December 31, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Stock price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_za3eAJEpvUg4" style="width: 16%; text-align: right" title="Warrants measurement input">6.18</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zz2npUQSdEdd" style="width: 16%; text-align: right">8.93</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Strike price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputStrikePriceMember_zTHjStxkGZ7d" style="text-align: right" title="Warrants measurement input">9.13</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputStrikePriceMember_zeQyIHyXFiD7" style="text-align: right">9.13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zCTHGvL6FAhl" style="text-align: right" title="Warrants measurement input">77.50</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zgzZ47AMeA9" style="text-align: right">80.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zakllESA7O3k" style="text-align: right" title="Warrants measurement input">2.40</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zd39BWd7xZZi" style="text-align: right">1.30</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220331_zvUDBAY5x1e6" title="Expected term">4.8</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231_zxHQ9Ir6Xws1" title="Expected term">5.0</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AB_zJouvqIAqTWh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_z1TUnPHxPCpf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the assets measured at fair value on a recurring basis as of March 31, 2022, and December 31, 2021, by level within the fair value hierarchy:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zn0KXPJ85aM5" style="display: none">Schedule of Fair Value Assets and Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_492_20220331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zGoKCJzpIDg1" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(Level 1)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20220331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zzmeErf3pD07" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(Level 2)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_490_20220331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zO0RfpKIVpef" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(Level 3)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_494_20220331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zKMZBJbGrbO4" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Total</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">March 31, 2022</td><td style="padding-bottom: 1pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(Level 1)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(Level 2)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(Level 3)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Total</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--FairValueOfContingentConsiderationToCommonStock_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 36%; text-align: left">Contingent consideration - common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">     <span style="-sec-ix-hidden: xdx2ixbrl0608"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">    <span style="-sec-ix-hidden: xdx2ixbrl0609"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">6,013,939</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">6,013,939</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--FairValueOfContingentConsiderationToWarrants_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Contingent consideration - warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0613"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0614"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,038,812</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,038,812</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left">Total liabilities measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0618">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0619">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,052,751</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,052,751</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zAmUwVrBVhw" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(Level 1)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_497_20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zYpB9BBZWTFb" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(Level 2)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4YHECf1mR8a" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(Level 3)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_496_20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zPwwxwJxes51" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Total</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December 31, 2021</td><td style="padding-bottom: 1pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(Level 1)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(Level 2)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(Level 3)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Total</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--MarketableSecurities_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt; width: 36%; text-align: left">Marketable securities (certificates of deposit)</td><td style="padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">    <span style="-sec-ix-hidden: xdx2ixbrl0623"> </span>-</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">1,255,266</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0625">-</span></td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">1,255,266</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_zgIfNXbnLOh2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Total assets measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0628">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,255,266</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0630">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,255,266</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--FairValueOfContingentConsiderationToCommonStock_iI_pp0p0_zgr84fZvOWrl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Contingent consideration - common stock</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0633">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0634">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,684,669</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,684,669</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--FairValueOfContingentConsiderationToWarrants_iI_pp0p0_z0x9aLWcjeha" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Contingent consideration - warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0638"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0639"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,747,972</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,747,972</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_zO5KsAJZbvZd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Total liabilities measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0643">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0644">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,432,641</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,432,641</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 6013939 6013939 1038812 1038812 7052751 7052751 1255266 1255266 1255266 1255266 8684669 8684669 1747972 1747972 10432641 10432641 <p id="xdx_89F_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zmbwcccQ4PC3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The changes for Level 3 items measured at fair value on a recurring basis are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 60pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zyJTykKEdo26" style="display: none">Schedule of Changes in Fair Value Measurement</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20220101__20220331_zg7E92CjoGm9" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--BusinessCombinationContingentConsiderationLiabilityNoncurrent_iS_pp0p0_zvJD5kRCGtD1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Fair value as of December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">10,432,641</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--ContingentConsideredIssuedForBusinessAcquisitions_i_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Change in fair value of contingent consideration issued for business acquisitions</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,379,890</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--BusinessCombinationContingentConsiderationLiabilityNoncurrent_iE_zrChinXAcgF1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Fair value as of March 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,052,751</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 10432641 -3379890 7052751 <p id="xdx_890_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zwZSxdEWWSng" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the contingent consideration is based on the fair value of the contingent consideration-common stock and contingent consideration-warrants. The fair value of the contingent consideration-common stock is equal to the probability-adjusted value of the Company’s common stock as of March 31, 2022. The fair value of the contingent consideration-warrants is equal to the probability adjusted value of a call option with terms consistent with the terms of the warrants as of March 31, 2022. Prior to the probability adjustments, the warrants were valued based on the following inputs:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_zPgps9VUSTF9" style="display: none">Schedule of Contingent Consideration Common Stock and Warrants</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0"><b>March 31, 2022</b></p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December 31, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Stock price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_za3eAJEpvUg4" style="width: 16%; text-align: right" title="Warrants measurement input">6.18</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zz2npUQSdEdd" style="width: 16%; text-align: right">8.93</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Strike price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputStrikePriceMember_zTHjStxkGZ7d" style="text-align: right" title="Warrants measurement input">9.13</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputStrikePriceMember_zeQyIHyXFiD7" style="text-align: right">9.13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zCTHGvL6FAhl" style="text-align: right" title="Warrants measurement input">77.50</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zgzZ47AMeA9" style="text-align: right">80.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zakllESA7O3k" style="text-align: right" title="Warrants measurement input">2.40</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zd39BWd7xZZi" style="text-align: right">1.30</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220331_zvUDBAY5x1e6" title="Expected term">4.8</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231_zxHQ9Ir6Xws1" title="Expected term">5.0</span></td><td style="text-align: left"> </td></tr> </table> 6.18 8.93 9.13 9.13 77.50 80.00 2.40 1.30 P4Y9M18D P5Y <p id="xdx_80B_eus-gaap--RevenueFromContractWithCustomerTextBlock_zpqPoGw7nbef" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 6 – <span id="xdx_82B_zcoVpJOpGVii">Revenue</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_zjzpB3Z6a1Vl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth revenue by geographic area:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zOk31aA4QC46" style="display: none">Summary of Revenue by Geographic Area</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Three Months Ended March 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">United States</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20220101__20220331__srt--StatementGeographicalAxis__srt--AmericasMember_zO6KdVB6crp3" style="width: 16%; text-align: right" title="Revenue">14,218,398</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20210101__20210331__srt--StatementGeographicalAxis__srt--AmericasMember_zH1raLFWw5ak" style="width: 16%; text-align: right" title="Revenue">12,493,950</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Rest of World</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20220101__20220331__srt--StatementGeographicalAxis__custom--RestOfWorldMember_zZCwleu1HUqf" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">8,480,646</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20210101__20210331__srt--StatementGeographicalAxis__custom--RestOfWorldMember_zQMBfqldHG95" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">7,530,819</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20220101__20220331_zNqA66xgGJe2" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">22,699,044</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20210101__20210331_zzGdsVCWa1l4" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">20,024,769</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Percentage of revenue by area:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">United States</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--StatementGeographicalAxis__srt--AmericasMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zJNqsVftaIP7" style="text-align: right" title="Percentage of revenue">63</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210331__srt--StatementGeographicalAxis__srt--AmericasMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_z3vDjFJaFwp" style="text-align: right" title="Percentage of revenue">62</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Rest of World</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--StatementGeographicalAxis__custom--RestOfWorldMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zvHtnH8YfXr4" style="text-align: right" title="Percentage of revenue">37</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210331__srt--StatementGeographicalAxis__custom--RestOfWorldMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zpCmkodyV2Dc" style="text-align: right" title="Percentage of revenue">38</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A0_zIfegbnW6Uyf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Deferred Revenue</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zRNSM86TC98g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in the Company’s deferred revenue balance for the three months ended March 31, 2022 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zb02F7FPfdY3" style="display: none">Schedule of Deferred Revenue</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Balance as of December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ContractWithCustomerLiability_iS_c20220101__20220331_zOG7i8rV0ufb" style="width: 18%; text-align: right" title="Deferred revenue, beginning balance">150,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt; text-align: left">Revenue recognized included in deferred revenue balance at the beginning of the period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_iN_di_c20220101__20220331_zK22NJYy1kc5" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue recognized included in deferred revenue balance at the beginning of the period">(150,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of March 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ContractWithCustomerLiability_iE_c20220101__20220331_zAnWErWeVaAb" style="border-bottom: Black 2.5pt double; text-align: right" title="Deferred revenue, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl0704">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_zVNoM1I0FPw6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_891_eus-gaap--ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_zjzpB3Z6a1Vl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth revenue by geographic area:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zOk31aA4QC46" style="display: none">Summary of Revenue by Geographic Area</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Three Months Ended March 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">United States</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20220101__20220331__srt--StatementGeographicalAxis__srt--AmericasMember_zO6KdVB6crp3" style="width: 16%; text-align: right" title="Revenue">14,218,398</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20210101__20210331__srt--StatementGeographicalAxis__srt--AmericasMember_zH1raLFWw5ak" style="width: 16%; text-align: right" title="Revenue">12,493,950</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Rest of World</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20220101__20220331__srt--StatementGeographicalAxis__custom--RestOfWorldMember_zZCwleu1HUqf" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">8,480,646</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20210101__20210331__srt--StatementGeographicalAxis__custom--RestOfWorldMember_zQMBfqldHG95" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">7,530,819</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20220101__20220331_zNqA66xgGJe2" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">22,699,044</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20210101__20210331_zzGdsVCWa1l4" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">20,024,769</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Percentage of revenue by area:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">United States</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--StatementGeographicalAxis__srt--AmericasMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zJNqsVftaIP7" style="text-align: right" title="Percentage of revenue">63</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210331__srt--StatementGeographicalAxis__srt--AmericasMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_z3vDjFJaFwp" style="text-align: right" title="Percentage of revenue">62</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Rest of World</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--StatementGeographicalAxis__custom--RestOfWorldMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zvHtnH8YfXr4" style="text-align: right" title="Percentage of revenue">37</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210331__srt--StatementGeographicalAxis__custom--RestOfWorldMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zpCmkodyV2Dc" style="text-align: right" title="Percentage of revenue">38</td><td style="text-align: left">%</td></tr> </table> 14218398 12493950 8480646 7530819 22699044 20024769 0.63 0.62 0.37 0.38 <p id="xdx_89A_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zRNSM86TC98g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in the Company’s deferred revenue balance for the three months ended March 31, 2022 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zb02F7FPfdY3" style="display: none">Schedule of Deferred Revenue</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Balance as of December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ContractWithCustomerLiability_iS_c20220101__20220331_zOG7i8rV0ufb" style="width: 18%; text-align: right" title="Deferred revenue, beginning balance">150,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt; text-align: left">Revenue recognized included in deferred revenue balance at the beginning of the period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_iN_di_c20220101__20220331_zK22NJYy1kc5" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue recognized included in deferred revenue balance at the beginning of the period">(150,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of March 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ContractWithCustomerLiability_iE_c20220101__20220331_zAnWErWeVaAb" style="border-bottom: Black 2.5pt double; text-align: right" title="Deferred revenue, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl0704">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 150000 150000 <p id="xdx_80F_eus-gaap--EarningsPerShareTextBlock_zqzsARI95O1j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 7 – <span id="xdx_82D_zMHulP5k08b2">Earnings Per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zIjgl2JqHws8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share for three months ended March 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_z6hrEutjv8gc" style="display: none">Schedule of Basic and Diluted Earnings Per Share</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_491_20220101__20220331_zUpmCzAFxnG6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20210101__20210331_zqoPs1NUpO15" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Numerator</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--NetIncomeLoss_zMI7jvntCw3g" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; width: 60%; text-align: left">Net income, as reported</td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">11,714,595</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">7,898,975</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Denominator</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--WeightedAverageNumberOfBasicSharesOutstanding_zCAt5rFLNPri" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average shares, basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33,935,570</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">28,662,885</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_zlKviuHvxXe" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">Dilutive effect of stock options, warrants and RSUs</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">775,906</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,339,844</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zeqgFoJIoihh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Shares used to compute diluted earnings per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">34,711,476</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">30,002,729</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--EarningsBasicPerShare_pid_zILOrADzfQfl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Basic earnings per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.35</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.28</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--EarningsPerShareDiluted_pid_z5ENeZbAszth" style="vertical-align: bottom; background-color: White"> <td>Diluted earnings per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.34</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.26</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A9_zBU4s7DXTxFh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended March 31, 2022, potentially dilutive securities of <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331_zaGQ8FbYzGAh" title="Securities excluded from computation of diluted earnings per share">1,271,304</span> were excluded from the calculation because their effect would have been anti-dilutive. For the three months ended March 31, 2021, potentially dilutive securities of <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210331_zzuhUVLMdw6i" title="Securities excluded from computation of diluted earnings per share">2,320,907</span> were excluded from the calculation because their effect would have been anti-dilutive. The computation of diluted earnings per share for the three months ended March 31, 2022 also excludes the approximately <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn5n6_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeyzTTcNPUS9" title="Securities excluded from computation of diluted earnings per share">1.4</span> million shares of common stock and approximately <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWt0YFewv1vd" title="Securities excluded from computation of diluted earnings per share">456,000</span> warrants to purchase shares of common stock that are contingent upon the achievement of certain milestones.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zIjgl2JqHws8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share for three months ended March 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_z6hrEutjv8gc" style="display: none">Schedule of Basic and Diluted Earnings Per Share</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_491_20220101__20220331_zUpmCzAFxnG6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20210101__20210331_zqoPs1NUpO15" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Numerator</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--NetIncomeLoss_zMI7jvntCw3g" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; width: 60%; text-align: left">Net income, as reported</td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">11,714,595</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">7,898,975</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Denominator</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--WeightedAverageNumberOfBasicSharesOutstanding_zCAt5rFLNPri" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average shares, basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33,935,570</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">28,662,885</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_zlKviuHvxXe" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">Dilutive effect of stock options, warrants and RSUs</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">775,906</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,339,844</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zeqgFoJIoihh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Shares used to compute diluted earnings per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">34,711,476</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">30,002,729</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--EarningsBasicPerShare_pid_zILOrADzfQfl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Basic earnings per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.35</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.28</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--EarningsPerShareDiluted_pid_z5ENeZbAszth" style="vertical-align: bottom; background-color: White"> <td>Diluted earnings per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.34</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.26</td><td style="text-align: left"> </td></tr> </table> 11714595 7898975 33935570 28662885 775906 1339844 34711476 30002729 0.35 0.28 0.34 0.26 1271304 2320907 1400000 456000 <p id="xdx_803_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_ztGLRUjhkhz1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 8 – <span id="xdx_823_zEOuy9NOjafe">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock Incentive Plans</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Co-Diagnostics, Inc. Amended and Restated 2015 Long Term Incentive Plan (the “Incentive Plan”) reserves an aggregate of <span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20220331__us-gaap--PlanNameAxis__custom--TwoThousandFifteenLongTermIncentivePlanMember_zpD8EaQDAGt2" title="Aggregate number of common shares reserved">6,000,000</span> shares of common stock issuable upon the grant of awards under the Incentive Plan. The number of awards available for issuance under the Incentive Plan was <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20220331__us-gaap--PlanNameAxis__custom--TwoThousandFifteenLongTermIncentivePlanMember_zuIpJWFska7j" title="Number of common shares availalble for issuance">2,095,266</span> at March 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock Options</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ztKgdy8Bqvh3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes option activity during the three months ended March 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zFj1t5YgHYJ7" style="display: none">Schedule of Option Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Number of Options</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Weighted Average Fair Value</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; width: 36%">Outstanding at December 31, 2021</td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20220331_zm8ni8HOyp94" style="padding-bottom: 2.5pt; width: 12%; text-align: right" title="Number of Options Outstanding, Beginning">1,111,363</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="padding-bottom: 2.5pt; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20220331_zjFS2oGGdLC" style="padding-bottom: 2.5pt; width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning">2.12</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="padding-bottom: 2.5pt; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20220331_zAqHrRACGyn1" style="padding-bottom: 2.5pt; width: 12%; text-align: right" title="Weighted Average Fair Value Outstanding, Beginning">1.31</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pid_dtY_c20220101__20220331_zjmfQduMY8Jh" style="padding-bottom: 2.5pt; width: 12%; text-align: right" title="Weighted-average Remaining Contractual Life (years) Outstanding, Beginning">6.62</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220101__20220331_zFZq5mwhakx6" style="text-align: right" title="Number of Options Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0752">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20220331_zLJwzTPT313j" style="text-align: right" title="Weighted Average Exercise Price Granted"><span style="-sec-ix-hidden: xdx2ixbrl0754">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20220331_zMNO7zKKMxqh" style="text-align: right" title="Weighted Average Fair Value Granted"><span style="-sec-ix-hidden: xdx2ixbrl0756">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20220101__20220331_z2lnJiwKu0kd" style="text-align: right" title="Number of Options Outstanding, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0758">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20220331_zpscqZ4oqLGf" style="text-align: right" title="Weighted Average Exercise Price Expired"><span style="-sec-ix-hidden: xdx2ixbrl0760">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20220101__20220331_ziJTEheYQg9i" style="text-align: right" title="Weighted Average Fair Value Expired"><span style="-sec-ix-hidden: xdx2ixbrl0762">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Forfeited/Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20220101__20220331_zm9zTDNfUqg1" style="text-align: right" title="Number of Options Outstanding, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0764">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20220331_zI60XZcOrfIg" style="text-align: right" title="Weighted Average Exercise Price Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0766">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_c20220101__20220331_zTusk0Q1HwEi" style="text-align: right" title="Weighted Average Fair Value Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0768">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_iN_di_c20220101__20220331_zmfWwUWz21fk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Exercised">(45,456</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331_zH4PiywzNzl7" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price Exercised">1.10</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised_iE_pid_c20220101__20220331_zctHiNPIvZE" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Fair Value Exercised">0.51</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20220331_z1G0zrKY3xE6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Ending">1,065,907</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220331_zWUT54m7tuGe" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price Outstanding, Ending">2.17</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20220101__20220331_z1CaCrgSNUX5" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Fair Value Outstanding, Ending">1.35</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20220331_zHaUED7Uv6C1" title="Weighted-average Remaining Contractual Life (years) Outstanding, Ending">6.65</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable at March 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20220331_ziLdpTMQn0j3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable Ending">1,049,241</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20220331_zwUa7Rgtndfk" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Exercisable Ending">2.05</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_984_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable_iE_pid_c20220101__20220331_z1WB4Z83K5md" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Fair Value, Exercisable Ending">1.21</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331_zNnzpFa7cASa" title="Weighted-average Remaining Contractual Life (years), Exercisable Ending">6.63</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zRuBH60lvY9g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total intrinsic value of options exercised during the three months ended March 31, 2022 was approximately $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn5n6_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zZoD4nPdZNT" title="Intrinsic value of options value exercised">0.3</span> million. The aggregate intrinsic value of outstanding options at March 31, 2022 was approximately $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn5n6_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zV1WjMkJrShi" title="Aggregate intrinsic value of outstanding options">4.5</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation cost is measured at the grant date based on the fair value of the award granted and recognized as expense over the vesting period using the straight-line method. The Company uses the Black-Scholes model to value options granted.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2022, there were <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z2p1NoWfTHW1" title="Unvested options">16,666</span> of unvested options and $<span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pip0_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zcU9HUokbRth" title="Unrecognized stock-based compensation">37,241</span> of unrecognized stock-based compensation expense. The unrecognized stock-based compensation expense is expected to be recognized over <span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zUlhK2OM32Il" title="Unrecognized stock-based compensation recognition period">0.2</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted Stock Units</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zkR6cdqpf4h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The grant date fair value of RSUs granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the awards. The following table sets forth the outstanding RSUs and related activity for the three months ended March 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zCzRWJbV2WC1" style="display: none">Schedule of Outstanding Restricted Stock Units and Related Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Number of RSUs</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Weighted Average Grant Date Fair Value</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; width: 60%">Unvested at December 31, 2021</td><td style="padding-bottom: 1pt; width: 2%"> </td> <td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zj0haNKa41L6" style="padding-bottom: 1pt; width: 16%; text-align: right" title="Number of Restricted Stock Units, Outstanding Beginning">1,267,415</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1pt; width: 2%"> </td> <td style="padding-bottom: 1pt; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPDQwjPVPZQ7" style="padding-bottom: 1pt; width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding Beginning">9.94</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBvpfwns7NXf" style="text-align: right" title="Number of Restricted Stock Units, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0808">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbfceDCgQzG1" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0810">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsr2FAUFsY15" style="text-align: right" title="Number of Restricted Stock Units, Vested">(68,750</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdoJlsjmka6f" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested">10.23</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt">Forfeited/Cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zd2CW2RnTX41" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Restricted Stock Units, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0816">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRdW35RSmsJ5" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0818">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Unvested at March 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zF15KGf5pLSi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Restricted Stock Units, Outstanding Ending">1,198,665</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4ziqRB3cBJe" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding Ending">9.92</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_za2eDRK6cH34" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2022, there was approximately $<span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgZJ8XzuxWVg" title="Unrecognized stock-based compensation">10.3</span> million of unrecognized stock-based compensation expense related to outstanding RSUs which is expected to be recognized over a weighted-average period of <span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zE8TYnrDazh1" title="Unrecognized stock-based compensation recognition period">2.1</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has issued warrants related to financings, acquisitions and as compensation to third parties for services provided. The Company estimates the fair value of issued warrants on the date of issuance as determined using a Black-Scholes pricing model. The Company amortizes the fair value of issued warrants using a vesting schedule based on the terms and conditions of each warrant if granted for services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z1wJP62NylF4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes warrant activity during the three months ended March 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zmWowKLiH7td" style="display: none">Schedule of Warrant Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; width: 36%">Outstanding at December 31, 2021</td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20220331_zINttDYfthV3" style="padding-bottom: 2.5pt; width: 12%; text-align: right" title="Number of Warrants Outstanding, Beginning">526,281</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="padding-bottom: 2.5pt; width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220331_zaEjjCFGB8If" style="padding-bottom: 2.5pt; width: 12%; text-align: right" title="Weighted Average Exercise Price, Beginning">8.15</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="padding-bottom: 2.5pt; width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue_iS_c20220101__20220331_zAMBLeDQI2xc" style="padding-bottom: 2.5pt; width: 12%; text-align: right" title="Weighted Average Fair Value, Beginning">4.01</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 2.5pt; width: 12%; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331_zXxfhiYJ8YQj" title="Weighted-average Remaining Contractual Life (Years) Outstanding, Beginning">4.7</span></td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20220331_zFTwFSliwhhb" style="text-align: right" title="Number of Warrants Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0838">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20220331_zOtZnFemB6X9" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0840">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20220331_z8woLIlZ5ZZb" style="text-align: right" title="Weighted Average Fair Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0842">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20220331_zwxKLvtGG0Z4" style="text-align: right" title="Number of Warrants Outstanding, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0844">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20220331_z5XhppworVa7" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0846">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsExpirationsWeightedAverageGrantDateFairValue_c20220101__20220331_zI1ZFD4Jam0g" style="text-align: right" title="Weighted Average Fair Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0848">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Forfeited/Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20220331_z0igDcUrLtCg" style="text-align: right" title="Number of Warrants Outstanding, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0850">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20220331_zSDpvx9C9ii6" style="text-align: right" title="Weighted Average Exercise Price, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0852">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue_c20220101__20220331_znqvowCE0we1" style="text-align: right" title="Weighted Average Fair Value, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0854">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20220331_zUDzI34kvrZi" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Outstanding, Exercised">(50,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20220331_zi3iWflCO9Kc" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Exercised">2.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_c20220101__20220331_zCkH6fj1orj5" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Fair Value, Exercised">1.22</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20220331_zUIDeoF7zjq5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Ending">476,281</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOutstandingWeightedAverageExercisePrice_iE_c20220101__20220331_zi0ar9QRWgNe" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Ending">8.80</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue_iE_c20220101__20220331_zKatffPbVt73" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Fair Value, Ending">2.82</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331_zujqIlxFtNni" title="Weighted-average Remaining Contractual Life (Years) Outstanding, Ending">4.8</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zVsjyVbN7idg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The intrinsic value of warrants exercised during the three months ended March 31, 2022 and 2021 was approximately $<span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriodTotalIntrinsicValue_pn5n6_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zAkC7w0Nbmvi" title="Intrinsic value of warrants exercised">0.3</span> million and $<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriodTotalIntrinsicValue_pn5n6_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zkeBUQsXknG" title="Intrinsic value of warrants exercised">0</span>, respectively. The aggregate intrinsic value of outstanding warrants at March 31, 2022 was approximately $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn5n6_c20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKHKKGZnifxl" title="Aggregate intrinsic value of options outstanding">0.1</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total number of warrants exercisable at March 31, 2022 are <span id="xdx_90B_ecustom--ClassOfWarrantExercisable_iI_c20220331_zQ0Gkr3LALMh" title="Warrants exercisable">20,000</span>. The ability to exercise the approximately <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220331_zFgoIyvT3tO8" title="Warrants to purchase a common stock">456,000</span> warrants issued in connection with acquisitions in the prior year is contingent upon the achievement of certain development and revenue milestones on or before January 1, 2027. There was no unrecognized stock-based compensation expense related to warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock Issued for Services</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has issued restricted stock to third parties for services provided. The grant date fair value of the restricted stock granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the stock awards. The Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220101__20220331__srt--TitleOfIndividualAxis__custom--ThirdPartiesMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zj2SYp8VDwg2" title="Number of shares issued for services">0</span> and <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20210331__srt--TitleOfIndividualAxis__custom--ThirdPartiesMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zi6LabDAx2Uh" title="Number of shares issued for services">4,290</span> shares of restricted stock for services during the three months ended March 31, 2022 and 2021, respectively. There was no unrecognized stock-based compensation expense related to restricted stock issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based Compensation Expense</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zPYBrbJSqFV2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized stock-based compensation expense related to the types of awards discussed above as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_z76fbZFhXxG8" style="display: none">Schedule of Recognized Stock-based Compensation Expense</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_491_20220101__20220331_zSzyjgXgojKj" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_498_20210101__20210331_zLEHlnmmSMdb" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Three Months Ended March 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ze6yUBk9hx1k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">40,874</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">76,672</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsQ7WzlCG6c3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,334,223</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,396,440</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_zm2AWY00LFua" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0892"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">39,900</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_zeoC4gLwIlK9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,375,097</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,513,012</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_zmSgsxVv7dqd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 6000000 2095266 <p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ztKgdy8Bqvh3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes option activity during the three months ended March 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zFj1t5YgHYJ7" style="display: none">Schedule of Option Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Number of Options</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Weighted Average Fair Value</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; width: 36%">Outstanding at December 31, 2021</td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20220331_zm8ni8HOyp94" style="padding-bottom: 2.5pt; width: 12%; text-align: right" title="Number of Options Outstanding, Beginning">1,111,363</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="padding-bottom: 2.5pt; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20220331_zjFS2oGGdLC" style="padding-bottom: 2.5pt; width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning">2.12</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="padding-bottom: 2.5pt; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20220331_zAqHrRACGyn1" style="padding-bottom: 2.5pt; width: 12%; text-align: right" title="Weighted Average Fair Value Outstanding, Beginning">1.31</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pid_dtY_c20220101__20220331_zjmfQduMY8Jh" style="padding-bottom: 2.5pt; width: 12%; text-align: right" title="Weighted-average Remaining Contractual Life (years) Outstanding, Beginning">6.62</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220101__20220331_zFZq5mwhakx6" style="text-align: right" title="Number of Options Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0752">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20220331_zLJwzTPT313j" style="text-align: right" title="Weighted Average Exercise Price Granted"><span style="-sec-ix-hidden: xdx2ixbrl0754">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20220331_zMNO7zKKMxqh" style="text-align: right" title="Weighted Average Fair Value Granted"><span style="-sec-ix-hidden: xdx2ixbrl0756">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20220101__20220331_z2lnJiwKu0kd" style="text-align: right" title="Number of Options Outstanding, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0758">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20220331_zpscqZ4oqLGf" style="text-align: right" title="Weighted Average Exercise Price Expired"><span style="-sec-ix-hidden: xdx2ixbrl0760">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20220101__20220331_ziJTEheYQg9i" style="text-align: right" title="Weighted Average Fair Value Expired"><span style="-sec-ix-hidden: xdx2ixbrl0762">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Forfeited/Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20220101__20220331_zm9zTDNfUqg1" style="text-align: right" title="Number of Options Outstanding, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0764">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20220331_zI60XZcOrfIg" style="text-align: right" title="Weighted Average Exercise Price Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0766">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_c20220101__20220331_zTusk0Q1HwEi" style="text-align: right" title="Weighted Average Fair Value Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0768">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_iN_di_c20220101__20220331_zmfWwUWz21fk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Exercised">(45,456</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331_zH4PiywzNzl7" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price Exercised">1.10</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised_iE_pid_c20220101__20220331_zctHiNPIvZE" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Fair Value Exercised">0.51</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20220331_z1G0zrKY3xE6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Ending">1,065,907</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220331_zWUT54m7tuGe" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price Outstanding, Ending">2.17</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20220101__20220331_z1CaCrgSNUX5" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Fair Value Outstanding, Ending">1.35</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20220331_zHaUED7Uv6C1" title="Weighted-average Remaining Contractual Life (years) Outstanding, Ending">6.65</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable at March 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20220331_ziLdpTMQn0j3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable Ending">1,049,241</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20220331_zwUa7Rgtndfk" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Exercisable Ending">2.05</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_984_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable_iE_pid_c20220101__20220331_z1WB4Z83K5md" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Fair Value, Exercisable Ending">1.21</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331_zNnzpFa7cASa" title="Weighted-average Remaining Contractual Life (years), Exercisable Ending">6.63</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1111363 2.12 1.31 P6Y7M13D 45456 1.10 0.51 1065907 2.17 1.35 P6Y7M24D 1049241 2.05 1.21 P6Y7M17D 300000 4500000 16666 37241 P0Y2M12D <p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zkR6cdqpf4h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The grant date fair value of RSUs granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the awards. The following table sets forth the outstanding RSUs and related activity for the three months ended March 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zCzRWJbV2WC1" style="display: none">Schedule of Outstanding Restricted Stock Units and Related Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Number of RSUs</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Weighted Average Grant Date Fair Value</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; width: 60%">Unvested at December 31, 2021</td><td style="padding-bottom: 1pt; width: 2%"> </td> <td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zj0haNKa41L6" style="padding-bottom: 1pt; width: 16%; text-align: right" title="Number of Restricted Stock Units, Outstanding Beginning">1,267,415</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1pt; width: 2%"> </td> <td style="padding-bottom: 1pt; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPDQwjPVPZQ7" style="padding-bottom: 1pt; width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding Beginning">9.94</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBvpfwns7NXf" style="text-align: right" title="Number of Restricted Stock Units, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0808">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbfceDCgQzG1" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0810">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsr2FAUFsY15" style="text-align: right" title="Number of Restricted Stock Units, Vested">(68,750</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdoJlsjmka6f" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested">10.23</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt">Forfeited/Cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zd2CW2RnTX41" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Restricted Stock Units, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0816">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRdW35RSmsJ5" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0818">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Unvested at March 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zF15KGf5pLSi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Restricted Stock Units, Outstanding Ending">1,198,665</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4ziqRB3cBJe" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding Ending">9.92</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1267415 9.94 68750 10.23 1198665 9.92 10300000 P2Y1M6D <p id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z1wJP62NylF4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes warrant activity during the three months ended March 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zmWowKLiH7td" style="display: none">Schedule of Warrant Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; width: 36%">Outstanding at December 31, 2021</td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20220331_zINttDYfthV3" style="padding-bottom: 2.5pt; width: 12%; text-align: right" title="Number of Warrants Outstanding, Beginning">526,281</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="padding-bottom: 2.5pt; width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220331_zaEjjCFGB8If" style="padding-bottom: 2.5pt; width: 12%; text-align: right" title="Weighted Average Exercise Price, Beginning">8.15</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="padding-bottom: 2.5pt; width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue_iS_c20220101__20220331_zAMBLeDQI2xc" style="padding-bottom: 2.5pt; width: 12%; text-align: right" title="Weighted Average Fair Value, Beginning">4.01</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 2.5pt; width: 12%; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331_zXxfhiYJ8YQj" title="Weighted-average Remaining Contractual Life (Years) Outstanding, Beginning">4.7</span></td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20220331_zFTwFSliwhhb" style="text-align: right" title="Number of Warrants Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0838">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20220331_zOtZnFemB6X9" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0840">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20220331_z8woLIlZ5ZZb" style="text-align: right" title="Weighted Average Fair Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0842">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20220331_zwxKLvtGG0Z4" style="text-align: right" title="Number of Warrants Outstanding, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0844">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20220331_z5XhppworVa7" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0846">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsExpirationsWeightedAverageGrantDateFairValue_c20220101__20220331_zI1ZFD4Jam0g" style="text-align: right" title="Weighted Average Fair Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0848">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Forfeited/Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20220331_z0igDcUrLtCg" style="text-align: right" title="Number of Warrants Outstanding, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0850">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20220331_zSDpvx9C9ii6" style="text-align: right" title="Weighted Average Exercise Price, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0852">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue_c20220101__20220331_znqvowCE0we1" style="text-align: right" title="Weighted Average Fair Value, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0854">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20220331_zUDzI34kvrZi" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Outstanding, Exercised">(50,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20220331_zi3iWflCO9Kc" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Exercised">2.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_c20220101__20220331_zCkH6fj1orj5" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Fair Value, Exercised">1.22</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20220331_zUIDeoF7zjq5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Ending">476,281</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOutstandingWeightedAverageExercisePrice_iE_c20220101__20220331_zi0ar9QRWgNe" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Ending">8.80</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue_iE_c20220101__20220331_zKatffPbVt73" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Fair Value, Ending">2.82</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331_zujqIlxFtNni" title="Weighted-average Remaining Contractual Life (Years) Outstanding, Ending">4.8</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 526281 8.15 4.01 P4Y8M12D 50000 2.00 1.22 476281 8.80 2.82 P4Y9M18D 300000 0 100000 20000 456000 0 4290 <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zPYBrbJSqFV2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized stock-based compensation expense related to the types of awards discussed above as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_z76fbZFhXxG8" style="display: none">Schedule of Recognized Stock-based Compensation Expense</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_491_20220101__20220331_zSzyjgXgojKj" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_498_20210101__20210331_zLEHlnmmSMdb" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Three Months Ended March 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ze6yUBk9hx1k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">40,874</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">76,672</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsQ7WzlCG6c3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,334,223</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,396,440</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_zm2AWY00LFua" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0892"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">39,900</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_zeoC4gLwIlK9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,375,097</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,513,012</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 40874 76672 1334223 1396440 39900 1375097 1513012 <p id="xdx_80E_eus-gaap--IncomeTaxDisclosureTextBlock_zppyCcVYXcO" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9 – <span id="xdx_823_zf2PBTQeSRoj">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended March 31, 2022, the Company recognized expense from income taxes of $<span id="xdx_908_eus-gaap--IncomeTaxExpenseBenefit_c20220101__20220331_z1tCSpWLmFo7" title="Income tax expense benefit">1,386,087</span>, representing an effective tax rate of <span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20220331_zPyFA3rZrKqc" title="Effective tax rate">10.6</span>%. The Company’s effective tax rate will generally differ from the U.S. Federal statutory rate of <span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20220331_zWmLJWvwz8Qe" title="Effective federal statutory tax rate">21.0</span>% due to state taxes, permanent items, and discrete items. For the three months ended March 31, 2021, the Company recognized expense from income taxes of $<span id="xdx_90F_eus-gaap--IncomeTaxExpenseBenefit_c20210101__20210331_zHYWtUxgSXP3" title="Income tax expense benefit">1,985,640</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1386087 0.106 0.210 1985640 <p id="xdx_805_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zy9OByMN4GHl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 10 – <span id="xdx_823_z8hNhd2P3LZ5">Related Party Transactions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company acquired the exclusive rights to the CoPrimer technology pursuant to an exclusive license agreement, dated April 2014 (the “Exclusive License Agreement”), between the Company and DNA Logix, Inc., which was assigned to Dr. Brent Satterfield, a former executive officer, prior to the Company’s acquisition of DNA Logix, Inc. On March 1, 2017, the Company entered into an amendment to its Exclusive License Agreement for its Cooperative Primers (“License”) technology with Dr. Satterfield. The amendment provides in part that all accrued royalties under the License cease as of January 1, 2017, and the Company began in January 2017 to pay to Dr. Satterfield $<span id="xdx_90F_eus-gaap--AccruedRoyaltiesCurrent_iI_pp0p0_c20170130__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--DrBrentSatterfieldMember_z0VdzYJIufjj" title="Accrued royalties">700,000</span> of accrued royalties at the rate of $<span id="xdx_905_eus-gaap--PaymentsForRoyalties_c20170101__20170130__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--DrBrentSatterfieldMember_pp0p0" title="Payment for royalties per month">10,000</span> per month. At March 31, 2022 and 2021, the aggregate balance of this related party liability was $<span id="xdx_90E_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20220331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--DrBrentSatterfieldMember_zgoU24xJvbxj" title="Due to related party">0</span> and $<span id="xdx_908_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20210331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--DrBrentSatterfieldMember_z7iPe3fPq6f" title="Due to related party">120,000</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 700000 10000 0 120000 <p id="xdx_80C_eus-gaap--LesseeOperatingLeasesTextBlock_zPEbg8C0gI9k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 11 – <span id="xdx_826_zSmjfgkGNaak">Leases</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company leases office space under a non-cancelable operating lease and leases cancellable with one month notice. The Company expenses the cancellable leases in the period incurred in accordance with the practical expedient elected. As such, one lease makes up the entirety of the right-of-use asset and lease liability disclosed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--LeaseCostTableTextBlock_zhGVF0ucspb4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended March 31, 2022, components of lease expense are summarized as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zouiYmOacxib" style="display: none">Schedule of Lease Expense</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_495_20220101__20220331_z6tVJLHMb66l" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Three Months Ended March 31, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseCost_maLCz2lp_zH9otZYmiV92" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 72%; text-align: left">Operating lease costs</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 24%; text-align: right">86,588</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ShortTermLeaseCost_maLCz2lp_z0BHr5iP7Dwf" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">Short-term lease costs</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">76,080</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LeaseCost_iT_mtLCz2lp_zrKTVxoTGlc7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total lease costs</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">162,668</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A8_z4RdnrnG9Vse" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term lease costs under month-to-month lease agreements are paid to related parties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_ecustom--ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesTableTextBlock_zVVzrDGvgdsf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2022, the maturities of the Company’s lease liabilities are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zUJ5ZslRfQX1" style="display: none">Schedule of Maturities on Company Lease Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_494_20220331_zBhZuJRG2BR2" style="border-bottom: Black 1pt solid; font-weight: bold"><p style="text-align: center; margin-top: 0; margin-bottom: 0">Year Ending</p> <p style="text-align: center; margin-top: 0; margin-bottom: 0">December 31,</p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPz8za_zhHwGPyV3gdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 78%">2022 (remainder)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">221,350</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz8za_zLFPq8utmS88" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">303,059</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz8za_zDoXm5VHYgdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,774</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz8za_z15HGB0gFQv5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">2025</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0936"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz8za_zBWq2EvaX9C9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">2026</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0938"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_maLOLLPz8za_zhoLnWbBfXpa" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0940"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz8za_zEuyMBoF1m2g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">575,183</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_zBlcdvQfROwh" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">Less: imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">16,212</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zzYB8uOuq2r3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Present value of operating lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">558,971</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zCddX53lu3fi" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">Less: current portion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">283,299</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zVaNJB2rcYo4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Long-term portion</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">275,672</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A2_zeNKcpFpfg2i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_ecustom--ScheduleOfOperatingLeaseTableTextBlock_z2pxsh2kbXMk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other information related to operating leases was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zcoHjjw4IjUj" style="display: none">Schedule of Other Information Related to Operating Lease</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_497_20220101__20220331_zsSIqJQrcOkd" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Three Months Ended March 31, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingLeasePayments_zpgMXeWO2Xme" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Cash paid for operating leases included in operating cash flows</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">154,882</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Remaining lease term of operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220331_zuSeRQcIqvPb" title="Remaining lease term of operating leases">2</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Discount rate of operating leases</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20220331_zON7zcW1s8cl" style="text-align: right" title="Discount rate of operating leases">3.1</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8AC_zeUrWUVup369" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zFGBOl3587Fi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021, future lease payments under ASC 840 for operating leases were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_z4qq0XhUJzac" style="display: none">Schedule of Future Minimum Lease Payments</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Year Ending December 31,</td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20220331_zCSh6K2O3S73" style="border-bottom: Black 1pt solid; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_iI_maOLFMPz5Lk_z2Nsfjwe9kN" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 78%; text-align: left">2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">293,595</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueCurrent_iI_maOLFMPz5Lk_zzEsZPvLCn8a" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">303,059</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_maOLFMPz5Lk_zVhhO38N9Mid" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">50,774</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iTI_mtOLFMPz5Lk_zus8e4KpaRV4" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left">Total lease payments</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">647,428</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zi80tmDcFWj8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--LeaseCostTableTextBlock_zhGVF0ucspb4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended March 31, 2022, components of lease expense are summarized as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zouiYmOacxib" style="display: none">Schedule of Lease Expense</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_495_20220101__20220331_z6tVJLHMb66l" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Three Months Ended March 31, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseCost_maLCz2lp_zH9otZYmiV92" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 72%; text-align: left">Operating lease costs</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 24%; text-align: right">86,588</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ShortTermLeaseCost_maLCz2lp_z0BHr5iP7Dwf" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">Short-term lease costs</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">76,080</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LeaseCost_iT_mtLCz2lp_zrKTVxoTGlc7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total lease costs</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">162,668</td><td style="text-align: left"> </td></tr> </table> 86588 76080 162668 <p id="xdx_896_ecustom--ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesTableTextBlock_zVVzrDGvgdsf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2022, the maturities of the Company’s lease liabilities are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zUJ5ZslRfQX1" style="display: none">Schedule of Maturities on Company Lease Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_494_20220331_zBhZuJRG2BR2" style="border-bottom: Black 1pt solid; font-weight: bold"><p style="text-align: center; margin-top: 0; margin-bottom: 0">Year Ending</p> <p style="text-align: center; margin-top: 0; margin-bottom: 0">December 31,</p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPz8za_zhHwGPyV3gdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 78%">2022 (remainder)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">221,350</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz8za_zLFPq8utmS88" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">303,059</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz8za_zDoXm5VHYgdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,774</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz8za_z15HGB0gFQv5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">2025</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0936"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz8za_zBWq2EvaX9C9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">2026</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0938"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_maLOLLPz8za_zhoLnWbBfXpa" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0940"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz8za_zEuyMBoF1m2g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">575,183</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_zBlcdvQfROwh" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">Less: imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">16,212</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zzYB8uOuq2r3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Present value of operating lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">558,971</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zCddX53lu3fi" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">Less: current portion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">283,299</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zVaNJB2rcYo4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Long-term portion</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">275,672</td><td style="text-align: left"> </td></tr> </table> 221350 303059 50774 575183 16212 558971 283299 275672 <p id="xdx_89C_ecustom--ScheduleOfOperatingLeaseTableTextBlock_z2pxsh2kbXMk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other information related to operating leases was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zcoHjjw4IjUj" style="display: none">Schedule of Other Information Related to Operating Lease</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_497_20220101__20220331_zsSIqJQrcOkd" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Three Months Ended March 31, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingLeasePayments_zpgMXeWO2Xme" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Cash paid for operating leases included in operating cash flows</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">154,882</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Remaining lease term of operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220331_zuSeRQcIqvPb" title="Remaining lease term of operating leases">2</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Discount rate of operating leases</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20220331_zON7zcW1s8cl" style="text-align: right" title="Discount rate of operating leases">3.1</td><td style="text-align: left">%</td></tr> </table> 154882 P2Y 0.031 <p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zFGBOl3587Fi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021, future lease payments under ASC 840 for operating leases were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_z4qq0XhUJzac" style="display: none">Schedule of Future Minimum Lease Payments</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Year Ending December 31,</td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20220331_zCSh6K2O3S73" style="border-bottom: Black 1pt solid; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_iI_maOLFMPz5Lk_z2Nsfjwe9kN" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 78%; text-align: left">2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">293,595</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueCurrent_iI_maOLFMPz5Lk_zzEsZPvLCn8a" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">303,059</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_maOLFMPz5Lk_zVhhO38N9Mid" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">50,774</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iTI_mtOLFMPz5Lk_zus8e4KpaRV4" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left">Total lease payments</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">647,428</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 293595 303059 50774 647428 <p id="xdx_804_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zhotIR4Z9cd4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 12 –<span id="xdx_82A_z1MdzimMC083"> Commitments and Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Litigation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is currently a defendant in five different securities class action complaints that were filed by certain stockholders of the Company claiming that the Company promulgated false and misleading press releases to increase the price of our stock to improperly benefit the officers and directors of the Company. The plaintiffs demand compensatory damages sustained as a result of the Company’s alleged wrongdoing in an amount to be proven at trial. The Company believes these lawsuits are without merit and intends to defend the cases vigorously. The Company is unable to estimate a range of loss, if any, that could result were there to be an adverse final decision in these cases. As of the date of this report, the Company does not believe it is probable that these cases will result in an unfavorable outcome; however, if an unfavorable outcome were to occur in these cases, it is possible that the impact could be material to the Company’s results of operations in the period(s) in which any such outcome becomes probable and estimable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_807_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zkgBojtQKENl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 13 – <span id="xdx_827_zp7H4K9bbtt9">Share Repurchase Program</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span> </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2022, the Company’s Board of Directors authorized a share repurchase program that would allow the Company to repurchase up to $<span id="xdx_900_eus-gaap--StockRepurchaseProgramAuthorizedAmount1_iI_pn5n6_c20220331_z6xGkHaVHpM7" title="Stock repurchase program authorized amount">30.0</span> million of CODX common stock. The repurchase program does not obligate the Company to acquire any particular amount of common shares, and the repurchase program may be suspended or discontinued at any time at the Company’s discretion. The timing and amount of any share repurchases under the share repurchase program will be determined by Co-Diagnostics’ management at its discretion based on ongoing assessments of the capital needs of the business, the market price of the Company’s common stock, corporate and regulatory requirements, and general market conditions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has not made any repurchases under the share purchase program since its implementation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 30000000.0 <p id="xdx_80A_eus-gaap--SubsequentEventsTextBlock_zZ26vTghGtkh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 14 – <span id="xdx_82D_zKe8NmtZ1Yuj">Subsequent Events</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluated subsequent events pursuant to ASC Topic 855 and has determined that there are no events that need to be reported.</span></p> Based on weighted-average useful life established as of the acquisition date. EXCEL 62 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 64 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 65 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 92 286 1 true 37 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://codiagnostics.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets (Unaudited) Sheet http://codiagnostics.com/role/BalanceSheets Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://codiagnostics.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://codiagnostics.com/role/StatementsOfOperations Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://codiagnostics.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://codiagnostics.com/role/StatementsOfStockholdersEquity Consolidated Statements of Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Overview and Basis of Presentation Sheet http://codiagnostics.com/role/OverviewAndBasisOfPresentation Overview and Basis of Presentation Notes 7 false false R8.htm 00000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://codiagnostics.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Business Combinations Sheet http://codiagnostics.com/role/BusinessCombinations Business Combinations Notes 9 false false R10.htm 00000010 - Disclosure - Goodwill and Intangible Assets Sheet http://codiagnostics.com/role/GoodwillAndIntangibleAssets Goodwill and Intangible Assets Notes 10 false false R11.htm 00000011 - Disclosure - Fair Value Measurements Sheet http://codiagnostics.com/role/FairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 00000012 - Disclosure - Revenue Sheet http://codiagnostics.com/role/Revenue Revenue Notes 12 false false R13.htm 00000013 - Disclosure - Earnings Per Share Sheet http://codiagnostics.com/role/EarningsPerShare Earnings Per Share Notes 13 false false R14.htm 00000014 - Disclosure - Stock-Based Compensation Sheet http://codiagnostics.com/role/Stock-basedCompensation Stock-Based Compensation Notes 14 false false R15.htm 00000015 - Disclosure - Income Taxes Sheet http://codiagnostics.com/role/IncomeTaxes Income Taxes Notes 15 false false R16.htm 00000016 - Disclosure - Related Party Transactions Sheet http://codiagnostics.com/role/RelatedPartyTransactions Related Party Transactions Notes 16 false false R17.htm 00000017 - Disclosure - Leases Sheet http://codiagnostics.com/role/Leases Leases Notes 17 false false R18.htm 00000018 - Disclosure - Commitments and Contingencies Sheet http://codiagnostics.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 18 false false R19.htm 00000019 - Disclosure - Share Repurchase Program Sheet http://codiagnostics.com/role/ShareRepurchaseProgram Share Repurchase Program Notes 19 false false R20.htm 00000020 - Disclosure - Subsequent Events Sheet http://codiagnostics.com/role/SubsequentEvents Subsequent Events Notes 20 false false R21.htm 00000021 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://codiagnostics.com/role/SummaryOfSignificantAccountingPolicies 21 false false R22.htm 00000022 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://codiagnostics.com/role/GoodwillAndIntangibleAssetsTables Goodwill and Intangible Assets (Tables) Tables http://codiagnostics.com/role/GoodwillAndIntangibleAssets 22 false false R23.htm 00000023 - Disclosure - Fair Value Measurements (Tables) Sheet http://codiagnostics.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://codiagnostics.com/role/FairValueMeasurements 23 false false R24.htm 00000024 - Disclosure - Revenue (Tables) Sheet http://codiagnostics.com/role/RevenueTables Revenue (Tables) Tables http://codiagnostics.com/role/Revenue 24 false false R25.htm 00000025 - Disclosure - Earnings Per Share (Tables) Sheet http://codiagnostics.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://codiagnostics.com/role/EarningsPerShare 25 false false R26.htm 00000026 - Disclosure - Stock-Based Compensation (Tables) Sheet http://codiagnostics.com/role/Stock-basedCompensationTables Stock-Based Compensation (Tables) Tables http://codiagnostics.com/role/Stock-basedCompensation 26 false false R27.htm 00000027 - Disclosure - Leases (Tables) Sheet http://codiagnostics.com/role/LeasesTables Leases (Tables) Tables http://codiagnostics.com/role/Leases 27 false false R28.htm 00000028 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies 28 false false R29.htm 00000029 - Disclosure - Business Combinations (Details Narrative) Sheet http://codiagnostics.com/role/BusinessCombinationsDetailsNarrative Business Combinations (Details Narrative) Details http://codiagnostics.com/role/BusinessCombinations 29 false false R30.htm 00000030 - Disclosure - Schedule of Goodwill (Details) Sheet http://codiagnostics.com/role/ScheduleOfGoodwillDetails Schedule of Goodwill (Details) Details 30 false false R31.htm 00000031 - Disclosure - Schedule of Intangible Assets, Net (Details) Sheet http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails Schedule of Intangible Assets, Net (Details) Details 31 false false R32.htm 00000032 - Disclosure - Schedule of Fair Value Assets and Liabilities (Details) Sheet http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails Schedule of Fair Value Assets and Liabilities (Details) Details 32 false false R33.htm 00000033 - Disclosure - Schedule of Changes in Fair Value Measurement (Details) Sheet http://codiagnostics.com/role/ScheduleOfChangesInFairValueMeasurementDetails Schedule of Changes in Fair Value Measurement (Details) Details 33 false false R34.htm 00000034 - Disclosure - Schedule of Contingent Consideration Common Stock and Warrants (Details) Sheet http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails Schedule of Contingent Consideration Common Stock and Warrants (Details) Details 34 false false R35.htm 00000035 - Disclosure - Summary of Revenue by Geographic Area (Details) Sheet http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails Summary of Revenue by Geographic Area (Details) Details 35 false false R36.htm 00000036 - Disclosure - Schedule of Deferred Revenue (Details) Sheet http://codiagnostics.com/role/ScheduleOfDeferredRevenueDetails Schedule of Deferred Revenue (Details) Details 36 false false R37.htm 00000037 - Disclosure - Schedule of Basic and Diluted Earnings Per Share (Details) Sheet http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails Schedule of Basic and Diluted Earnings Per Share (Details) Details 37 false false R38.htm 00000038 - Disclosure - Earnings Per Share (Details Narrative) Sheet http://codiagnostics.com/role/EarningsPerShareDetailsNarrative Earnings Per Share (Details Narrative) Details http://codiagnostics.com/role/EarningsPerShareTables 38 false false R39.htm 00000039 - Disclosure - Schedule of Option Activity (Details) Sheet http://codiagnostics.com/role/ScheduleOfOptionActivityDetails Schedule of Option Activity (Details) Details 39 false false R40.htm 00000040 - Disclosure - Schedule of Outstanding Restricted Stock Units and Related Activity (Details) Sheet http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails Schedule of Outstanding Restricted Stock Units and Related Activity (Details) Details 40 false false R41.htm 00000041 - Disclosure - Schedule of Warrant Activity (Details) Sheet http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails Schedule of Warrant Activity (Details) Details 41 false false R42.htm 00000042 - Disclosure - Schedule of Recognized Stock-based Compensation Expense (Details) Sheet http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails Schedule of Recognized Stock-based Compensation Expense (Details) Details 42 false false R43.htm 00000043 - Disclosure - Stock-Based Compensation (Details Narrative) Sheet http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative Stock-Based Compensation (Details Narrative) Details http://codiagnostics.com/role/Stock-basedCompensationTables 43 false false R44.htm 00000044 - Disclosure - Income Taxes (Details Narrative) Sheet http://codiagnostics.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://codiagnostics.com/role/IncomeTaxes 44 false false R45.htm 00000045 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://codiagnostics.com/role/RelatedPartyTransactions 45 false false R46.htm 00000046 - Disclosure - Schedule of Lease Expense (Details) Sheet http://codiagnostics.com/role/ScheduleOfLeaseExpenseDetails Schedule of Lease Expense (Details) Details 46 false false R47.htm 00000047 - Disclosure - Schedule of Maturities on Company Lease Liabilities (Details) Sheet http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails Schedule of Maturities on Company Lease Liabilities (Details) Details 47 false false R48.htm 00000048 - Disclosure - Schedule of Other Information Related to Operating Lease (Details) Sheet http://codiagnostics.com/role/ScheduleOfOtherInformationRelatedToOperatingLeaseDetails Schedule of Other Information Related to Operating Lease (Details) Details 48 false false R49.htm 00000049 - Disclosure - Schedule of Future Minimum Lease Payments (Details) Sheet http://codiagnostics.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails Schedule of Future Minimum Lease Payments (Details) Details 49 false false R50.htm 00000050 - Disclosure - Share Repurchase Program (Details Narrative) Sheet http://codiagnostics.com/role/ShareRepurchaseProgramDetailsNarrative Share Repurchase Program (Details Narrative) Details http://codiagnostics.com/role/ShareRepurchaseProgram 50 false false All Reports Book All Reports form10-q.htm codx-20220331.xsd codx-20220331_cal.xml codx-20220331_def.xml codx-20220331_lab.xml codx-20220331_pre.xml ex31-1.htm ex31-2.htm ex32-1.htm ex32-2.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 68 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-q.htm": { "axisCustom": 0, "axisStandard": 17, "contextCount": 92, "dts": { "calculationLink": { "local": [ "codx-20220331_cal.xml" ] }, "definitionLink": { "local": [ "codx-20220331_def.xml" ] }, "inline": { "local": [ "form10-q.htm" ] }, "labelLink": { "local": [ "codx-20220331_lab.xml" ] }, "presentationLink": { "local": [ "codx-20220331_pre.xml" ] }, "schema": { "local": [ "codx-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 437, "entityCount": 1, "hidden": { "http://codiagnostics.com/20220331": 20, "http://fasb.org/us-gaap/2022": 68, "http://xbrl.sec.gov/dei/2022": 4, "total": 92 }, "keyCustom": 38, "keyStandard": 248, "memberCustom": 10, "memberStandard": 27, "nsprefix": "CODX", "nsuri": "http://codiagnostics.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://codiagnostics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Goodwill and Intangible Assets", "role": "http://codiagnostics.com/role/GoodwillAndIntangibleAssets", "shortName": "Goodwill and Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Fair Value Measurements", "role": "http://codiagnostics.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Revenue", "role": "http://codiagnostics.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Earnings Per Share", "role": "http://codiagnostics.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Stock-Based Compensation", "role": "http://codiagnostics.com/role/Stock-basedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Income Taxes", "role": "http://codiagnostics.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Related Party Transactions", "role": "http://codiagnostics.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Leases", "role": "http://codiagnostics.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Commitments and Contingencies", "role": "http://codiagnostics.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Share Repurchase Program", "role": "http://codiagnostics.com/role/ShareRepurchaseProgram", "shortName": "Share Repurchase Program", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Balance Sheets (Unaudited)", "role": "http://codiagnostics.com/role/BalanceSheets", "shortName": "Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Subsequent Events", "role": "http://codiagnostics.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Goodwill and Intangible Assets (Tables)", "role": "http://codiagnostics.com/role/GoodwillAndIntangibleAssetsTables", "shortName": "Goodwill and Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Fair Value Measurements (Tables)", "role": "http://codiagnostics.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Revenue (Tables)", "role": "http://codiagnostics.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Earnings Per Share (Tables)", "role": "http://codiagnostics.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://codiagnostics.com/role/Stock-basedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Leases (Tables)", "role": "http://codiagnostics.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "role": "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Business Combinations (Details Narrative)", "role": "http://codiagnostics.com/role/BusinessCombinationsDetailsNarrative", "shortName": "Business Combinations (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-12-302021-12-31_custom_AdvancedConceptionsIncAndIdahoMolecularIncMember", "decimals": "-5", "lang": null, "name": "CODX:StockIssuedDuringPeriodSharesExchanged", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)", "role": "http://codiagnostics.com/role/BalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Schedule of Goodwill (Details)", "role": "http://codiagnostics.com/role/ScheduleOfGoodwillDetails", "shortName": "Schedule of Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "lang": null, "name": "us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Schedule of Intangible Assets, Net (Details)", "role": "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails", "shortName": "Schedule of Intangible Assets, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "0", "first": true, "lang": null, "name": "CODX:FairValueOfContingentConsiderationToCommonStock", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Schedule of Fair Value Assets and Liabilities (Details)", "role": "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails", "shortName": "Schedule of Fair Value Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "0", "first": true, "lang": null, "name": "CODX:FairValueOfContingentConsiderationToCommonStock", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Schedule of Changes in Fair Value Measurement (Details)", "role": "http://codiagnostics.com/role/ScheduleOfChangesInFairValueMeasurementDetails", "shortName": "Schedule of Changes in Fair Value Measurement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Schedule of Contingent Consideration Common Stock and Warrants (Details)", "role": "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails", "shortName": "Schedule of Contingent Consideration Common Stock and Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - Summary of Revenue by Geographic Area (Details)", "role": "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "shortName": "Summary of Revenue by Geographic Area (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - Schedule of Deferred Revenue (Details)", "role": "http://codiagnostics.com/role/ScheduleOfDeferredRevenueDetails", "shortName": "Schedule of Deferred Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - Schedule of Basic and Diluted Earnings Per Share (Details)", "role": "http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails", "shortName": "Schedule of Basic and Diluted Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "INF", "lang": null, "name": "CODX:WeightedAverageNumberOfBasicSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - Earnings Per Share (Details Narrative)", "role": "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative", "shortName": "Earnings Per Share (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - Schedule of Option Activity (Details)", "role": "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails", "shortName": "Schedule of Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Statements of Operations (Unaudited)", "role": "http://codiagnostics.com/role/StatementsOfOperations", "shortName": "Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - Schedule of Outstanding Restricted Stock Units and Related Activity (Details)", "role": "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails", "shortName": "Schedule of Outstanding Restricted Stock Units and Related Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - Schedule of Warrant Activity (Details)", "role": "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails", "shortName": "Schedule of Warrant Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - Schedule of Recognized Stock-based Compensation Expense (Details)", "role": "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails", "shortName": "Schedule of Recognized Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "CODX:ClassOfWarrantExercisable", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - Stock-Based Compensation (Details Narrative)", "role": "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative", "shortName": "Stock-Based Compensation (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "CODX:ClassOfWarrantExercisable", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - Income Taxes (Details Narrative)", "role": "http://codiagnostics.com/role/IncomeTaxesDetailsNarrative", "shortName": "Income Taxes (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "INF", "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2017-01-30_custom_ExclusiveLicenseAgreementMember_custom_DrBrentSatterfieldMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedRoyaltiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - Related Party Transactions (Details Narrative)", "role": "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related Party Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2017-01-30_custom_ExclusiveLicenseAgreementMember_custom_DrBrentSatterfieldMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedRoyaltiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - Schedule of Lease Expense (Details)", "role": "http://codiagnostics.com/role/ScheduleOfLeaseExpenseDetails", "shortName": "Schedule of Lease Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "CODX:ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - Schedule of Maturities on Company Lease Liabilities (Details)", "role": "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails", "shortName": "Schedule of Maturities on Company Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "CODX:ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "CODX:ScheduleOfOperatingLeaseTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - Schedule of Other Information Related to Operating Lease (Details)", "role": "http://codiagnostics.com/role/ScheduleOfOtherInformationRelatedToOperatingLeaseDetails", "shortName": "Schedule of Other Information Related to Operating Lease (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "CODX:ScheduleOfOperatingLeaseTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - Schedule of Future Minimum Lease Payments (Details)", "role": "http://codiagnostics.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails", "shortName": "Schedule of Future Minimum Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "role": "http://codiagnostics.com/role/StatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000050 - Disclosure - Share Repurchase Program (Details Narrative)", "role": "http://codiagnostics.com/role/ShareRepurchaseProgramDetailsNarrative", "shortName": "Share Repurchase Program (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited)", "role": "http://codiagnostics.com/role/StatementsOfStockholdersEquity", "shortName": "Consolidated Statements of Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - Overview and Basis of Presentation", "role": "http://codiagnostics.com/role/OverviewAndBasisOfPresentation", "shortName": "Overview and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Summary of Significant Accounting Policies", "role": "http://codiagnostics.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Business Combinations", "role": "http://codiagnostics.com/role/BusinessCombinations", "shortName": "Business Combinations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 37, "tag": { "CODX_AdvancedConceptionsIncAndIdahoMolecularIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Advanced Conceptions, Inc. and Idaho Molecular, Inc. [Member]", "label": "Advanced Conceptions, Inc. and Idaho Molecular, Inc. [Member]" } } }, "localname": "AdvancedConceptionsIncAndIdahoMolecularIncMember", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/BusinessCombinationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_ClassOfWarrantExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant exercisable.", "label": "Warrants exercisable" } } }, "localname": "ClassOfWarrantExercisable", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "CODX_ContingentConsideredIssuedForBusinessAcquisitions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contingent considered issued for business acquisitions.", "label": "Change in fair value of contingent consideration issued for business acquisitions" } } }, "localname": "ContingentConsideredIssuedForBusinessAcquisitions", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfChangesInFairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "CODX_DisclosureLeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases", "terseLabel": "Schedule Of Maturities On Company Lease Liabilities", "verboseLabel": "Schedule Of Lease Expense" } } }, "localname": "DisclosureLeasesAbstract", "nsuri": "http://codiagnostics.com/20220331", "xbrltype": "stringItemType" }, "CODX_DrBrentSatterfieldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dr. Brent Satterfield [Member]", "label": "Dr. Brent Satterfield [Member]" } } }, "localname": "DrBrentSatterfieldMember", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_EarningsBasicPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Earnings basic per share.", "label": "Basic earnings per share" } } }, "localname": "EarningsBasicPerShare", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "CODX_ExclusiveLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exclusive License Agreement [Member]", "label": "Exclusive License Agreement [Member]" } } }, "localname": "ExclusiveLicenseAgreementMember", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_FairValueOfContingentConsiderationToCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of contingent consideration to common stock.", "label": "Contingent consideration - common stock" } } }, "localname": "FairValueOfContingentConsiderationToCommonStock", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "CODX_FairValueOfContingentConsiderationToWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of contigent consideration to warrants.", "label": "Contingent consideration - warrants" } } }, "localname": "FairValueOfContingentConsiderationToWarrants", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "CODX_GainOnRemeasurementOfAcquisitionContingencies": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://codiagnostics.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain on remeasurement of acquisition contingencies.", "label": "Gain on remeasurement of acquisition contingencies", "negatedLabel": "Change in fair value of acquisition contingencies" } } }, "localname": "GainOnRemeasurementOfAcquisitionContingencies", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows", "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "CODX_IndefiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indefinite lived intangible asset useful life.", "label": "Estimated useful lives in years, term" } } }, "localname": "IndefiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "stringItemType" }, "CODX_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability payments due after year four.", "label": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "CODX_LossOnEquityMethodInvestmentInJointVenture": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Loss on equity method investment in joint venture", "label": "(Loss) on equity method investment in joint venture" } } }, "localname": "LossOnEquityMethodInvestmentInJointVenture", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "CODX_MeasurementInputStrikePriceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input Strike Price [Member]", "label": "Measurement Input Strike Price [Member]" } } }, "localname": "MeasurementInputStrikePriceMember", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "xbrltype": "domainItemType" }, "CODX_NoncashLeaseExpense": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash lease expense", "label": "Non-cash lease expense" } } }, "localname": "NoncashLeaseExpense", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "CODX_NoncashOrPartNoncashInventoryMovedToPropertyPlantAndEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash or part noncash inventory moved to property plant and equipment", "label": "Inventory moved to property, plant and equipment" } } }, "localname": "NoncashOrPartNoncashInventoryMovedToPropertyPlantAndEquipment", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "CODX_PaymentsToAcquireInterestInJointVentures": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments to acquire interest in joint ventures", "label": "PaymentsToAcquireInterestInJointVentures", "negatedLabel": "Investment in joint venture" } } }, "localname": "PaymentsToAcquireInterestInJointVentures", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "CODX_ProceedsFromExerciseOfOptionsAndWarrants": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from exercise of options and warrants", "label": "Proceeds from exercise of options and warrants" } } }, "localname": "ProceedsFromExerciseOfOptionsAndWarrants", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "CODX_RecentlyAdoptedAccountingStandardsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Recently adopted accounting standards [Policy Text Block]", "label": "Recently Adopted Accounting Standards" } } }, "localname": "RecentlyAdoptedAccountingStandardsPolicyTextBlock", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "CODX_RestOfWorldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rest of World [Member]", "label": "Rest of World [Member]" } } }, "localname": "RestOfWorldMember", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "CODX_ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of maturities on company lease liabilities [Table Text Block]", "label": "Schedule of Maturities on Company Lease Liabilities" } } }, "localname": "ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesTableTextBlock", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "CODX_ScheduleOfOperatingLeaseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of operating lease [Table Text Block]", "label": "Schedule of Other Information Related to Operating Lease" } } }, "localname": "ScheduleOfOperatingLeaseTableTextBlock", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "CODX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value, exercised.", "label": "Weighted Average Fair Value, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, non-option, granted in period, weighted average exercise price.", "label": "Weighted Average Fair Value, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price, beginning.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice", "periodStartLabel": "Weighted Average Exercise Price, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the non-option plan.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOutstandingWeightedAverageExercisePrice", "periodEndLabel": "Weighted Average Exercise Price, Ending" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOutstandingWeightedAverageExercisePrice", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of warrants exercised.", "label": "Intrinsic value of warrants exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "CODX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price, forfeited/cancelled.", "label": "Weighted Average Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to non-options of the plan that expired.", "label": "Weighted Average Exercise Price, Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price, forfeited/cancelled.", "label": "Weighted Average Exercise Price, Forfeited/Cancelled" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price, granted.", "label": "Weighted Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted-average remaining contractual life (years) outstanding, beginning.", "label": "Weighted-average Remaining Contractual Life (Years) Outstanding, Beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "durationItemType" }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted-average remaining contractual life (years) outstanding, ending.", "label": "Weighted-average Remaining Contractual Life (Years) Outstanding, Ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "durationItemType" }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value, beginning.", "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue", "periodEndLabel": "Weighted Average Fair Value, Ending", "periodStartLabel": "Weighted Average Fair Value, Beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsExpirationsWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options non vested weighted average grant date fair value exercised.", "label": "Weighted Average Fair Value, Expired" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsExpirationsWeightedAverageGrantDateFairValue", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value, forfeited/cancelled.", "label": "Weighted Average Fair Value, Forfeited/Cancelled" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options non vested weighted average grant date fair value exercisable.", "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable", "periodEndLabel": "Weighted Average Fair Value, Exercisable Ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options non vested weighted average grant date fair value exercised.", "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised", "periodEndLabel": "Weighted Average Fair Value Exercised" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options non vested weighted average term.", "label": "Weighted-average Remaining Contractual Life (years) Outstanding, Ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "durationItemType" }, "CODX_StockIssuedDuringPeriodSharesContingentConsideration": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares contingent consideration.", "label": "Number of shares on contingent consideration" } } }, "localname": "StockIssuedDuringPeriodSharesContingentConsideration", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/BusinessCombinationsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "CODX_StockIssuedDuringPeriodSharesExchanged": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares exchanged.", "label": "Number of shares exchanged" } } }, "localname": "StockIssuedDuringPeriodSharesExchanged", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/BusinessCombinationsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "CODX_StockIssuedDuringPeriodSharesStockOptionsExercised1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "StockIssuedDuringPeriodSharesStockOptionsExercised1", "negatedLabel": "Number of Options Outstanding, Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised1", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "CODX_StockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Options [Member]", "label": "Stock Options [Member]" } } }, "localname": "StockOptionsMember", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_TaxesPayableNoncurrent": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Taxes payable non current.", "label": "TaxesPayableNoncurrent", "verboseLabel": "Income taxes payable" } } }, "localname": "TaxesPayableNoncurrent", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "CODX_ThirdPartiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Parties [Member]", "label": "Third Parties [Member]" } } }, "localname": "ThirdPartiesMember", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_ThreeCustomersTogetherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Customers Together [Member]", "label": "Three Customers Together [Member]" } } }, "localname": "ThreeCustomersTogetherMember", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_TwoCustomersTogetherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Customers Together [Member]", "label": "Two Customers Together [Member]" } } }, "localname": "TwoCustomersTogetherMember", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_TwoThousandFifteenLongTermIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2015 Long Term Incentive Plan [Member]", "label": "2015 Long Term Incentive Plan [Member]" } } }, "localname": "TwoThousandFifteenLongTermIncentivePlanMember", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_WeightedAverageNumberOfBasicSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average number of basic shares outstanding.", "label": "Weighted average shares, basic" } } }, "localname": "WeightedAverageNumberOfBasicSharesOutstanding", "nsuri": "http://codiagnostics.com/20220331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r547" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r547" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r546" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r544", "r546", "r547" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r545" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r546" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r546" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r536" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r547" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r546" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r540" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r534" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r542" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_AmericasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Americas [Member]" } } }, "localname": "AmericasMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r146", "r250", "r256", "r501" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r200", "r201", "r202", "r203", "r218", "r224", "r272", "r274", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r499", "r502", "r530", "r531" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r200", "r201", "r202", "r203", "r218", "r224", "r272", "r274", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r499", "r502", "r530", "r531" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r146", "r250", "r256", "r501" ], "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r196", "r200", "r201", "r202", "r203", "r218", "r224", "r262", "r272", "r274", "r312", "r313", "r314", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r499", "r502", "r530", "r531" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r196", "r200", "r201", "r202", "r203", "r218", "r224", "r262", "r272", "r274", "r312", "r313", "r314", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r499", "r502", "r530", "r531" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r144", "r145", "r250", "r255", "r500", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529" ], "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r144", "r145", "r250", "r255", "r500", "r516", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r147", "r444" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r38", "r449" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableGrossCurrent": { "auth_ref": [ "r9", "r26", "r148", "r149" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable" } } }, "localname": "AccountsReceivableGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r148", "r149" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetNoncurrent": { "auth_ref": [ "r148", "r476", "r487" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as noncurrent.", "label": "Accounts Receivable, after Allowance for Credit Loss, Noncurrent", "verboseLabel": "Note receivable" } } }, "localname": "AccountsReceivableNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses, current" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r12", "r41" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued royalties" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r27", "r449" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r86", "r87", "r88", "r319", "r320", "r321", "r380" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r89", "r90", "r91", "r92", "r101", "r158", "r159", "r163", "r164", "r165", "r166", "r167", "r168", "r319", "r320", "r321", "r338", "r339", "r340", "r341", "r360", "r361", "r362", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r412", "r413", "r417", "r418", "r419", "r420", "r435", "r436", "r437", "r438", "r439", "r440", "r467", "r468", "r469", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income to cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r316" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r32", "r154", "r169" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Securities excluded from computation of diluted earnings per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r365" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as current.", "label": "Contingent consideration liabilities, current" } } }, "localname": "AssetAcquisitionContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r365" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent.", "label": "Contingent consideration liabilities" } } }, "localname": "AssetAcquisitionContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r20", "r80", "r132", "r135", "r141", "r162", "r205", "r206", "r207", "r209", "r210", "r211", "r212", "r213", "r214", "r216", "r217", "r368", "r370", "r396", "r447", "r449", "r473", "r488" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets [Default Label]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r10", "r37", "r80", "r162", "r205", "r206", "r207", "r209", "r210", "r211", "r212", "r213", "r214", "r216", "r217", "r368", "r370", "r396", "r447", "r449" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r384" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Total assets measured at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r279", "r280", "r281", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r297", "r298", "r299", "r300", "r301", "r302", "r304", "r305", "r307", "r308", "r311", "r312", "r313", "r314", "r315" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails", "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r271", "r273", "r357" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BusinessCombinationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r271", "r273", "r355", "r356", "r357" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BusinessCombinationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BusinessCombinationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r363", "r364" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "periodEndLabel": "Fair value as of March 31, 2022", "periodStartLabel": "Fair value as of December 31, 2021" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfChangesInFairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r358", "r366" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combinations" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BusinessCombinations" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "verboseLabel": "Business Combinations" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r6", "r85", "r127" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Overview and Basis of Presentation" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/OverviewAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r7", "r17", "r71" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r64", "r71", "r74" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r64", "r405" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r23", "r24", "r25", "r79", "r80", "r104", "r105", "r106", "r108", "r110", "r119", "r120", "r121", "r162", "r205", "r210", "r211", "r212", "r216", "r217", "r222", "r223", "r225", "r226", "r227", "r396", "r549" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Warrants to purchase shares of common stock", "verboseLabel": "Warrants to purchase a common stock" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BusinessCombinationsDetailsNarrative", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r43", "r478", "r492" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (Note 12)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r197", "r198", "r199", "r204", "r518" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Aggregate number of common shares reserved" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r86", "r87", "r380" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative", "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r25", "r227" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r25", "r449" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.001 par value; 100,000,000 shares authorized; 33,984,068 and 33,819,862 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r125", "r126", "r146", "r394", "r395", "r517" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r125", "r126", "r146", "r394", "r395", "r515", "r517" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r125", "r126", "r146", "r394", "r395", "r515", "r517" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r122", "r486" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentrations Risk and Significant Customers" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r125", "r126", "r146", "r394", "r395" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration risk percentage", "verboseLabel": "Percentage of revenue" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r125", "r126", "r146", "r394", "r395", "r517" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Schedule of Deferred Revenue" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r231", "r232", "r251" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "periodEndLabel": "Deferred revenue, Ending balance", "periodStartLabel": "Deferred revenue, beginning balance" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r231", "r232", "r251" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r252" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "negatedLabel": "Revenue recognized included in deferred revenue balance at the beginning of the period" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r222", "r223", "r225" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r58", "r80", "r162", "r205", "r206", "r207", "r210", "r211", "r212", "r213", "r214", "r216", "r217", "r396" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of revenue" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r123", "r146" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r69", "r81", "r336", "r344", "r345", "r346" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r327", "r328" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r69", "r130" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://codiagnostics.com/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows", "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r250", "r254", "r255", "r256", "r257", "r258", "r259", "r260" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r278", "r318" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Stock-Based Compensation" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r84", "r208", "r210", "r211", "r215", "r216", "r217", "r443", "r477", "r494" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due to related party" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r54", "r93", "r94", "r95", "r96", "r97", "r102", "r104", "r108", "r109", "r110", "r114", "r115", "r381", "r382", "r482", "r496" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings per common share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r54", "r93", "r94", "r95", "r96", "r97", "r104", "r108", "r109", "r110", "r114", "r115", "r381", "r382", "r482", "r496" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Diluted", "verboseLabel": "Diluted earnings per share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails", "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r111", "r112" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Net Income per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r111", "r112", "r113", "r116" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r82", "r330", "r347" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective federal statutory tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r317" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Unrecognized stock-based compensation" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Unrecognized stock-based compensation recognition period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r49", "r50", "r51", "r86", "r87", "r88", "r90", "r98", "r100", "r118", "r166", "r227", "r229", "r319", "r320", "r321", "r340", "r341", "r380", "r406", "r407", "r408", "r409", "r410", "r411", "r440", "r505", "r506", "r507" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative", "http://codiagnostics.com/role/StatementsOfStockholdersEquity", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity method investment ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BusinessCombinationsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestmentsPolicy": { "auth_ref": [ "r63", "r161", "r396" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.", "label": "Equity-Method Investments" } } }, "localname": "EquityMethodInvestmentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r384", "r385", "r392" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r384", "r385", "r386", "r391", "r392" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Schedule of Changes in Fair Value Measurement" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Schedule of Contingent Consideration Common Stock and Warrants" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value Assets and Liabilities" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r219", "r220", "r221", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r385", "r452", "r453", "r454" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r384", "r385", "r388", "r389", "r393" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r219", "r263", "r264", "r269", "r270", "r385", "r452" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r219", "r220", "r221", "r263", "r264", "r269", "r270", "r385", "r453" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r219", "r220", "r221", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r385", "r454" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency." } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r219", "r220", "r221", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r452", "r453", "r454" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r390", "r393" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Estimated useful lives in years" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r19", "r192" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Less accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r188", "r189", "r192", "r193", "r466", "r470" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r192", "r470" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Intangible assets, gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r188", "r191" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r69" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://codiagnostics.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Loss on disposition of assets", "negatedLabel": "Loss on disposition of assets" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows", "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfInvestments": { "auth_ref": [ "r69" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.", "label": "Gain (Loss) on Sale of Investments", "negatedLabel": "Loss from equity method investment" } } }, "localname": "GainLossOnSaleOfInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r59" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r124", "r517" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r18", "r174", "r175", "r182", "r186", "r449", "r472" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill - Ending", "periodStartLabel": "Goodwil - beginning" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/ScheduleOfGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r194" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/GoodwillAndIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments": { "auth_ref": [ "r183", "r354" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from foreign currency translation adjustments and purchase accounting adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Measurement period adjustments" } } }, "localname": "GoodwillTranslationAndPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r57", "r80", "r132", "r134", "r137", "r140", "r142", "r162", "r205", "r206", "r207", "r210", "r211", "r212", "r213", "r214", "r216", "r217", "r396" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r52", "r132", "r134", "r137", "r140", "r142", "r471", "r480", "r483", "r497" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r82", "r331", "r332", "r335", "r342", "r348", "r350", "r351", "r352" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r83", "r99", "r100", "r131", "r329", "r343", "r349", "r498" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income tax provision", "verboseLabel": "Income tax expense benefit" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/IncomeTaxesDetailsNarrative", "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r48", "r325", "r326", "r332", "r333", "r334", "r337" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r73" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income taxes paid" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r68" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Accounts payable, accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r68" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r68" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "verboseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r68", "r462" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "verboseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r68" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r68" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r187", "r190" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest income" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r62", "r65", "r73" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r33" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r8", "r36", "r449" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r13", "r35", "r76", "r117", "r171", "r172", "r173", "r463" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "verboseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r34" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r431", "r433" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfLeaseExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease costs" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Schedule of Lease Expense" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "verboseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Schedule of Future Minimum Lease Payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r432" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r432" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r432" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r432" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r432" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r432" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "2022 (remainder)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r432" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "verboseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r40", "r80", "r136", "r162", "r205", "r206", "r207", "r210", "r211", "r212", "r213", "r214", "r216", "r217", "r369", "r370", "r371", "r396", "r447", "r448" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r31", "r80", "r162", "r396", "r449", "r474", "r490" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r11", "r42", "r80", "r162", "r205", "r206", "r207", "r210", "r211", "r212", "r213", "r214", "r216", "r217", "r369", "r370", "r371", "r396", "r447", "r448", "r449" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r384" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Total liabilities measured at fair value" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r14", "r15", "r16", "r21", "r22", "r80", "r162", "r205", "r206", "r207", "r210", "r211", "r212", "r213", "r214", "r216", "r217", "r369", "r370", "r371", "r396", "r447", "r448" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-term liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecurities": { "auth_ref": [ "r479" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security.", "label": "Marketable securities (certificates of deposit)" } } }, "localname": "MarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable investment securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Investment Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Measurement Input, Share Price [Member]" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r64" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r64" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r64", "r67", "r70" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r5", "r46", "r47", "r51", "r53", "r70", "r80", "r89", "r93", "r94", "r95", "r96", "r99", "r100", "r107", "r132", "r134", "r137", "r140", "r142", "r162", "r205", "r206", "r207", "r210", "r211", "r212", "r213", "r214", "r216", "r217", "r382", "r396", "r481", "r495" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://codiagnostics.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net income", "totalLabel": "Net income", "verboseLabel": "Net income, as reported" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails", "http://codiagnostics.com/role/StatementsOfCashFlows", "http://codiagnostics.com/role/StatementsOfOperations", "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of non-cash investing and financing transactions" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncompeteAgreementsMember": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.", "label": "Noncompete Agreements [Member]" } } }, "localname": "NoncompeteAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r60" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesAndLoansReceivableNetCurrent": { "auth_ref": [ "r148", "r149", "r475" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.", "label": "Note receivable" } } }, "localname": "NotesAndLoansReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r132", "r134", "r137", "r140", "r142" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r425", "r433" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfLeaseExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating lease costs" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r422" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Present value of operating lease liabilities", "verboseLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r422" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liability, current", "verboseLabel": "Less: current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r422" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liability", "verboseLabel": "Long-term portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r423", "r427" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Cash paid for operating leases included in operating cash flows" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOtherInformationRelatedToOperatingLeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r421" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use asset", "verboseLabel": "Operating right use of asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r430", "r433" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Discount rate of operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOtherInformationRelatedToOperatingLeaseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r429", "r433" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Remaining lease term of operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOtherInformationRelatedToOperatingLeaseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r414", "r415" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases, Future Minimum Payments Due", "totalLabel": "Total lease payments" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r414", "r415" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next 12 Months", "verboseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r414", "r415" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "verboseLabel": "2024" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRoyalties": { "auth_ref": [ "r66" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for royalties during the current period.", "label": "Payment for royalties per month" } } }, "localname": "PaymentsForRoyalties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r61" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r279", "r280", "r281", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r297", "r298", "r299", "r300", "r301", "r302", "r304", "r305", "r307", "r308", "r311", "r312", "r313", "r314", "r315" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r279", "r280", "r281", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r297", "r298", "r299", "r300", "r301", "r302", "r304", "r305", "r307", "r308", "r311", "r312", "r313", "r314", "r315" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r24", "r222" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Convertible preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Convertible preferred stock , shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r24", "r222" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Convertible preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Convertible preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r24", "r449" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from maturities of marketable investment securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Information [Line Items]" } } }, "localname": "ProductInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r195", "r449", "r485", "r491" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r195", "r519", "r520" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Estimated useful life of property" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r55", "r170" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Bad debt expense" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentsJointVentures": { "auth_ref": [ "r493" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The book value of investments in real estate joint ventures including direct and indirect investments.", "label": "Investment in joint venture" } } }, "localname": "RealEstateInvestmentsJointVentures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r441", "r442", "r443", "r445", "r446" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r324", "r464", "r532" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails", "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r28", "r229", "r449", "r489", "r509", "r514" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r86", "r87", "r88", "r90", "r98", "r100", "r166", "r319", "r320", "r321", "r340", "r341", "r380", "r505", "r507" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r128", "r129", "r133", "r138", "r139", "r143", "r144", "r146", "r249", "r250", "r465" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r128", "r129", "r133", "r138", "r139", "r143", "r144", "r146", "r249", "r250", "r465" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r77", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r261" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Deferred Revenue" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r253", "r261" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r77", "r78" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r428", "r433" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-use assets obtained in exchange for new operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r125", "r146" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r355", "r356", "r357" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BusinessCombinationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Basic and Diluted Earnings Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r188", "r191", "r466" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r188", "r191" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Intangible Assets, Net" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/GoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/GoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.", "label": "Schedule of Product Information [Table]" } } }, "localname": "ScheduleOfProductInformationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": { "auth_ref": [ "r56", "r144" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Summary of Revenue by Geographic Area" } } }, "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r296", "r303", "r306" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Schedule of Recognized Stock-based Compensation Expense" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r275", "r276", "r279", "r280", "r281", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r297", "r298", "r299", "r300", "r301", "r302", "r304", "r305", "r307", "r308", "r311", "r312", "r313", "r314", "r315" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails", "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule of Outstanding Restricted Stock Units and Related Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r283", "r303", "r306" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r230", "r277" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Warrant Activity" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.", "label": "Share Repurchase Program" } } }, "localname": "ScheduleOfStockholdersEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ShareRepurchaseProgram" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r68" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Number of Restricted Stock Units, Forfeited/Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Weighted Average Grant Date Fair Value, Forfeited/Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Number of Restricted Stock Units, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Weighted Average Grant Date Fair Value, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r297", "r298" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Number of Restricted Stock Units, Outstanding Ending", "periodStartLabel": "Number of Restricted Stock Units, Outstanding Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r297", "r298" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted Average Grant Date Fair Value, Outstanding Ending", "periodStartLabel": "Weighted Average Grant Date Fair Value, Outstanding Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Number of Restricted Stock Units, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Weighted Average Grant Date Fair Value, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails", "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised", "negatedLabel": "Number of Warrants Outstanding, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations", "negatedLabel": "Number of Warrants Outstanding, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.", "label": "Number of Warrants Outstanding, Forfeited/Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Number of Warrants Outstanding, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r284", "r285" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Number of Warrants Outstanding, Ending", "periodStartLabel": "Number of Warrants Outstanding, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Number of common shares availalble for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "periodEndLabel": "Number of Options Exercisable Ending" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Exercisable Ending" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r305" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Intrinsic value of options value exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Number of Options Outstanding, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Number of Options Outstanding, Forfeited/Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Number of Options Outstanding, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Weighted Average Fair Value Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r318" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Aggregate intrinsic value of options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r284", "r285" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of Options Outstanding, Ending", "periodStartLabel": "Number of Options Outstanding, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r284", "r285" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price Outstanding, Ending", "periodStartLabel": "Weighted Average Exercise Price Outstanding, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r279", "r280", "r281", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r297", "r298", "r299", "r300", "r301", "r302", "r304", "r305", "r307", "r308", "r311", "r312", "r313", "r314", "r315" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails", "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Weighted Average Exercise Price Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Weighted Average Exercise Price Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Weighted Average Exercise Price Forfeited/Cancelled" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted Average Exercise Price Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r282", "r309", "r310", "r311", "r312", "r315", "r322", "r323" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Stock-based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted-average Remaining Contractual Life (years), Exercisable Ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Unvested options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options forfeited.", "label": "Weighted Average Fair Value Forfeited/Cancelled" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Fair Value Outstanding, Ending", "periodStartLabel": "Weighted Average Fair Value Outstanding, Beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted-average Remaining Contractual Life (years) Outstanding, Beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Weighted Average Fair Value Expired" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r426", "r433" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfLeaseExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term lease costs" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r75", "r85" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r23", "r24", "r25", "r79", "r80", "r104", "r105", "r106", "r108", "r110", "r119", "r120", "r121", "r162", "r205", "r210", "r211", "r212", "r216", "r217", "r222", "r223", "r225", "r226", "r227", "r396", "r549" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r45", "r49", "r50", "r51", "r86", "r87", "r88", "r90", "r98", "r100", "r118", "r166", "r227", "r229", "r319", "r320", "r321", "r340", "r341", "r380", "r406", "r407", "r408", "r409", "r410", "r411", "r440", "r505", "r506", "r507" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative", "http://codiagnostics.com/role/StatementsOfStockholdersEquity", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative", "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r86", "r87", "r88", "r118", "r465" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative", "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Share-Based Payment Arrangement [Member]" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Number of shares issued for services" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Common stock issued for warrant exercises, shares" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock-based compensation expense, shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r24", "r25", "r227", "r229", "r289" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Common stock issued for option exercises, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Common stock issued for warrant exercises" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r45", "r227", "r229" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Common stock issued for option exercises" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock repurchase program authorized amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ShareRepurchaseProgramDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r25", "r29", "r30", "r80", "r156", "r162", "r396", "r449" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r450", "r451" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Income taxes payable" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r150", "r151", "r152", "r153", "r155", "r157" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r89", "r90", "r91", "r92", "r101", "r158", "r159", "r163", "r164", "r165", "r166", "r167", "r168", "r319", "r320", "r321", "r338", "r339", "r340", "r341", "r360", "r361", "r362", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r412", "r413", "r417", "r418", "r419", "r420", "r435", "r436", "r437", "r438", "r439", "r440", "r467", "r468", "r469", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards." } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants measurement input" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Dilutive effect of stock options, warrants and RSUs" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r103", "r110" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Shares used to compute diluted earnings per share", "verboseLabel": "Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails", "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r102", "r110" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "verboseLabel": "Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r116": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r127": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r173": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r194": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org/topic&trid=2144416" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r199": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r204": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r261": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r323": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r352": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492" }, "r366": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r434": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r446": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r451": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(7))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(9))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(d))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r533": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r534": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r535": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r536": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r537": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r538": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r539": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r540": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r541": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r542": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r543": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r544": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r545": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r546": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r547": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r548": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r549": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r550": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r551": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r552": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r553": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" } }, "version": "2.1" } ZIP 69 0001493152-22-013020-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-013020-xbrl.zip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end